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The present thesis deals with Helicobacter suis (H. suis), a bacterium that naturally colonizes the stomach of 
pigs and non-human primates. Infections with this microorganism have also been associated with gastric 
disease in humans.  
Here, we first present an overview of the genus Helicobacter and the prevalence, phylogeny and clinical 
significance of gastric Helicobacter infections in humans. Then, the different diagnostic methods for detection 
of gastric Helicobacter infections are discussed. Additionally, the prevalence of H. suis in pigs and the 
pathogenic significance of this agent for pigs, non-human primates and experimentally infected lab animals are 
considered. Subsequently, more information is provided on the genomics and genetics as well as the host 
immune response against H. suis infections. However, since only limited information is available for H. suis on 
these two subjects, other gastric Helicobacter spp. and in particular H. pylori, are considered here as well. 
Finally, a brief overview is presented on the association between H. pylori infections and extragastric 
manifestations, with emphasis on Parkinson’s disease (PD).  
 
1. The rise of the genus Helicobacter 
In 1984, Marshall and Warren reported the presence of a typical curved bacterium in patients with active 
chronic gastritis, duodenal or gastric ulcers and highlighted its importance in the etiology of these diseases 
(Marshall and Warren, 1984). Initially this microorganism was believed to be a member of the genus 
Campylobacter. However, major differences in ultrastructural features, cellular fatty acids and the 5S and/or 
16S rRNA gene sequences suggested that this bacterium did not belong to the genus Campylobacter but to a 
novel genus. This microorganism was therefore designated Helicobacter pylori (Goodwin et al., 1989). Since the 
description of this human pathogen, many other species in the genus Helicobacter have been described. 
Several of those possess the ability to colonize animal hosts and some of them have a zoonotic potential in 
humans (Haesebrouck et al., 2009; Flahou et al., 2016). The Helicobacter bacteria can roughly be divided into 
gastric and enterohepatic species. Gastric Helicobacter species are able to survive the hostile, acidic 
environment in the stomach by expressing urease at a high level (Weeks et al., 2000; Pot et al., 2007). 
Enterohepatic helicobacters thrive on the mucosal surfaces of the intestinal tract and/or the liver (Sterzenbach 
et al., 2007). Currently the Helicobacter genus comprises 46 identified species. An overview of the different 
species, their hosts, disease associations and zoonotic potential is shown in Table 1.  
 
Table 1: Helicobacter spp. and their pathogenic significance for humans and animals (adapted from Flahou et al., 2016). 






‘Candidatus H. bovis’* cattle ND yes 
 ‘Candidatus H. homininae’* chimpanzee, gorilla ND unknown 
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 H. acinonychis cheetah, tiger, lion severe chronic gastritis unknown 






 H. baculiformis cat ND unknown 




 H. cetorum whale, dolphin asymptomatic, gastritis, 
peptic ulcers 
unknown 
 H. cynogastricus dog ND unknown 
 H. felis dog, cat, cheetah, new 





 H. heilmannii dog, cat, cheetah, bobcat, 





 H. mustelae ferret asymptomatic, gastritis, 




 H. pylori human asymptomatic, gastritis, 








 H. suis pig, crabeating macaque, 








‘Candidatus H. colifelis’* cat ND unknown 
 H. anseris goose ND unknown 
 H. aurati hamster asymptomatic, hepatic 
and intestinal disease 
unknown 
 H. bilis mouse, rat, Mongolian 
gerbil, dog, cat, sheep 
asymptomatic, hepatic 
and intestinal disease 
yes 
 H. brantae goose ND unknown 
 H. callitrichis marmoset ND unknown 
 H. canadensis bird, pig ND yes 
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 H. cholecystus hamster asymptomatic, hepatic 
and intestinal disease 
unknown 
 H. cinaedi hamster, cat, dog, rat, 
rhesus monkey, baboon 
asymptomatic, hepatic 
and intestinal disease 
Yes 
 H. equorum horse ND Unknown 




 H. ganmani mouse asymptomatic, hepatic 
and intestinal disease 
Yes 
 H. hepaticus mouse, Mongolian gerbil asymptomatic, hepatic 
and intestinal disease 
Yes 




 H. marmotae cat, woodchuck asymptomatic, 
hepatitis, typhlocolitis 
Unknown 
 H. magdeburgensis mouse asymptomatic, hepatic 
and intestinal disease 
Unknown 
 H. mastomyrinus rodents asymptomatic, hepatic 
and intestinal disease 
Unknown 
 H. mesocricetorum hamster asymptomatic, hepatic 
and intestinal disease 
Unknown 
 H. muricola mouse asymptomatic, hepatic 
and intestinal disease 
Unknown 
 H. muridarum rat, mouse asymptomatic, hepatic 
and intestinal disease 
Unknown 
 H. pamatensis pig, cat, bird ND Yes 




 H. rappini sheep, dog, mouse ND Yes 
 H. rodentium rat, mouse asymptomatic, hepatic 
and intestinal disease 
Unknown 





 H. suncus house musk shrew ND Unknown 
 H. trogontum sheep, pig, mouse asymptomatic, hepatic 
and intestinal disease 
Unknown 
 H. typhlonius rat, mouse asymptomatic, hepatic 
and intestinal disease 
Unknown 
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 H. valdiviensis wild birds ND Unknown 




 H. winghamensis human, wild rodents asymptomatic, 
gastroenteritis 
Yes 
ND: Not described 
*: Helicobacter species that has not yet been isolated and cultivated in vitro 
 
2. Gastric Helicobacter species in humans with emphasis on zoonotic pathogens 
H. pylori is the best studied and most prevalent of the Helicobacter species which colonize the human stomach. 
Infections with this microorganism have not only been associated with gastritis and peptic ulcer disease as 
described above, but also with more severe gastric pathologies including mucosa-associated lymphoid tissue 
(MALT-) lymphoma and adenocarcinoma (Stolte et al., 1993; Kusters et al., 2006). H. pylori infections are 
frequently acquired during early childhood and the disease progresses with age (Suerbaum & Josenhans, 2007). 
Most of the H. pylori infections remain asymptomatic. Only 10-20% of the people carrying H. pylori will develop 
gastric disorders (Kusters et al., 2006; Suerbaum and Josenhans, 2007). Figure 1 provides an overview of the 
different H. pylori-associated gastric disease outcomes in human patients. 
 
Figure 1: Sequential steps of gastric disease resulting from H. pylori infection. Depending on the localization of the H. pylori-
induced chronic gastritis, no gastric disease, duodenal ulcers, gastric ulcer disease or cancer may develop. In 85% of the 
patients, an infection with H. pylori will not result in the development of gastric diseases. In 10-15% of the H. pylori-infected 
patients, gastritis is mainly localized in the antrum (antrum predominant gastritis), which results in increased acid secretion 
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and successively in the development of duodenal ulcers. In only 2-5% of the patients, H. pylori infection will lead to the 
development of atrophic gastritis in the corpus of the stomach. This latter pathology is accompanied by decreased acid 
secretion as a result of atrophy of the acid producing glands, thereby increasing the risk to develop gastric cancer. The 
precancerous cascade progresses from multifocal atrophic gastritis, through intestinal metaplasia, to dysplasia, the severe 
grade represents carcinoma in situ, then invasive adenocarcinoma. Chronic gastritis is associated with MALT-lymphoma. 
Gastric ulcer occurs with corpus gastritis, before the stage of achlorhydria. Depending on the virulence of the H. pylori 
strain, the environmental factors and the host immune response, infections with this bacterium will or will not result in the 
development of gastric adenocarcinoma (Karczewska et al., 2014). 
 
It is estimated that half of the human population in the world is infected with H. pylori albeit with large 
geographical variations. In developing countries, more than 80% of the human population is infected with H. 
pylori, whereas the prevalence rate of H. pylori in developed countries varies from 20 to 50% (Kusters et al., 
2006; Pounder and Ng, 1995). This drop in prevalence in the Western world may create a niche for colonization 
of the human stomach by other organisms (Pounder and Ng 1995; Kusters et al., 2006).  
Indeed, gastric disease in humans has also been associated with other, long, spiral-shaped bacteria. These 
gastric non-H. pylori Helicobacter spp. (NHPH) are similar in morphology to bacteria earlier reported in the 
stomach of pigs, cats, dogs and non-human primates (Salomon, 1898; Mendes et al., 1990; Queiroz et al., 
1990). Generally, they have been found in 0.2 to 6% of gastric biopsies from humans with severe gastric 
complaints (Heilmann and Borchard, 1991; Stolte et al., 1994; Svec et al., 2000; Solnick et al., 2003). NHPH 
include H. suis from pigs and non-human primates and H. felis, H. bizzozeronii, H. salomonis and H. heilmannii 
from cats and dogs (Haesebrouck et al., 2009; Flahou et al., 2016). Although H. cynogastricus, H. baculiformis 
and H. ailurogastricus also have pets as natural host, their zoonotic significance currently remains unknown. 
Besides these long spiral-shaped helicobacters, 3 other animal-associated gastric Helicobacter spp., with a 
slightly-curved morphology more similar to that of H. pylori, are known: H. acinonychis from wild large felines, 
H. cetorum from marine mammals and H. mustelae from ferrets (Paster et al., 1991; Harper et al., 2002; Eaton 
et al., 1993). Infections of humans with those agents have not been described.  
 
2.1 Phylogeny of animal-associated gastric Helicobacter species 
Although minor differences in morphology among the porcine, feline and canine gastric NHPH have been 
described (Haesebrouck et al., 2009, Smet et al., 2011; Joosten et al., 2015), species identification based on 
microscopic analysis of human biopsy samples is not recommended (Eaton et al., 1996). Therefore, analysis of 
the Helicobacter 16S rRNA gene sequence has frequently been used in the past for differentiation between 
gastric Helicobacter species (O'Rourke et al., 2004b). However, sequencing of the 16S rRNA gene cannot 
distinguish between the canine and feline helicobacters, including H. bizzozeronii, H. felis, H. salomonis, H. 
baculiformis, H. cynogastricus and H. heilmannii (Smet et al., 2011; Baele et al., 2008a; Van den Bulck et al., 
2006; Dewhirst et al., 2005). For differentiation between those species, analyses of the ureA and ureB and the 
hsp60 gene sequences have been performed. The similarity of their ureAB genes is lower than 85%, which is 
sufficient for discrimination between these species (O’Rourke et al., 2004b). It has recently been shown that 
the newly described H. ailurogastricus species from cats can not be distinguished from its closest relative H. 
heilmannii by means of its 16S rRNA and ureAB genes but by comparison of their complete genome sequences 
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(Joosten et al., 2015). This means that the discriminatory capacity of these gene sequences is not high enough 
for the distinction of closely related gastric Helicobacter species. In this respect, genome sequencing based 
approaches are superior compared to the traditional 16S rRNA sequence analysis for studying phylogeny 
because they are based on the complete genome content and have a better resolution for discriminating both 
distantly and closely related bacteria (Vandamme, 2014). Figure 2 is an illustration of a phylogenetic tree based 
on the core genomes of all gastric helicobacters from which the genome sequence is publically available 
(Joosten et al., 2015).  
 
Figure 2: Phylogenetic tree based on the aligned and concatenated core genes of Helicobacter species from which the 
genomic content is known. The phylogram represents a maximum-likelyhood tree of gastric and enterohepatic Helicobacter 
spp. based on 303 aligned and concatenated core genes. The enterohepatic Helicobacter spp. (H. cinaedi, H. hepaticus, H. 
winghamensis, H. canadensis, H. pullorum, H. billis, H. canis) were used as an outgroup. Approximate likelihood ratio test 
values of >99% were obtained for all nodes. Optimization of topology, branch length and parameters of the starting tree 
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2.2 Clinical significance of gastric non-Helicobacter pylori Helicobacter infections in humans  
A number of reports have highlighted that people having close contact with dogs, cats and pigs are more likely 
to be infected with an animal-associated gastric Helicobacter species (Chung et al., 2014; De Bock et al., 2007; 
Joosten et al., 2013; Meining et al., 1998). Helicobacter DNA has been detected in saliva from cats, dogs and 
pigs, indicating that the oral cavity of these animals may act as source of NHPH infections for humans (Ekman 
et al., 2013; Casagrande Proieti et al., 2010; ShojaeeTabrizi et al., 2010). Fecal-oral transmission has also been 
suggested as a possible route for infection in cats (Ghil et al., 2009). Besides direct contact with animals, other 
routes of transmission of NHPH should not be neglected. It has been shown that H. felis is able to survive in 
water for several days highlighting the possible role for water in the transmission of this species as well 
(Azevedo et al., 2008). H. suis can be present on and survive in minced pork indicating that raw or undercooked 
pork may also constitute a source of H. suis infection for humans (De Cooman et al., 2013). 
H. suis, H. heilmannii, H. bizzozeronii, H. felis and H. salomonis (Table 1) have been associated with gastritis, 
gastric and duodenal ulcers and low grade MALT-lymphoma in humans (Haesebrouck et al., 2009; Matsumoto 
et al., 2014; Iwanczak et al., 2012; Duquenoy and Le Luyer, 2009). They have not been associated so far with 
gastric adenocarcinoma. The gastritis induced by NHPH is usually less active and less severe compared to H. 
pylori but the risk to develop MALT-lymphoma is higher (Morgner et al., 2000; Haesebrouck et al., 2009). 
Clinical signs associated with NHPH infections in humans include: epigastric pain, nausea, hematemesis, 
irregular defecation frequency and consistency, vomiting, recurrent dyspepsia, heartburn, dysphagia and 
decreased appetite (Dieterich et al., 1998; Goddard et al., 1997; Heilmann and Borchard, 1991; Kaklikkaya et 
al., 2002; Mention et al., 1999; Oliva et al., 1993; Schildt et al., 2000; Seo et al., 2003; Sykora et al., 2003; Van 
Loon et al., 2003; Wegmann et al., 1991; Yang et al., 1998; Yoshimura et al., 2002). In patients undergoing 
endoscopy, a variety of lesions can be observed ranging from a normal to slightly hyperaemic mucosa, mucosal 
oedema, nodular inflammation and the presence of ulcerations in the antrum of the stomach or in the 
duodenum (Haesebrouck et al., 2009; Sykora et al., 2003; Van Loon et al., 2003; Yang et al., 1995; Yoshimura et 
al., 2002). Histological examination of gastric biopsies generally reveals infiltration of lymphocytes and plasma 
cells. In some cases, lymphocytic aggregates or intestinal metaplasia have been described (Ierardi et al., 2001; 
Joosten et al., 2013; Matsumoto et al., 2014; Morgner et al., 2000; Yakoob et al., 2012).  
In several studies the prevalence of gastric NHPH was investigated by analyzing human biopsies from patients 
with gastric complaints (Trebesius et al., 2001; De Groote et al., 2005; Van den Bulck et al., 2005). In general, 
NHPH have been detected in 0.2–6% of these patients, with H. suis being the most prevalent NHPH species 
(Haesebrouck et al., 2009).  
Treatment of gastric Helicobacter infections is recommended in case of Helicobacter-related symptoms or in 
order to prevent the evolution to atrophic gastritis and gastric cancer (Cats et al., 1998; Kusters and Kuipers, 
2001). Like for H. pylori eradication, the treatment of a NHPH infection consists of the administration of a 
proton pump inhibitor (PPI) in combination with two antibiotics, such as clarithromycin and tetracycline or 
amoxicillin. However, failure of successful eradication of both H. pylori and NHPH infections has been reported 
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and may be due to an increasing occurrence of antimicrobial resistance (Kivisto et al., 2010; Megraud et al., 
2004; Horiki et al., 2008; Graham et al., 2010). An overview of what is known so far for NHPH is given below.  
Van den Bulck et al. (2005) studied the susceptibilities of animal-derived H. felis, H. bizzozeronii, and H. 
salomonis isolates to 10 antimicrobial agents. All species were highly susceptible to ampicillin, clarithromycin, 
tetracycline, tylosin, enrofloxacin, gentamicin, and neomycin. This was demonstrated by low Minimum 
Inhibitory Concentrations (MICs). Higher MICs were obtained for lincomycin and spectinomycin. Two H. felis 
strains showed a MIC of 16 µg/ml for metronidazole, suggesting acquired resistance to this antimicrobial agent 
(Van den Bulck et al., 2005). Another study highlighted that H. bizzozeronii and potentially other NHPH easily 
acquire clinically relevant resistance to metronidazole due to the high mutation rate of the simple sequence 
cytosine repeat (SSCR) located in the 3′ region of the oxygen-insensitive NAD(P)H-nitroreductase (rdxA) gene 
(Kondadi et al., 2013). For this reason, metronidazole, lincomycin and spectinomycin are considered as second 
line therapy. Vermoote et al. (2011) reported the presence of acquired resistance to fluoroquinolones in a 
porcine H. suis isolate. For all tested H. suis strains, the MIC of ampicillin was higher than described for H. felis, 
H. bizzozeronii, H. salomonis and H. pylori, possibly indicating intrinsic reduced susceptibility of H. suis to 
aminopenicillins compared to other gastric Helicobacter species. The significance of this finding for the 
treatment of H. suis infections is currently not known. However there is a report of a patient with a spiral 
gastric Helicobacter infection, which relapsed after triple therapy including amoxicillin and clarithromycin, and 
was then eradicated by quadruple therapy containing tetracycline and bismuth (Dobbs et al 2005). This 
organism was reported to be H. heilmannii by 16S rRNA based PCR, but was later shown to be H. suis. 
 
2.3 Diagnosis of gastric Helicobacter infections 
To date, several non-invasive and invasive diagnostic tools are available for the detection of gastric infections 
with Helicobacter in general and H. pylori in particular. An overview is given in Table 2 and the most frequently 
used tests are described below in more detail. 
 
Table 2: Overview of the available non- or minor invasive diagnostic tests for the identification of gastric Helicobacter spp. 
Diagnostic 
test 
Type Identification Advantages Disadvantages References 
urea breath test non-
invasive 












case of partial 
gastrectomy and peptic 
ulcer bleeding 
Malfertheiner et al., 
2012; Guarner et al., 
2010 ; Barkun et al., 
2010 ; Velayos et al., 
2012 ; Wardi et al., 2012 
gastric NHPH 
species 
- simple and safe 
- initial screening 
- false negative results 
- difficult use in animals 
- test results depending on 
colonization, speed of 
gastric emptying and 
recent use of antibiotics 
Okiyama et al., 2005; 
Matsui et al., 2014 ; 
Blaecher et al.,2013 ; 





H. pylori - safe, fast and reliable 
- use in children 
- variable accuracy 
- reduced sensitivity in 
Gisbert and Pajares, 
2006; Saez et al., 2012; 
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- reduced accuracy in 
unformed or watery stool 
samples 
Cardenas et al., 2008; 
Quieroz et al., 2013 ; 
Adamopoulos et al., 
2009 ; Yan et al., 2010 
gastric NHPH 
species 
 - not available  
serology non-
invasive 
H. pylori - use for initial 
screening, patients 
using antibiotics, 
patients suffering from 
acute bleeding 
- variability in sensitivity 
and specificity 
- variability in efficiency 
depending on H. pylori 
strain (heterogeneity 
between strains), 
geographical area and 
host genetic differences 
- no discrimination 
between past and present 
infection 
Rubicz et al., 2011; 
Mégraud et al., 2012 ; 
Burucoa et al., 2013; 
Vale et al., 2008-2009 ; 
Vitoriano et al., 2011 ; 
Malfertheiner et al., 
2007 ; Hirschl and Rotter, 
1996 ; Choi et al., 2011 ; 










H. pylori - easy and reliable 
- rather high sensitivity 
and specificity 
- use for saliva and 
dental plaques 
- use in young children 
(development adaptive 
immune system) 
Bode et al., 2002; 
Raymond et al., 1996 ; 
Luzza et al., 1997 ; De 
Pascalis et al., 1999 ; 
Sunnerstam et al., 1999 ; 
Malaty et al., 2000 
gastric NHPH 
species 






H. pylori - use for fecal samples 
- use for dental 
plaques, saliva 
- fecal samples: false 
negative results as a result 
of food degradation 
products, PCR- inhibitory 
factors and overload of 
bacterial species 
Teoman et al., 2007; 




- fecal samples: decent 
image on the presence 
of enterohepatic 
Helicobacter spp. 
- fecal samples: false 
negative results as a result 
of food degradation 
products, PCR- inhibitory 
factors and overload of 
bacterial species 
Shinozaki et al., 2002 
Invasive H. pylori - identification and 
quantification in gastric 
biopsies 




- variation as a result of 
transport conditions and 
number of specimens 
Qin et al., 2016; 
Schabereiter-Gurtner et 
al., 2004; Ndip et al., 
2003; Ricci et al., 2007; 
De Martel et al., 2010 
gastric NHPH 
species 
- identification and 
quantification in gastric 
biopsies 
- high sensitivity and 
specificity 
- differentiation 
between gastric NHPH 
species 
- strain differentiation 
- variation as a result of 
transport conditions and 
number of specimens 
-aspecific interactions 
with host DNA and DNA 
from other NHPH species 
Dieterich et al., 1998; De 
Groote et al., 2001; 
Hwang et al., 2002; Baele 
et al., 2004; O’Rourke et 
al., 2004; Trebesius et al., 
2001; Matsumoto et al., 
2009; Kivisto et al., 2010; 
Wuppenhorst et al., 
2013; Joosten et al., 
2013; Liang et al., 2013; 
Matsui et al., 2014 
endoscopy Invasive H. pylori and gastric 
NHPH species 
- visualization of 
macroscopic 
abnormalities in the 
stomach 
- not reliable 
- low sensitivity and 
specificity 
- no differentiation 
between gastric 
Helicobacter spp. 
Haesebrouck et al., 2009; 
Kato et al., 2013; Oguri 
et al., 2007; Watanabe et 
al., 2012; Kusters et al., 
2006; 
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Invasive H. pylori and gastric 
NHPH species 
- relatively high 
specificity and 
sensitivity 
- low cost and rapid 
diagnosis 
- semi-quantitative 
- lower sensitivity in case 
of: peptic ulcer bleeding, 
partial gastrectomy and 
formalin contamination of 
forceps 
- false negatives in case of 
low grade colonization 
Tseng et al., 2005; 
Gisbert et al., 2006; 
Ozaslan et al., 2010; Choi 
et al., 2012; Tian et al., 
2012; Happonen et al., 
1998 
histology Invasive H. pylori - evaluation of status 
gastric mucosa 
- cheap versus 
expensive staining 
- reliability depends on 
localization and number of 
gastric biopsies 
- variability as a result of 
use of proton pump 
inhibitors, leading to false 
negative results 
Wang et al., 2010; 
Aggarwal et al., 2011; El-
Zimaity et al., 2013; Lash 
and Genta et al., 2013 
gastric NHPH 
species 
- evaluation of status 
gastric mucosa 
- cheap versus 
expensive staining 
- detection hampered by 
focal distribution of 
bacteria 
- not recommended for 
identification up to 
species level 
Wang et al., 2010; 
Aggarwal et al., 2011; 
Lash and Genta et al., 
2013; Happonen et al., 
1998; Stoffel et al., 2000 
isolation and 
cultivation 
Invasive H. pylori - golden standard 
-specificity up to 100% 
 
- variability in sensitivity 
depending on quality, 
quantity and transport 
conditions of gastric 
biopsies. 
Ndip et al., 2003; Ricci et 




-specificity up to 100% 
 
- low sensitivity  
- low success rate 
- laborious procedure 
Ndip et al., 2003; Ricci et 
al., 2007; Kusters et al., 
2006; Happonen et al., 
1998; Javala et al., 1998; 
Haesebrouck et al., 2009 
 
2.3.1 Non- or minor invasive tests 
2.3.1.1 The urea breath test 
A frequently used test for the detection of gastric Helicobacter species is the urea breath test. This simple and 
safe non-invasive test has been reported to be highly sensitive (88%-95%) and specific (95%-100%) for the 
detection of H. pylori in adults, whereas in children a large variability in sensitivity and specificity, ranging from 
75% up to 100% has been observed (Malfertheiner et al., 2012; Guarner et al., 2010). Because of the rather low 
sensitivity and specificity, the reliability of the urea breath test has likewise been questioned when applied 
after emergency endoscopy in peptic ulcer bleeding and in case of partial gastrectomy (Barkun et al., 2010; 
Velayos et al., 2012; Wardy et al., 2012). The principle of the urea breath test is based on the urease activity of 
gastric Helicobacter species. The presence of urease in the stomach breaks down the orally administered 
13
C-
labeled or radioactive 
14
C-labeled urea into ammonia and soluble 
13/14
CO2, which is absorbed by the gastric 
mucosa, transported by the systemic circulation and excreted in the exhaled breath. Finally the amount of 
exhaled 
13/14




C in the exhaled breath or the serum of 
the patient (Logan, 1998; Savarino et al. 1999; Graham and Klein, 2000; Gisbert and Pajares, 2004). An increase 
over baseline, 30 minutes after urea ingestion, more than a specified value constitutes a positive result. In 
general, the use of the urea breath test is recommended in case of initial diagnosis of Helicobacter and for 
confirmation of Helicobacter eradication after treatment (Malfertheiner et al., 2012). Up to date, limited 
information is available on the sensitivity and specificity of the urea breath test for the detection of NHPH 
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infections in humans. Although all gastric NHPH species are characterized by their urease activity (Haesebrouck 
et al., 2009), false negative results are often obtained when the urea breath test is performed in NHPH-infected 
human patients (Okiyama et al.. 2005; Matsui et al., 2014). Possible explanations might be the patchy 
distribution of these microorganisms in the human stomach (Haesebrouck et al., 2009) and the relative low 
colonization density (Matsui et al., 2014).  
 
2.3.1.2 Stool antigen test (SAT) 
The stool antigen test (SAT) is a non-invasive diagnostic tool based on the detection of H. pylori antigens in 
human fecal samples (Gisbert and Pajares, 2006). This test is frequently applied for the screening of H. pylori in 
children (Cirak et al., 2007; Choi et al., 2011; Chehter et al., 2013). Although SATs are considered to be safe, fast 
and reliable for the identification of H. pylori infections (Gisbert et Pajares, 2006), the accuracy is influenced by 
antigenicity of the H. pylori strains as well as by the time between sample collection and measurements 
(Ritchie et al., 2009; Queiroz et al., 2013). A decreased sensitivity is found in patients suffering from 
gastrointestinal bleeding, whereas unformed or watery stool samples can result in a reduced accuracy because 
of the diluting effect on the H. pylori antigens (Saez et al., 2012). Two types of highly sensitive and specific SATs 
are available: the immunochromatography assay (ICA) and the enzyme immune assay (EIA). As ICA-tests are 
easy to apply and do not require any specialized equipment, they are frequently used for rapid diagnosis 
(Shibayama et al., 2011). They are, however, less reliable than the EIA- tests (Gisbert et al., 2006; Shibayama et 
al., 2011; Sato et al., 2012; Korkmaz et al., 2013). The ICA tests are often presented as a test-strip (eg. Testmate 
rapid pylori antigen). The presence of H. pylori antigens in a suspended stool sample results in the formation of 
immune complexes with color-labeled monoclonal antibodies. Migration of these antigen-antibody complexes 
over the surface of strip results in binding with secondary antibodies, which is visualized by the appearance of a 
colored line on the test-strip (Suzuki et al., 2002). In EIA tests the optical density is measured after incubation 
and washing of a mixture of suspended stool and peroxidase-conjugated H. pylori antibodies (Suzuki et al., 
2002). Except for controversial results in post-eradication assessment, EIAs based on polyclonal antibodies are 
reliable diagnostic tests for the detection of H. pylori infections (Odaka et al., 2002; Veijola et al., 2005). 
Nevertheless, monoclonal antibody based SATs generally represent a higher specificity compared to polyclonal 
based SATs (Dominguez et al., 2006; Deguchi et al., 2009) and they are considered more reliable than the urea 
breath test in children (Cardenas et al., 2008; Queiroz et al., 2013) and in patients who underwent distal 
gastrectomy (Adamopoulos et al., 2009; Yan et al., 2010). Currently, no antigen assays have been developed for 
the detection of gastric NHPH infections in human patients.  
 
2.3.2 Invasive tests 
2.3.2.1 Endoscopy and analysis of gastric biopsies 
Endoscopy is frequently performed to evaluate the gastric mucosa for the presence of gross abnormalities. 
Endoscopic findings characteristic for an H. pylori infection are: diffuse redness, spotted redness, mucosal 
swelling, erosions and peptic ulcers (Haesebrouck et al., 2009; Kato et al., 2013). Diagnosis of Helicobacter 
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infections based solely on endoscopic findings is not reliable enough because of the low sensitivity and 
specificity. In order to obtain a more trustworthy diagnosis, gastric biopsy samples need to be further 
examined using histology, PCR techniques and/or in vitro cultivation. Biopsy is, of course, needed for gastric 
RUT. Here the biopsy is placed in a chamber containing urea and an indicator, which changes colour in 
presence of ammonia. Several studies have indicated that the corpus greater curve, in general, is the most 
optimal biopsy site for the diagnosis of H. pylori infections (Calvet et al. 2013; El-Zimaity et al., 2013). It may not 
be appropriate in antral or pan gastritis. 
 
2.3.2.1.1 Histology 
In general, histological examination of gastric biopsies is considered as a standard method for the detection of 
an H. pylori infection. However, the reliability depends on the location of biopsy collection in the stomach and 
the number of biopsies (El-Zimaity et al., 2013). Histology has the advantage that additional information can be 
obtained on the status of the gastric mucosa, such as the presence of acute or chronic inflammation, lymphoid 
aggregates, intestinal metaplasia and glandular atrophy (Lash and Genta, 2013). 
For identification of H. pylori, the haematoxylin eosin (HE) staining is, in terms of cost-effectiveness, the most 
designated staining (Figure 3) (Wang et al., 2010). Other stainings that have been applied for the detection of 
H. pylori in gastric biopsies, brush cytology and impression smear cytology specimens are: Warthin-Starry-
staining, Gram-staining, Genta-staining, modified Giemsa-staining, toluidine-blue-staining and Romanowski-
staining (Warren and Marshall, 1983; Mendoza et al. 1993; Mirsa et al., 1993). Although H. pylori visualization 
is also possible using immunohistochemical stainings, application of these specialized, more expensive stainings 
is only justified for analysis of biopsies derived from patients with chronic active and inactive gastritis and for 
biopsies collected to confirm Helicobacter eradication therapy (Wang et al., 2010; Aggarwal et al., 2011). Like 
for H. pylori, diagnosis of infections with other gastric Helicobacter species in human biopsies is also routinely 
performed by histology and cytology (Debongnie et al. 1995). However, detection of NHPH infections is 
hampered by the focal distribution of these bacteria and therefore infection with these agents is often missed 
(Haesebrouck et al., 2009).  
 
Figure 3: HE staining of the gastric mucosa of Helicobacter-infected human patients. (A) HE staining of the gastric mucosa of 
a H. pylori-infected human patient. The slightly curved H. pylori bacteria, visualized within the black circle, are mainly 
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located at the surface of the gastric epithelial cells or in the mucus layer in the stomach (adapted from Batts et al., 2013), 
(B) HE staining of the gastric mucosa of a H. suis-infected human patient. These spiral-shaped bacteria (within the black 
circle) are more frequently found in the gastric pits (adapted from Joosten et al., 2013).  
 
2.3.2.1.2 Polymerase chain reaction 
The polymerase chain reaction (PCR) can be used as a diagnostic tool to screen gastric biopsies for the presence 
of Helicobacter DNA. Moreover, using real-time (RT)-PCR, quantitation of bacteria in gastric biopsies is possible 
as well. In H. pylori-positive patients with severe precancerous lesions, detection of the vacuolating cytotoxin 
(VacA) gene in gastric biopsies using PCR has been proven really valuable (Schabereiter-Gurtner et al., 2004). 
PCR assays for the detection of gastric NHPH species are mainly based on the amplification of a part of the 16S 
rRNA gene or the ureA/B genes (De Groote et al., 2001; Hwang et al., 2002; Baele et al., 2004; O’Rourke et al., 
2004). Recently, a study was published describing the development of a PCR based on the H. suis-specific carR 
gene for identification of H. suis infections (Matsui et al., 2014). Despite the development of different PCR 
assays for the detection of NHPH in general and H. suis in particular, no information on their sensitivity and 
specificity is available.  
 
2.3.2.1.3 Culture 
Another method for the identification of gastric Helicobacter infections by analyses of gastric biopsies is 
isolation and cultivation of Helicobacter. Generally, Helicobacter grows under micro-aerobic conditions (5% O2, 
10% CO2 and 85% N2) at 37°C and at a pH ranging between 5.5 and 8 (Scott et al., 2002; Stingl et al., 2002; 
Kusters et al., 2006; Haesebrouck et al., 2009). The specificity for the detection of H. pylori infections by 
cultivation reaches up to 100% (Ndip et al., 2003), whereas significant variability in sensitivity has been 
described, depending on the quality, the quantity and the transportation conditions of the gastric biopsies 
(Ricci et al., 2007). Because of the high specificity and relative high sensitivity, cultivation is considered the 
golden standard for the diagnosis of H. pylori infections (Kusters et al., 2006). Compared to H. pylori, isolation 
and cultivation of gastric NHPH species has a low success rate due to the very fastidious nature of these 
bacteria (Happonen et al., 1998; Javala et al., 1998). So far, only H. felis (Wüppenhorst et al., 2012) and H. 
bizzozeronii (Andersen et al., 1999; Kivistö et al., 2010; Schott et al., 2011) have successfully been isolated from 
the human stomach.  
 
2.3.3 Conclusion 
Apart from histology, no commercial tests are currently available for the diagnosis of infections with NHPH in 
general and H. suis in particular. Therefore the development of accurate and reliable diagnostic techniques for 
the identification of gastric NHPH infections is required to obtain a credible picture on the prevalence of NHPH 
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3. H. suis: a porcine pathogen with a zoonotic potential for humans 
3.1 Prevalence of H. suis in pigs 
In general, a prevalence rate of 60% has been described for H. suis infections in pigs at slaughter age in Europe, 
Asia and South- and North-America (Barbosa et al., 1995; Grasso et al., 1996; Cantet et al., 1999; Roosendaal et 
al., 2000; Choi et al., 2001; Hellemans et al., 2007; Kopta et al., 2010). It has been suggested that H. suis is 
transmitted between pigs via the oral-oral route through saliva or via the gastric-oral route through vomiting or 
regurgitation, but this requires further investigation (Haesebrouck et al., 2009; Flahou et al., 2016). 
A very high prevalence has been reported in adult pigs (> 80%). Lower infection rates have been shown in 
younger animals ranging from 2% in suckling piglets (Hellemans et al., 2007), 25 % in piglets after weaning 
(Hellemans et al., 2007) and 76 % in slaughter pigs of approximately 6 months old (Bosschem et al., 2016). This 
remarkable increase in prevalence of H. suis after weaning may suggest the presence of protective antibodies 
in the sow milk (Melnichouk et al., 1999; Hellemans et al., 2007). The protective effect of maternal milk against 
the colonization of H. pylori in the human and mouse stomach has also been described (Corthésy-Theulaz et al., 
2003; Bhuiyan et al., 2010). In young piglets and animals at slaughter age, H. suis is mainly localized in the 
antrum and the pylorus region of the stomach, whereas this bacterium is mainly located in the fundus of the 
stomach in adult pigs (Hellemans et al., 2007; De Bruyne et al., 2012).  
 
3.2 Pathogenic significance of H. suis in its natural hosts and experimentally infected 
laboratory animals 
3.2.1 H. suis infections in pigs 
Experimental and natural H. suis infections in pigs have been associated with chronic gastritis in the antrum of 
the stomach. Inflammation is mainly characterized by the infiltration of lymphoid cells and the development of 
lymphoid follicles (Mendes et al., 1991, Grasso et al., 1996, Queiroz et al., 1996; Park et al., 2000; Hellemans et 
al., 2007; De Bruyne et al., 2012). Besides the strong association with gastritis, infection with H. suis has also 
been associated with ulceration of pars oesophagea of the stomach (Figure 4) (Barbosa et al., 1995; Queiroz et 
al., 1996; Roosendaal et al., 2000; Choi et al., 2001), although H. suis does not colonize this area of the 
stomach. The exact role of H. suis in the development of this pathology remains to be further elucidated. H. 
suis infection in pigs has been associated with an increased number of gastrin producing cells and a decreased 
number of somatostatin producing cells in the antrum of the stomach (Sapierzynski et al., 2007). Since gastrin 
stimulates and somatostatin inhibits the secretion of hydrochloric acid by parietal cells, this may influence 
gastric acid production, which may also be altered due to the tropism of this bacterium for parietal cells 
(Hellemans et al., 2007). It has been suggested that such an altered gastric acid secretion might be involved in 
the development of ulceration of the pars oesophagea (Sapierzynski et al., 2007; Haesebrouck et al., 2009). 
Other research groups could not find a link between a H. suis infection and ulceration of the pars oesophagea 
(Grasso et al., 1996; Melnichouk et al., 1999; Park et al., 2000; Szeredi et al., 2005). Differences in virulence 
between H. suis strains, different sampling and laboratory techniques might explain these contradictory results. 
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Besides H. suis, other factors, such as particle size of the feed, the presence of short fatty acids in the stomach, 
the occurrence of concurrent diseases or changes in the microbiome, may also contribute to the development 
of gastric ulceration (Figure 4) (Hessing et al., 1992; Argenzio et al., 1996; Ayles et al., 1996; Krakowka et al., 
1998; Lindberg et al., 2001; Robertson et al., 2002; Amory et al., 2006; Miller et al., 2012). The presence of 
ulcers in the porcine non-glandular mucosa of the stomach may result in decreased feed intake, a decrease in 
daily weight gain and even sudden death due to fatal hemorrhage (Ayles et al. 1996; Haesebrouck et al. 2009), 
thus leading to significant economic losses (Figure 4). A decrease in daily weight gain of up to 10 % has been 
observed in weaned piglets (6-8 weeks old) after 4 and 6 weeks of experimental infection with H. suis, although 
without a clear association with the development of ulceration in the non-glandular part (De Bruyne et al., 
2012). 
 
Figure 4: Schematic overview of the contributing factors and the possible successive effects of ulcerations in the stomach of 
pigs. Apart from an infection with H. suis, the development of gastric ulceration has also been associated with a broad 
range of factors, such as particle size of the feed, the presence of short fatty acids in the stomach, concurrent diseases and 
changes in the microbiome. The presence of ulcers in the stomach of pigs may result in decreased feed intake, decreased 
daily weight gain and fatal hemorrhage. This figure was adapted from Baele et al., 2008 and Haesebrouck et al., 2009. 
 
3.2.2 H. suis infections in non-human primates: 
Besides in pigs, H. suis is also found in the stomach of non-human primates, including cynomolgus monkeys, 
mandrill monkeys and rhesus macaques (Haesebrouck et al., 2009; Flahou et al., 2016; O’Rourke et al., 2004; 
Nakamura et al., 2007; Martin et al., 2013; Matsui et al., 2014). This microorganism is mainly localized at the 
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surface epithelium, the gastric pits and superficial glands of the non-human primate stomach (O’Rourke et al., 
2004). Further research is required to determine the exact pathogenic significance of H. suis infections in non-
human primates (Haesebrouck et al., 2009; Flahou et al., 2016). 
 
3.2.3 H. suis infections in experimentally infected laboratory animals  
Specific pathogen free (SPF; free of Helicobacter spp.) inbred C57BL/6 and BALB/c mice have been shown to be 
useful models for the study of Helicobacter-related gastric disease (O’Rourke and Lee, 2003; Rogers and Fox, 
2004). Generally, in experimentally infected mice, inflammation caused by H. suis is characterized by the 
infiltration of mononuclear and polymorphonuclear cells in the lamina propria mucosae and/or the tunica 
submucosa (Figure 5A-B) (Flahou et al., 2010; Bosschem et al., 2016). Infiltration of macrophages can be 
visualized from 3 weeks post-infection onwards. At 9 weeks post-infection, an augmentation in the number of 
neutrophils and (CD3
+
) T-cells can be observed as well (Flahou et al., 2010). At 8 months post-infection large 
lymphoid aggregates were observed in the stomach of H. suis-infected rodents (Figure 5C) (Flahou et al., 2010). 
Apart from inflammation, H. suis infections in mice have also been shown to cause necrosis of parietal cells and 
an increase in mucosal epithelial cell proliferation (Flahou et al., 2010; O’Rourke et al., 2004; Nakamura et al., 
2007). Furthermore, gastric lymphoid nodules, hyperplasia of the gastric mucosa and mucus metaplasia, have 
been described as well after long term (>18 months) infection of mice with H. suis (O’Rourke et al., 2004; Park 
et al., 2008; Matsui et al., 2014). C57BL/6 and BALB/c mice genetically are predominant Th1 and Th2 
responders, respectively (Flahou et al., 2010). Differences in gastric inflammation and colonization after H. suis 
infection have been found in these mouse strains. A more pronounced gastric inflammation has been described 
in the BALB/c mice compared to C57BL/6 mice after infection with H. suis, whereas a higher colonization 
density (both in antrum and fundus) has been noted in H. suis-infected C57BL/6 mice compared to H. suis-
infected BALB/c mice. 
Mongolian gerbils are yet another useful rodent model to study Helicobacter-related gastric pathology. In these 
animals, inflammation and colonization is more confined to the antrum and a narrow zone at the forestomach-
stomach transition zone, which resembles the antrum predominant colonization by NHPH in humans. In 
addition, lesions observed in Mongolian gerbils infected with H. suis develop faster and are more pronounced 
than those in mice (Flahou et al., 2010; Bosschem et al., 2016). This includes the relatively fast development of 
severe inflammation-related pathologies, such as gastric MALT-lymphoma-like lesions. They already appear 
from 9 weeks post-infection onwards (Figure 5D) (Flahou et al., 2010; Bosschem et al., 2016). Humans suffering 
from a NHPH gastritis have also been shown to develop gastric MALT-lymphoma more frequently than those 
suffering from H. pylori gastritis (Stolte et al., 2002). These findings indicate that the outbred Mongolian gerbil 
may be more suitable than mice to study interactions of H. suis with its human host . Unfortunately, less 
molecular tools are available for the study of Helicobacter-related gastric pathology in gerbils compared to 
mice. 
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Figure 5: Images of HE stainings of the stomach of mice (A-C) and a Mongolian gerbil (D). (A) HE staining of the fundus of 
C57BL/6 mouse 4 weeks after inoculation of the growth medium of H. suis (control mouse). The arrow points to the normal 
composition and architecture of the mucosa of the fundus, characterized by no or negligible infiltration of mononuclear and 
polymorphonuclear cells in the lamina propria mucosae and tunica submucosa; (B) HE staining of the fundus of C57BL/6 
mouse 4 weeks after infection with a porcine H. suis strain. The arrow appoints the infiltration of mononuclear and 
polymorphonuclear cells in the lamina propria mucosae and tunica submucosa; (C) HE staining of the fundus of BALB/c 
mouse 8 month after infection with a porcine H. suis strain. The black arrows show the two large lymphoid aggregates in 
the lamina propria mucosae as a result of major infiltration of mononuclear and polymorphonuclear cells in the lamina 
propria mucosae in combination with a loss of the normal mucosal architecture. (D) HE staining of the antrum of a H. suis-
infected Mongolian gerbil at 8 months post-infection. The arrow shows the infiltration of mononuclear cells in the tunica 
muscularis (adapted from Flahou et al., 2010).  
 
3.2.3 H. suis infections in man  
H. suis is considered to be the most prevalent gastric NHPH species in humans (Haesebrouck et al., 2009). 
Infections with this zoonotic bacterium have been shown to comprise 13.9-78.5% of all diagnosed human 
gastric NHPH infections (Trebesius et al., 2001; Van den Bulck et al., 2005; Haesebrouck et al., 2009). It is not 
exactly known how H. suis is transmitted from pigs to humans, but direct and indirect contact with pigs and 
pork carcasses, as well as the consumption of raw or undercooked pig meat have been considered risk factors 
(Meining et al., 1998; Van den Bulck et al., 2005; Haesebrouck et al., 2009; Joosten et al., 2013; De Cooman et 
al., 2013). Similar to other gastric NHPH infections, infections with H. suis in humans have been associated with 
gastric disease and clinical signs may include epigastric pain, nausea, hematemesis, vomiting, irregular 
defecation frequency and consistency, recurrent dyspepsia, heartburn and decreased appetite (Dieterich et al., 
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1998; Goddard et al., 1997; Heilmann and Borchard, 1991; Kaklikkaya et al., 2002; Mention et al., 1999; Oliva et 
al., 1993; Schildt et al., 2000; Seo et al., 2003; Sykora et al., 2003; Van Loon et al., 2003; Wegmann et al., 1991; 
Yang et al., 1998; Yoshimura et al., 2002; Dobbs et al., 2005). A recent case report described an H. suis infection 
in a pig veterinarian suffering from reflux esophagitis and general dyspeptic symptoms (Joosten et al., 2013). 
Diagnosis in this patient was performed using ureA-based PCR on gastric biopsy samples and sequencing of the 
PCR amplicons. Additionally, histological examination revealed the presence of spiral-shaped bacteria in the 
lumen of the gastric glands as well as the presence of chronic, diffuse gastritis, characterized by a pronounced 
infiltration of lymphocytes and macrophages (Joosten et al., 2013). Apart from gastritis, H. suis infections in 
humans have also been associated with gastric and duodenal ulcers and MALT-lymphoma (Haesebrouck et al., 
2009, Matsumoto et al., 2014). Treatment of human H. suis infections generally consists of the administration 
of amoxicillin, clarithromycin and a proton pump inhibitor (Joosten et al., 2013). However in case of therapy 
failure, the administration of tetracycline might be recommended (Dobbs et al., 2005).   
Due to the extremely difficult diagnosis, the knowledge on human H. suis infections is rather limited. Further 
research is recommended in order to obtain more insights on the pathogenesis and clinical significance of H. 
suis infections in human patients.  
  
3.3 Use of genomics and genetics to obtain better insights in the pathogenesis of H. suis 
infections 
Comparison of the recent available whole genome sequences of NHPH, including H. suis, with that of H. pylori 
has revealed the presence of genes encoding homologues of H. pylori virulence factors involved in acid 
acclimation, motility, chemotaxis, oxidative stress resistance and gastric epithelial cell damage (Arnold et al., 
2011; Schott et al., 2011; Vermoote et al., 2011; Smet et al., 2013; Joosten et al., 2015). An overview is shown 
in Table 3. 
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Table 3: Overview of NHPH genes encoding homologues of H. pylori virulence factors and their role in the pathogenesis of 
Helicobacter infections. 
NHPH gene homologues encoding 




ureA/B/I/E/F/G/H - UreA and UreB 
- urease accessory proteins (UreEFGH) 
- UreI 
- acid resistance 
- regulation of urease activity 
- acid activated urea channel 
che, tlp - chemotaxis proteins (che) 
- methyl-accepting chemotaxis proteins 
(tlp) 
Chemotaxis 
katA, sodB, Ahpc - catalase (KatA) 
- superoxide dismutase (SodB) 
- alkyl hydroperoxide reductase (HhpC) 
oxidative stress resistance 
napA - neutrophil-activating protein (NAP) oxidative stress 
Ggt - γ-glutamyl transpeptidase induction of gastric lesions (apoptosis-
inducing and immunosuppressive) 
fldA - flavodoxin protein (FldA) electron acceptor of the pyruvate 
oxidoreductase enzyme complex 
porA/B/C/D - pyruvate oxidoreductase complex (Por) electron donor for FldA 
pgbA/B - plasminogen-binding protein (Pgb) induction of gastric lesions 
ansB - L-asparginase II cell-cycle inhibition of fibroblasts and 
gastric cell lines 
 
3.3.1 pH homeostasis 
Like all gastric Helicobacter spp., the genome of H. suis contains genes encoding the urease enzyme, which 
consists of two subunits (UreA and UreB) and plays a role in acid resistance by converting urea into ammonia 
and carbon dioxide (Eaton et al., 1991; Burn and Chen, 2000). By neutralizing the hydrochloric acid, the 
ammonia induces an elevated pH in the stomach (Eaton et al., 1991). Additionally, ammonia reduces the 
viability of the gastric epithelial cells (Smoot et al., 1990). The second urease gene clusters consists of the 
urease accessory ureEFGH genes and the ureI gene, encoding for the UreEFGH and the UreI proteins, 
respectively (Akada et al., 2000). The UreI protein forms an acid-activated urea channel, thereby controlling the 
transport of urea into the bacterial cell (Scott et al., 2000). In order to be functional, two nickel molecules (Ni
2+
) 
should be present within the metallocenter of the H. pylori urease (Ge et al., 2013). Together the UreEFGH 
proteins are responsible for the incorporation of nickel, thereby regulating the urease activity (Cussac et al., 
1992; Mobley et al., 1995). 
 
3.3.2 Chemotaxis and motility 
Genes coding for proteins involved in the chemotactic behavior (che and tlp genes) are typical for gastric 
helicobacters (Arnold et al., 2011; Schott et al., 2011; Vermoote et al., 2011; Smet et al., 2013; Joosten et al., 
2015). They allow bacterial movement towards urea, cholesterol, arginine and bicarbonate and away from 
hydrochloric acid (Foynes et al., 2000; McGee et al., 2005; Terry et al., 2005; Lertsethtakarn et al., 2011). 
Moreover, the presence of the TlpB receptor, which is required for pH-taxis, is also needed for the colonization 
of Helicobacter spp. (O’Toole et al., 1994; Kim et al., 1999). 
   
 
                                                                                                                          Review of the Literature 
 26  
 
All gastric Helicobacter spp. are able to migrate to the epithelial cell surface of the stomach and towards a 
more neutral pH using flagellae (Salama et al., 2013; Arnorld et al., 2011; Schott et al., 2011; Vermoote et al., 
2011, Smet et al., 2011). The flagellae are composed of a body and flagellar filaments, consisting of two 
flagellins A (FlaA) and B (FlaB), a flagellar hook (FlgE) and a flagellar cap (FlgD) (Josenhans et al., 1995; Andrutis 
et al., 1997; O’Toole et al., 1994; Kim et al., 1999).  
Both flagellum dependent motility and chemotaxis are important for successful colonization of the stomach 
(Moens and Vanderleyden, 1996; Otteman et al 1997).  
 
3.3.3 Oxidative stress 
Catalase (KatA), superoxide dismutase (SodB) and alkyl hydroperoxide reductase (AhpC) allow gastric 
helicobacters to counteract oxidative stress induced by the host immune response (Seyler et al., 2001; Harris et 
al., 2002; Olczak et al., 2003; Ernst et al., 2005, Schott et al., 2011; Smet et al., 2011; Arnold et al., 2011; 
Vermoote et al., 2011). The neutrophil-activating protein (NAP) is another virulence factor present in all gastric 
Helicobacter spp., which is involved in oxidative stress resistance (Arnold et al., 2011; Schott et al., 2011; 
Vermoote et al., 2011; Smet et al., 2013; Joosten et al., 2015). Additionally it induces the production of reactive 
oxygen radicals (ROS) (Olczak et al., 2003; de Bernard et al., 2010; Evans et al., 1995) and it is responsible for 
chemotaxis of neutrophils and monocytes, increased adhesion of neutrophils, activation of monocytes, mast 
cells and neutrophils as well as increasing the lifespan of monocytes and neutrophils (Satin et al., 2000; 
Montemurro et al., 2001; 2002; Amedei et al., 2006; Polenghi et al., 2007; Cappon et al., 2010).  
 
3.3.4 Outer membrane proteins 
Adhesion plays a crucial role in the initial colonization of the stomach by Helicobacter (McGuckin et al., 2011). 
Approximately 64 outer membrane proteins (OMPs) have been identified in the genome of H. pylori. Their role 
in the colonization of the stomach has been studied thoroughly (Alm et al., 2000; Odenbreit et al., 2009). These 
OMPs can be divided into 5 families. The first family consists of the Helicobacter outer membrane porin (Hop) 
and the Hop related (Hor) proteins. The second is the Helicobacter OMP family (Hof) protein family. The third is 
the Helicobacter outer membrane (Hom) protein family. The fourth is the iron-regulated OMPs family. The fifth 
is the efflux pump OMPs family (Oleastro and Ménard, 2013). Hop proteins include adhesins and porins, which 
play an important role in the adhesion of H. pylori to the gastric mucosa (Alm et al., 2000; Aspholm et al., 2006; 
Odenbreit, 2005; Gerhard et al., 2001). The two most important adhesins in H. pylori are the blood group 
antigen binding adhesin A (BabA) and the sialic acid binding adhesin A (SabA). BabA binds to human 
fucosylated Lewis b group antigen or related terminal fucose residues in blood group A, B and O antigens, 
expressed on Mucin 1 (MUC1) and Mucin 5AC (MUC5AC), whereas SabA binds to sialylated carbohydrate 
structures upregulated in the inflamed gastric mucosa (Boren et al., 1993; Ilver et al., 1998; Mahdavi et al., 
2002).  
Although ca. 55-60 OMPs have been identified in the genome of the gastric NHPH (Joosten et al., 2015; Alm et 
al., 2000), comparative genomics revealed that none of the genes encoding the H. pylori adhesins were present 
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within the NHPH genomes (Joosten et al., 2015). Genes encoding homologs of all members of the H. pylori Hof 
proteins appear to be present in all NHPH genomes, except for H. mustelae (Smet et al., 2014). A recent study 
showed that the H. heilmannii HofE and HofF play a role in the adhesion of this bacterium to gastric mucins and 
epithelial cells (Liu et al., 2016). Further research, however, is recommended in order to determine which other 
OMPs contribute to the adhesion process.  
 
3.3.5 Virulence factors contributing to the gastric lesions 
Major virulence factors of H. pylori involved in the induction of gastric lesions are the cytotoxin-associated gene 
pathogenicity island (cagPAI) and the vacuolating cytotoxin A (VacA). Both virulence factors are, however, 
absent in all NHPH with the exception of H. cetorum carrying a functional VacA toxin (Vermoote et al., 2011). 
CagPAI consists of 30 genes encoding a type IV secretion system (T4SS), which penetrates the epithelial cells of 
the stomach, allowing injection of the CagA protein into the host cells. Phosphorylation of this protein induces 
morphological changes in the epithelial cells by changes in the cytoskeleton and indirect activation of the pro-
inflammatory nuclear factor (NF)-κB (Akopyants et al, 1998; Segal et al., 1999; Asahi et al., 2000; Christie and 
Vogel, 2000; Odenbreit et al., 2000; Fisher, 2001; Yamazaki et al., 2003; Brandt et al., 2005; Mimuro et al., 
2007; Backert et al., 2008). VacA, on the other hand, induces vacuolization of the epithelial cells and 
mitochondrial-mediated apoptosis. The toxicity of this protein depends on the formation of membrane 
channels, which are induced by this protein (Cover and Blaser, 1992; Szabo et al., 1999; Kimura et al., 1999, 
Willhite and Blanke, 2004).  
Another virulence factor, which on the contrary is present in all gastric Helicobacter species is the gamma-
glutamyltranspeptidase (GGT) (Arnold et al., 2011; Vermoote et al., 2011; Schott et al., 2011; Smet et al., 2013). 
For H. pylori, it has been shown that GGT causes damage to epithelial cells by inducing a depletion of glutamine 
and gluthatione, both important for the maintenance of healthy gastrointestinal tissue (Shibayama et al., 2003; 
2007). Additionally, it inhibits T cell proliferation and induces an upregulation of cyclo-oxygenase (COX)-2 and 
epithelial growth factor (EGF)-related peptide as well as apoptosis of human gastric adenocarcinoma (AGS) 
cells (Busiello et al., 2004; Schmees et al., 2007; Kim et al., 2007; 2010; Zhang et al., 2015). The contribution of 
the H. suis GGT in apoptotic and necrotic cell death of gastric epithelial cells has been described as well. By the 
disintegration of glutathione into pro-oxidant degradation products, H. suis GGT induces increased oxidative 
stress, resulting in lipid peroxidation and finally gastric epithelial cell death (Flahou et al., 2011).  
Besides VacA, CagPAI and GGT, other virulence factors have been associated with gastric lesions. These include 
PutA, PutP, AnsB, FldA, PgbA, PgbB, HtrA, PrtC and IceA. Most of them are present in all gastric Helicobacter 
spp. (Arnold et al., 2011; Schott et al., 2011; Vermoote et al., 2011; Kersulyte et al., 2013; Smet et al., 2013; 
Joosten et al., 2015). These factors have been studied in H. pylori. L-Asparginase II (AnsB) plays a role in the 
cell-cycle inhibition of fibroblasts and gastric cell lines (Scotti et al., 2010). FldA functions as an electron 
acceptor for the pyruvate oxidoreductase enzyme complex, whereas pyruvate oxidoreductase (Por) proteins 
function as electron donors for FldA. The presence of the FldA protein has been associated with MALT-
lymphoma (Chang et al., 1999). The plasminogen-binding proteins (PgbA and PgbB) will allow Helicobacter to 
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bind to host plasminogen, which may contribute to the obstruction of the natural healing process of gastric 
ulcers (Vermoote et al., 2011). Furthermore, HtrA is involved in cleavage of E-cadherin, and thus contributes to 
the disruption of the gastric epithelial barrier (Hoy et al., 2010; Lower et al., 2011). By the production of 
collagenase (PrtC), gastric helicobacters are able to induce the degradation of collagen (Zhang et al., 2015). 
Finally, IceA has been associated with peptic ulcer disease and seems to be induced by contact between 
epithelial cells and Helicobacter (Peek et al., 1998; 2000; Donahue et al., 2000).  
Although a substantial number of genes encoding putative virulence factors has been described in the NHPH 
genomes in general and the H. suis genome in particular, for the majority of these, their exact role in 
pathogenesis still remains unclear. 
 
3.4 Host immune response to gastric Helicobacter infections 
In general, Helicobacter causes a life-long gastric infection since the evoked host immune response is not able 
to eliminate Helicobacter from the stomach (Kusters et al., 2006; Flahou et al., 2012). Several studies describing 
the host immune response (both innate and adaptive host responses) against H. pylori are available, whereas 
only few reports have been published on the host immune responses against H. suis infections (Baele et al., 
2008; Flahou et al., 2010; Flahou et al., 2012; Bosschem et al., 2016). The next section is therefore particularly 
focused on the innate and adaptive host immune response induced by H. pylori and where possible, 
information about H. suis-induced immune responses is provided as well. 
 
3.4.1 Innate immune response to H. pylori and H. suis 
Dendritic cells (DC), macrophages and gastric epithelial cells form the first barrier against infections with H. 
pylori (Dubois and Borén, 2007). Like other invading pathogens, H. pylori bacteria are recognized by the cells of 
the innate immune system via distinct conserved structures, also referred to as pathogen-associated molecular 
patterns (PAMPs). These PAMPS are not expressed by the host cells, allowing recognition of pathogens by the 
host immune response (Takeda et al., 2004; Peek et al., 2010). The host cells, on their account, feature pattern 
recognition receptors (PRRs) on the cytoplasmatic and endosomal membranes as well as in the cytosol. These 
PRRs, including the surface-expressed Toll-like receptors (TLRs), are able to recognize the bacterial PAMPs. 
Specific interactions between PRRs and PAMPs result in the activation of intracellular signaling pathways 
inducing the transcription of various genes that are responsible for the production of inflammatory cytokines, 
chemokines, antigen-presenting molecules, etc (Peek et al., 2010). Gastric epithelial cells from H. pylori-
infected human patients have been shown to express TLR4, TLR5 and TLR9 (Figure 6A) (Schmausser et al., 
2004). TLR2 is generally expressed on the surface of intestinal and gastric epithelial cells (Cario et al., 2002; 
Smith et al., 2003) and in contrast to TLR4, TLR5 and TLR9, it is responsible for the recognition of multiple H. 
pylori PAMPs, e.g. lipopolysaccharide (LPS) and the H. pylori neutrophil-activating protein (HP-NAP) (Peek et al., 
2010) (Figure 6A). Interaction of HP-NAP with TLR2 leads to the activation of NF-κB, followed by the 
upregulation of pro-inflammatory cytokines interleukin (IL)-12, IL-23 and tumor necrosis factor (TNF) (Amedei 
et al., 2006). (Figure 6A). 
   
 
                                                                                                                          Review of the Literature 
 29  
 
Since H. pylori possesses 4 to 6 monopolar sheated flagella and TLR5 is known to recognize bacterial flagellin, 
TLR5 was assumed to be involved in the recognition of H. pylori flagellin (Eaton et al., 1996). However, full TLR5 
activation requires the presence of conserved amino acids. Because of the lack of these molecules, it has been 
reported that H. pylori flagellin cannot be recognized by TLR5 (Andersen-Nissen et al., 2005) (Figure 6A).  
Additionally to TLRs, gastric epithelial cells may express the cytosolic nucleotide-binding oligomerization 
domain (NOD), which is a cytosolic pathogen recognition molecule. By its involvement in the intracellular 
recognition of bacterial muropeptides, derived from bacterial peptidoglycan, NOD1 plays an important role in 
the innate immunity against H. pylori. Using the type 4 secretion system (T4SS), H. pylori secretes its 
peptidoglycan into the cytoplasma of the gastric epithelial cells, resulting in the activation of NOD1 (Viala et al., 
2004). H. pylori-induced NOD1 activation results in the activation of NF-κB, leading to the production of pro-
inflammatory cytokines and chemokines, eg CXCL-8 (IL-8), CXCL-2 (murine homologue of IL-8) and type 1 
interferon (IFN) (Viala et al., 2004; Watanabe et al., 2011) (Figure 6A).  
Furthermore, IL-8 production by gastric epithelial cells can also be mediated in a TLR/NOD1 independent 
manner by interaction with H. pylori OMPs (Oleastro & Menard, 2013) (Figure 6A). Via BabA and SabA 
adhesins, H. pylori is also able to bind to gastric mucins, such as MUC1, which also results in the secretion of IL-
8 by the gastric epithelial cells (Figure 6A) (Sheng et al., 2013). Additionally, interaction between the gastric 
epithelial cells and other H. pylori adhesins, including HopH, outer inflammatory protein A (OipA), HomB and 
adherence-associated lipoprotein A/B (AlpA/AlpB), may also induce gastric epithelial IL-8 secretion (Oleastro 
&Menard, 2013; Sheng et al., 2013) (Figure 6A).  
The production of chemokines by the epithelial cells of the stomach results in the recruitment of innate 
immune cells, eg. dendritic cells, monocytes, macrophages and neutrophils to the site of infection. They are 
considered to be the second stage of the innate immune response (Allen et al., 2000; 2001). Interaction 
between H. pylori and monocytes/macrophages results in the activation of both TLR2 and TLR4 signaling in 
these cells, leading to the secretion of inflammatory cytokines such as IL-1β, IL-6, IL-8, IL-10, IL-12 and TNF 
(Maeda et al., 2001; Gobert et al., 2004; Mandell et al., 2004). On the other hand, DC signaling in response to 
an H. pylori infection is mainly mediated by TLR2 and to a lesser extent by TLR9 and TLR4, inducing the 
secretion of IL-1β, IL-6, IL-10, IL-12 and TNF (Rad et al., 2007; 2009; Kim et al., 2013). The production of these 
pro-inflammatory cytokines by DC’s and macrophages leads to the recruitment, differentiation and activation 
of CD4
+
 Th cells, which organize the adaptive immune response (Wilson & Crabtree, 2007). Furthermore, 
macrophages and neutrophils are responsible for phagocytosis, which is an important antibacterial innate 
defense mechanism. However, by its ability to survive within the phagosomes, H. pylori partially evades 
phagocyte-mediated killing (Allen et al., 2000; 2001). In addition, H. pylori induces the extracellular release of 
ROS by phagocytes, but the bacterium is capable of surviving this response through catalase and superoxide 
dismutase activity (Ramarao et al., 2000).  
Little data is available on the innate immune response against an infection with H. suis. A recent in vivo study 
reported infiltration of neutrophils and mononuclear cells in the mucosa and submucosa of H. suis-infected 
BALB/c mice (Bosschem et al., 2016) (Figure 6B). The same study described enhanced expression of porcine DC 
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activation markers (CD25, CD40 and CD80/86), decreased expression of major histocompatibility complex 
(MHC)-II presentation at the surface of porcine DCs and DC-triggered expansion of regulatory T cells (Tregs) 
upon stimulation with H. suis lysate. Finally, H. suis stimulation of murine DCs resulted in an increased secretion 
of IL-6 and IL-23, inducing the differentiation from naïve T cells to T helper 17 (Th17) effector cells (Bosschem 
et al., 2016) (Figure 6B). Since no information is currently available on H. suis PAMPs (Figure 6B), further 
research is required to identify the H. suis genes that contribute in the activation of the host immune response.  
 
3.4.2 Acquired immune response to H. pylori and H. suis 
In response to the cytokine production by the innate immune cells, naïve T CD4
+
 helper (T CD4
+
) cells will 
differentiate towards either T helper 1 (Th1) cells, T helper 2 (Th2) cells, Th17 or regulatory T (Treg) cells. An 
overview of the cytokines responsible for the differentiation of naïve T CD4
+
 cells into the different effector 
cells in combination with the secretion of cytokines by the different T effector cells is presented in Table 4.  
 
Table 4: Overview of the cytokines responsible for the differentiation of naïve T CD4
+
 cells into the different T effector cells 
and their secreted cytokines. 
 Th1 effector cells Th2 effector cells Th17 effector cells Treg effector cells 
cytokines for 
differentiation 
- IL-12 - IL-6/ IL-4 
 
- IL-6/ IL-23 
 
- TGF-β 
secreted cytokines - IFN-γ/ IL-2/ TNF - IL-4/ IL-5/ IL-6/ IL-9/ 
IL-10/ IL-13 
 
- IL-17/ IL-21/ IL-22 - IL-10/ TGF-β 
references Romagnani et al., 
2000; Larussa et al., 
2015 ; Banchereau et 
al., 2000 
Romagnani et al., 
2000; Larussa et al., 
2015 ; Banchereau et 
al., 2000 
Larussa et al., 2015 Larussa et al., 2015 
 
3.4.2.1 T helper cells 
The T cell response evoked by H. pylori infections consists of the IFN-γ producing CD4
+ 
T cell phenotype, 
indicating a Th1 response (D’Elios et al., 1997; Bamford et al., 1998; Peek et al., 2010; Larussa et al., 2015). 
Differentiation of the naïve T CD4
+
 helper cells into Th1 helper cells is induced by IL-12 (Table 4), produced and 
secreted by activated monocytes, macrophages and DCs (Guiney et al., 2003; Hafsi et al., 2004) (Figure 6A). The 
severity of H. pylori-associated gastric pathology mainly depends on the Th1 responses and the Th1 produced 
cytokines (Mohammadi et al., 1996; Smythies et al., 2000; Sommer et al., 2001). These findings have been 
confirmed by the reduced gastric pathology in mouse models deficient in Th1 cell development (Sommer et al., 
2001) and IFN-γ
-/-
 mouse models (Smythies et al., 2000). Several H. pylori virulence factors have been 
associated with the stimulation of the Th1 cell response, including CagPAI and HP-NAP. H. pylori infections have 
also been associated with a Th2 response (Serrano et al., 2007; Robinson and Atherton, 2010), characterized by 
the secretion of multiple cytokines including IL4, IL6 and IL10 (Table 4)(Kusters et al., 2006; Smythies et al., 
2000; Odenbreit et al., 2006). H. pylori strains inducing a Th2 immune response typically lack genes encoding 
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major virulence factors such as the CagPAI and the VacA and the BabA and SabA adhesins (Liu et al., 2014). 
Apart from the production of multiple cytokines (Table 4), activated Th2 cells are also responsible for the 
inhibition of phagocytic cells (Romagnani et al., 2000). Indeed, several reports suggest the protective role of 
Th2 cells against severe lesions by suppressing the H. pylori-induced inflammation (Fox et al, 2000; Smythies et 
al., 2000). Other reports could not confirm these findings (Saldinger et al., 1998; Garhart et al., 2003) and 
further research is required to elucidate the exact role of the Th2 response in H. pylori infections. 
A Th2 host immune response has also been associated with an H. suis infection in mice (Park et al., 2008). This 
type of response was characterized by elevated expression levels of IL-10 and IL-4 (Flahou et al., 2012; Zhang et 
al., 2015) (Figure 6b), as well as by the formation of gastric MALT-lymphoma-like lesions (Greiner et al., 1997; 
Flahou et al., 2012). Gastric MALT-lymphoma is characterized by a strong proliferation of B lymphocytes which 
may be dependent on Th2-type cytokines. Since infection with NHPH in general and H. suis in particular results 
indeed in a higher risk for the development of MALT-lymphoma, it is more likely to induce a Th2 response 
rather than a Th1 response (Greiner et al., 1997; Knörr et al., 1999; Haesebrouck et al., 2009; Flahou et al., 
2010; Flahou et al., 2012). On the other hand, infections with H. suis in gerbils result in increased expression of 
IFN-γ in the stomach, suggesting the induction of a Th1 response by this pathogen as well (Vermoote et al., 
2012; 2013; Bosschem et al., 2015; Zhang et al., 2015) (Figure 6B). These results indicate that the H. suis-
evoked immune response might be host dependent. However, further investigation is recommended.  
Another important immune mechanism contributing to the development of H. pylori-induced gastritis is the 
Th17 response (Shiomi et al., 2008; Shi et al., 2010; Hitzler et al., 2012; Raghavan and Quiding-Järbrink, 2012; 
Gray et al., 2013; Larussa et al., 2015). Th17 cells secrete IL-17, which plays a role in the recruitment of 
neutrophils to the site of infection, as well as in the stimulation of IL-8 secretion by the gastric epithelial cells 
(Luzza et al., 2000; Mizuno et al., 2005) (Figure 6A).  
An infection with H. suis has also been associated with a Th17 response. The presence of Th17 cells and/or 
increased levels of IL-17 in the stomach of H. suis-infected mice, Mongolian gerbils and humans has been 
reported in several studies (Luzza et al., 2000; Mizuno et al., 2005, Flahou et al., 2012; Vermoote et al., 2012; 
2013; Zhang et al., 2015; Bosschem et al., 2015; 2016) (Figure 6B). However, the Th17 response upon H. suis-
infected mice appeared to be significantly higher in BALB/c mice than in C57BL/6 mice (Flahou et al., 2012). 
This finding can be explained by the fact that the overall inflammatory response in BALB/c mice is generally 
higher compared to C57BL/6 mice (Flahou et al., 2012). Additionally, a remarkable negative correlation 
between H. suis colonization and the expression levels of IL-17 mRNA has been reported (Flahou et al., 2012; 
Vermoote et al., 2012; 2013; Bosschem et al., 2015). Indeed, the higher inflammatory response in BALB/c mice 
might induce a less favorable environment for H. suis, thereby resulting in a lower colonization density (Flahou 
et al., 2012).  
An increased number of Treg cells in the gastric mucosa of H. pylori-infected human patients has been 
described, suggesting that H. pylori colonization could evoke proliferation and migration of Treg cells as well 





T cells in the gastric and duodenal mucosa of H. pylori-infected patients (Lundgren et al., 2005) (Figure 
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6A). By the production of anti-inflammatory cytokines (IL-10 and TGF-β), Treg cells are able to limit the 
proliferation and function of other immune cells, which may result in decreased inflammation and tissue 
damage (Eaton et al., 2001; Raghavan and Quiding-Järbrink, 2012). Indeed, Treg responses in H. pylori-infected 
children resulted in the inhibition of the Th1 and Th17 responses leading to a less severe inflammation and 
ulceration of the gastric mucosa (Harris et al., 2008). Moreover, the number of Treg cells was considerably 
higher in H. pylori-infected patients without peptic ulceration compared to patients suffering from peptic ulcers 
(Robinson et al., 2008).  
H. suis infections in mice and gerbils have also been associated with the induction of a Treg immune response 
and increased expression levels of IL-10 in the gastric mucosa (Vermoote et al., 2012; 2013; Zhang et al., 2015; 
Bosschem et al., 2015; 2016). Elevated expression of IL-10 and the FOXP3-gene were observed in H. suis-
infected mice (Zhang et al., 2015) (Figure 6B). Additionally, a positive correlation between IL-10 expression 
levels and H. suis colonization density has been described in BALB/c mice (Vermoote et al., 2012; 2013; Flahou 
et al., 2012).  
 
3.4.2.2 B-cells  
It has been suggested that B cells may also contribute to the immunopathogenesis of H. pylori infections. 
Uncontrolled proliferation of B lymphocytes has been reported in response to the production of certain 
cytokines, like IL-2, after interaction between T cells and H. pylori antigens (Wotherspoon et al., 1991). A 
minority of H. pylori-infected patients develop gastric MALT-lymphoma, which mainly arise by the proliferation 
of B cells (Kusters et al., 2006). Moreover, complete MALT-lymphoma regression has been described in more 
than 80% of the patients after successful H. pylori eradication (Parsonnet and Isaacson, 2004; Peek et al., 2010). 
Compared to wild-type mice, a reduced colonization and more severe gastritis combined with the increased 
infiltration of CD4
+
 cells was detected in B cell deficient mice at 8 and 16 weeks post-infection, indicating that B 
cells may temper the effect of the CD4
+
 cells (Akhiani et al., 2004). Further research is recommended to 
uncover the exact role of B cells as well as the role of T cell-B cell interactions in the pathology of the H. pylori-
evoked immune response (Peek et al., 2010).  
Although the exact role of B cells in H. suis infections remains to be elucidated, previous studies suggested that 
they might play a role in the pathogenesis as well (Vermoote et al., 2012; 2013, Zhang et al., 2015) (Figure 6B). 
Increased numbers of B cells have been reported after a 6 month-infection of mice and Mongolian gerbils with 
H. pylori and H. suis (Zhang et al., 2015). Inoculation of C57BL/6 mice with an H. suis strain evoked a host 
immune response characterized by activation and infiltration of B cells and CD4
+
 cells, which were mainly 
located in the surrounding of gastric lymphoid follicles. Moreover, their numbers were positively correlated 
with the duration of H. suis infection (Yamamoto et al., 2011). Additionally, a pronounced upregulation of 
chemokine ligand 13 (CXCL13), also called B cell attracting chemokine 1 or B lymphocyte chemoattractant, 
along with infiltration and proliferation of B cells in the centers of lymphocytic aggregates/follicles has been 
reported in the stomach of H. suis-infected, but not H. pylori-infected mice and Mongolian gerbils (Zhang et al., 
2015) (Figure 6B). In contrast, another study showed that H. suis-induced lymphoid follicles were not only 
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composed of B cells but also of CD4
+
 T helper cells and that the development of gastric lymphoid follicles could 
not be detected in H. suis-infected IFN-γ deficient mice, indicating that IFN-γ might play a role in the 
pathogenesis of H. suis-induced gastric lymphoid follicles (Mimura et al., 2011). 
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Figure 6: Comparison of H. pylori-induced and H. suis-induced innate and adaptive immune response. (A) Overview of the 
H. pylori-evoked host innate and adaptive immune response. Contact between epithelial cells and H. pylori or its bacterial 
products may lead to the activation of NF-κB, which results in the secretion of pro-inflammatory chemokines and cytokines, 
including IL-8. IL-8 induces the recruitment of immune cells to the lamina propria of the gastric mucosa. Depending on their 
effector functions, activated immune cells secrete pro-inflammatory cytokines (including IL-1β, TNF, IL-6, IL-12, and IFN-γ). 
Based on these cytokines, naïve T CD4
+
 cells will differentiate towards either Th1 cells, Th2 cells, Th17 or Treg cells. 
Depending on the type of T-helper cell, certain cytokines will be secreted. (B) Overview of the H. suis-evoked host innate 
and adaptive immune response. Contact between epithelial cells and H. suis or its bacterial products may lead to the 
activation of NF-κB, which results in the secretion of pro-inflammatory chemokines and cytokines, including IL-8 and IL-1β. 
In contrast to H. pylori, the virulence factors of H. suis that evoke the innate immune response remain unknown. 
Subsequently, the pro-inflammatory cytokines induce the recruitment of immune cells to the lamina propria of the gastric 
mucosa. Depending on their effector functions, activated immune cells secrete pro-inflammatory cytokines, such as IL-23 
and IL-6. Based on these cytokines, naïve T CD4
+
 cells will differentiate towards either Th1 cells, Th2 cells, Th17 or Treg cells. 
Depending on the type of T-helper cell, certain cytokines will be secreted. In conclusion, only limited information on the H. 
suis–induced innate and adaptive host immune response is currently available and thus further research is required. IL: 
interleukin; TNF: tumor necrosis factor; TLR: Toll-like receptor; IFN: interferon; Th: T-helper cell; NOD: nucleotide-binding 
oligomerization domain; NF: nuclear factor; CXCL-13: chemokine ligand 13; MUC1: mucin 1; T4SS: Type 4 secretion system; 
LPS: lipopolysaccharide; TGF: Tissue growth factor; NAP: Neutrophil-activating protein. 
 
4. Extragastric manifestations of Helicobacter infections with emphasis on Parkinson’s 
disease (PD) 
The bidirectional communication between the gastrointestinal tract and the brain via the gut-brain axis has 
been considered (Cryan et al., 2012; Mayer et al., 2014). Anatomically, the gut-brain axis consists of the central 
nervous system (CNS), the autonomic nervous system (ANS) and the peripheral nervous system (PNS) (also 
known as the enteric nervous system or “little brain”) (Caso et al., 2008; Konturek et al., 2011; Budzynski et al., 
2014). Via the gut-brain axis, changes in stress and emotions are able to influence the gastrointestinal immune 
system, the mucosal inflammation and the composition of gut microbiota and thereby the functionality of the 
gastrointestinal tract (Budzynski et al., 2014). On the other hand, alterations in the gut microbiota and the 
function and/or coordination of the gastrointestinal tract have been suggested to play a role in the overall 
physical and emotional state of the host (Cryan et al., 2012; Budzynski et al., 2014; Mayer et al., 2014). 
Infections with H. pylori have not only been associated with changes in the composition of the gastrointestinal 
microbiota (Engstrand et al., 2013; Budzynski et al., 2014), but also with disturbed gastric emptying (Miyaji et 
al., 1999). Additionally, Helicobacter spp. in general and H. suis in particular are able to cause damage to the 
gastric epithelial cell lining by inducing epithelial cell apoptosis as described above (De Bock et al., 2006; 
Kusters et al., 2006; Flahou et al., 2010). Furthermore, Helicobacter antigens were also detected in 
macrophages in the mesenteric lymph nodes during chronic infection in mice (unpublished results). Together, 
these findings suggest that the inflammatory effects caused by gastric helicobacters are not restricted to the 
stomach. At the start of this PhD, only one clinical association had been made between H. suis infections and 
extragastric disease (Dobbs et al., 2005). In contrast, H. pylori infections had been associated with several 
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extragastric manifestations. A concise overview is shown in Table 5. In this part of the thesis, only the possible 
link between H. pylori infections and Parkinson’s disease (PD) will be described in more detail.  
 
Table 5: Concise overview of H. pylori-associated extragastric disorders. (MS): multiple sclerosis; (AD): Alzheimer’s disease; 
(CNS): central nervous system; (PD): Parkinson’s disease; (IBD): inflammatory bowel disease. 








ischemic stroke stroke mainly caused by 
occlusion of the carotic or 
cerebral vessels 
positive Yang et al., 2011; Alvarez-Arellano et 
al., 2014 ; De Bastiani et al., 2008; 
Zhang et al., 2008; Wang et al., 2012; 
Wong et al., 2014 
migraine headaches severe headaches positive Deleu et al., 1998; Gervil et al., 1999; 
Gasbarrini et al., 1998; Yiannopoulou 
et al., 2007; Tunca et al., 2004 ; Hong 
et al., 2007 
Guillain-Barré syndrome acute, inflammatory 
autoimmune neuropathy 
characterized by progressive 
weakening of the motoric 
functions, mainly 
commencing in the legs 
positive Suzuki et al., 2006; Alvarez-Arellano et 
al., 2014 ; Kountouras et al., 2005; 
Chiba et al., 2002 
multiple sclerosis (MS) most prevalent inflammatory 
demyelinating disorder of 
the central nervous system 
(CNS) 
negative Wender, 2003; Li et al., 2007; Mohebi 
et al., 2013 
neuromyelitis optica disease characterized by 
inflammation of the optic 
nerves and the spinal cord 
positive Li et al., 2009; Long et al., 2013 
Alzheimer’s disease (AD) neurodegenerative disorder 
characterized by synaptic 
loss and neuronal cell death 
as a result of the intra- and 
extracellular accumulations 
of β-amyloid deposits in the 
brain 
positive Selkoe, 2002; Kountouras et al., 2006; 
Honjo et al., 2009; Chang et al., 2013; 
Alvarez-Arellano et al., 2014; 
Testerman et al., 2014; Wong et al., 
2014; Malaguarnera et al., 2004; 
Kountouras et al., 2009a; Roubaud-
Baudron et al., 2012 ; Kountouras et 
al., 2010 
Parkinson’s disease (PD) neurodegenerative disorder 
characterized by progressive 
loss of domaminergic 
neurons, mainly in the 
substantia nigra of the brain 
positive Altschuler, 1996; Tsolaki et al., 2015; 
Bjarnason et al., 2005; Dobbs et al., 
2010; Alvarez-Arellano et al., 2014 ; 
for review see Dobbs et al., 2016 
endocrine 
manifestations 
diabetes endocrine disorder 
characterized by a 
disturbance in the glucose 
metabolisation 
positive Simon et al., 1989, Oldenburg et al., 
1996; Quadri et al., 2000; Gulcelik et 
al., 2005; Bener et al., 2007; Longo-
Mbenza et al., 2007; Devrajani et al., 
2010; Zhou et al., 2013; Jeon et al., 
2012 
dyslipidemia manifestation characterized 
by disturbances in the 
production and clearance of 
plasma lipoproteins 
positive Laurila et al., 1999; Hoffmeister et al., 
2001; Majka et al., 2002; Takashima et 
al., 2002; Chimienti et al., 2003; 
Papamichael et al., 2009; He et al., 
2014; Feingold et al., 1992; Chimienti 




impairment of the thyroid 
gland 
positive Papamichael et al., 2009; Smyk et al., 
2014; Testerman et an 2014; Bassi et 
al., 2010; Bassi et al., 2012; Shi et al., 
2013; Tomb et al., 1997; Bassi et al., 
2010; Bertalot et al., 2004 
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iron deficiency anemia anemia as a result of a lack 
of iron often caused by 
gastrointestinal bleeding. 
positive Monzon et al., 2013; Blecker et al., 
1991; Bruel et al., 1993; Dufour et al., 
1993 ; Milman et al., 1998; Peach et 
al., 1998; Collett et al., 1999 ; Yip et 
al., 1997; Kang et al., 2011; Musumba 





disease characterized by low 
platelet counts and 
mucocutaneous bleedings 
caused by the autoimmune 
destruction of platelets 
positive Gasbarrini et al., 1998; Hino et al., 
2003; Huber et a., 2003; Stasi et al., 
2005; Suzuki et al., 2005; Campuzano-
Maya, 2014 ; Franceschi et al., 2004; 




manifestations, such as 
atherosclerosis and 
coronary artery disease 
narrowing of the lumen of 
the blood vessels 
positive Mendall et al., 1994; Huang et al., 
2011; Park et al., 2011; Vafaeimanesh 
et al., 2014; Kowalski et al., 2001; 
2002; Oshima et al., 2005; Tamer et 
al., 2009; Chimienti et al., 2003; 
Kucukazman et al., 2009; Franceschi 
et al., 2002 
asthma and allergies hypersensitivity reaction 
associated with a chronic 
Th2 response 
negative Amedei et al., 2010; Testerman et al., 
2014; Wong et al., 2014; Chen et al., 
2008; Zhou et al., 2013; Wang et al., 




non-alcoholic fatty liver 
disease 
a group of liver disorders 
ranging from non-alcoholic 
fatty liver to the 
development of non-
alcoholic steatohepatitis in 
which insulin resistance 
plays a role 
positive Rabelo-Gonçalves et al., 2015; Waluga 
et al., 2015; Cindoruk et al., 2008; 
Pirouz et al., 2009; Dogan et al., 2013; 
Abenavoli et al., 2013 
hepatic fibrosis, cirrhosis disease characterized by 
replacement of liver cells by 
extracellular matrix proteins, 
including collagen, as a result 
of chronic liver diseases 
positive Rabelo-Gonçalves et al., 2015; Waluga 
et al., 2015; Goo et al., 2009; Ki et al., 
2010; Ponzetto et al., 2000a; b; Feng 
et al., 2014; Esmat et al., 2012; Stalke 
et al., 2001 
hepatic encephalopathy complication of liver cirrhosis 
characterized by the 
occurrence of 
neuropsychiatric symptoms 
and the excessive ammonia 
levels 




primary malignant liver 
tumor 
positive Rabelo-Gonçalves et al., 2015; Waluga 
et al., 2015; Avenaud et al., 2000; 
Nilsson et al., 2001; Dore et al., 2002; 
Verhoef et al., 2003; Pellicano et al., 





IBD, an intestinal disorder of 
unknown pathogenesis, is 
considered a multifactorial 
manifestation mainly 
resulting from a complex 
interaction between 
environmental factors and 
gut microbiota in genetically 
susceptible humans 
negative Buchner et al., 2011; Papamichael et 
al., 2014; Ruuska et al., 1994; Thia et 
al., 2008; Luther et al., 2010; Rokkas 
et al., 2015; Tursi, 2006; Guiney et al., 






manifestation of unknown 
etiology characterized by the 
spontaneous occurrence of 
itchy wheals lasting for at 
least 6 weeks 
positive Zuberbier et al., 2009; Magen et al., 
2014; Smyk et al., 2014; Testerman et 
al., 2014, Wong et al., 2014; 
Federman et al., 2003; Fukuda et al., 
2004; Magen et al., 2007; Akashi et 
al., 2011; Chiu et al., 2013 
rosasea chronic skin disorder 
characterized by persistent 
positive Rebora et al., 1994; Gürer et al., 2002; 
Powell, 2005 ; Argenziano et al., 2003; 
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central facial erythema Bakar et al., 2007; Mashimo et al., 
2006 
psoriasis autoimmune skin disorder 
characterized by increased 
proliferation and less 
differentiation of the 
keratinocytes in the 
epidermis 
positive Magen et al., 2014; Smyk et al., 2014; 
Testerman et al., 2014; Qayoom et al., 
2003; Ali et al., 2008; Martin Hübner 
et al., 2008, Onsun et al., 2012 
Behçet’s disease autoimmune multisystemic 
inflammatory vascular 
disorder featured by uveitis, 
skin lesions, genital ulcers 
and recurrent oral aphthous 
ulcers 
positive Magen et al., 2014; Avci et al., 1999; 
Pay et al., 2007 
ocular 
manifestations 
glaucoma progressive ocular 
neuropathy is caused by 
apoptosis of retinal ganglion 
cells, leading to 
modifications of the optical 
nerve and vision loss 
positive Kountouras et al., 2001; 2002; 2003; 
Zavos et al., 2012; Tsolaki et al., 2015; 
Ritch, 2007; Sacca et al., 2014; Davies 
et al., 1994 
central serous 
chorioretinopathy 
this visual impairment is 
caused by the leakage of 
fluid in the subretinal space 
as a result of the break-down 
of blood-retina barrier 
consisting of retinal pigment 
epithelium 
positive Wang et al., 2008; Casella et al., 2012; 
Giusti, 2004; Cotticelli et al., 2006; 
Casella et al., 2012; Dang et al., 2013; 






Sjögren syndrome chronic inflammatory 
autoimmune disorder 
characterized by lymphoid 
cell infiltration and 
destruction of endocrine 
glands, specifically lacrimal 
and salivary glands 
positive Hasni et al., 2011; Radic et al., 2014; 
Aragona et al., 1999; Showji et al., 
1996 
rheumatoid arthritis autoimmune inflammatory 
disorder with symmetric 
destructive polyarthritis 
negative Hasni et al., 2011; Radic et al., 2014; 
Showji et al., 1996; Tanaka et al., 






affecting multiple organ 
systems such as skin, joints, 
kidneys, brain, etc 
negative Showji et al., 1996; Sawalha et al., 
2004; Hasni et al. 2011, Radic et al., 
2014; Yamanishi et al., 2006 
 
4.1 PD: clinical outcome 
4.1.1. History and pathological findings 
PD was first described in 1817 by James Parkinson as the “shaking palsy”, a disorder characterized by tremor, 
muscle rigidity and poverty and slowness of movement (hypo- and bradykinesia) (Parkinson, 1817) and is the 
second most common neurodegenerative disorder in the current human population (Wirdefeldt et al., 2011; 
Mhyre et al., 2012). This neurological manifestation is characterized by a degeneration of the dopamine 
producing neurons in the pars compacta of the substantia nigra (in the basal ganglia of the brain) (Figure 7), 
thereby inducing dystrophic striatial projections (Wirdefeldt et al., 2011; Mhyre et al., 2012; Kannarkat et al., 
2013). Inflammatory processes, characterized by oxidative stress, accumulation of cytokines and activation of 
microglia cells, have been suggested to contribute to the degeneration of the nigrostriatal pathway and 
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accelerate the disease progression, especially in case of idiopathic PD, a syndrome of unknown etiology (Tansey 
et al., 2007; Dobbs et al., 2008). Indeed, neuro-inflammation was more pronounced in the pons, striatum, 
substantia nigra, and frontal and temporal cortical regions in patients with early PD compared to age-matched 
control patients (Gerhard et al., 2006), and chronic use of non-steroidal anti-inflammatory drugs (NSAID) has 
been suggested to lower the risk of PD development (Tansey et al., 2007). Additionally, PD is considered as a 
chronic neuro-inflammatory disorder characterized by the occurrence of Lewy bodies, which are mainly 
localized in the surviving neurons. Lewy bodies are formed by the accumulation of intracellular protein 
aggregates, comprised mainly of misfolded α-synuclein. They are identified as eosinophilic inclusion bodies in 
neurons (Gibb et al.,1988; McNaught et al., 2003; Wirdefeldt et al., 2011; Mhyre et al., 2012; Kannarkat et al., 
2013). Furthermore, an abnormal mitochondrial morphology, characterized by a long, thin appearance, has 
been observed within the enterocytes of the duodenum of PD patients, whereas impaired functionality has 
been reported in nigral and platelet mitochondria (Dobbs et al., 2008; Dobbs et al., 2016). Mitochondria are 
responsible for the production of ROS as a byproduct of molecular oxygen consumption in the electron 
transport chain. Additionally, these subcellular organelles are targets for cytokines, such as TNF, resulting in the 
overproduction of ROS by the mitochondria. Finally, cell death may occur as a result of oxidative stress, caused 
by the intracellular accumulation of ROS (Tansey et al., 2007). 
 
 
Figure 7: Comparison between a healthy substantia nigra and a diminished substantia nigra in PD, characterized by a loss of 
dopamine producing neurons.  
   
 
                                                                                                                          Review of the Literature 
 40  
 
 
4.1.2 Motor and non-motor symptoms 
This progressive neurodegenerative disorder leads to a broad spectrum of motor and non-motor symptoms. In 
general, PD-associated motor symptoms, such as resting tremor, muscle rigidity, brady-and hypokinesia and 
stooped posture are commonly known (Parkinson, 1817; Wirdefelt et al., 2011, Kannarkat et al., 2013). 
However, degeneration of the majority of the dopamine producing neurons (up to 80%) in the substantia nigra 
is a prerequisite for the development of motoric symptoms in PD patients (Kordower et al., 2013). In the 
majority of the patients (60-70%), resting tremor is the first indicative symptom for PD that appears. Generally 
the tremor has an unilateral and distal character (e.g. hand, fingers, foot, forearm), but over time it tends to 
expand to the contralateral upper limb or ipsilateral lower limb (Wirdefelt et al., 2011; Mhyre et al., 2012). 
Rigidity has a rather unilateral character and is generally more pronounced in the flexor muscles than in the 
extensor muscles. Bradykinesia is characterized by decreased moving speed in combination with slower 
response in movement changes and reduced fine motor skills. Hypokinesia is defined as a decreased frequency 
and amplitude of the movements, such as reduced stride length, reduced arm swing etc. The typical stooped 
posture of PD patients is still absent in early PD and is caused by changes in body position and gait as a result of 
the increased rigidity (Mhyre et al., 2012).  
This age-related disease has also been associated with other, non-motor symptoms: 30-40% of the PD patients 
are diagnosed with dementia, apathy, anxiety, psychosis and depression, 80-90% suffer from sleeping disorders 
and up to 90% of the PD patients display an altered olfactory perception (Mhyre et al., 2012). Autonomic 
disorders, including cardiovascular, gastrointestinal and genitourinary disorders, have also frequently been 
reported in PD patients. In 30-58% of the PD patients orthostatic hypotension can be detected as a result of 
cardiovascular autonomic dysfunction (Goldstein, 2006). Genitourinary disorders, such as bladder dysfunction, 
decreased libido and impaired sexual performances, have been described in 40-80% of the PD patients (Winge 
et al., 2006; Sakakibara et al., 2008; Mhyre et al., 2012). Upper gastrointestinal tract disorders, like 
oropharyngeal dysphagia and esophageal motility impairment, are generally present in up to 70% to 80% of the 
PD patients. A major complication of upper gastrointestinal tract dysfunction is food aspiration (25-30% of the 
patients), possibly resulting in aspiration pneumonia. Bloating, nausea and altered absorption of medication in 
PD patients is related to a delayed gastric emptying. Furthermore, compared to control patients the occurrence 
of infrequent bowel contractions, potentially leading to obstipation, megacolon and volvulvus, is clearly higher 
in patients suffering from PD. James Parkinson noted constipation as a feature in his essay (Parkinson 1817). In 
PD, frequency of defaecation diverges from that of controls three decades before the median age of 
neurological diagnosis (Charlett et al., 1997). Morphological and neurochemical changes of PD are found 
throughout the enteric nervous system and in dorsal vagal nuclei (Dobbs et al., 2008). Indeed, the presence of 
infrequent bowel movements is considered a risk factor for the development of PD (Abbott et al., 2001; Pfeiffer 
et al., 2003; 2011; Mhyre et al., 2012).  
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4.1.3 Incidence and prevalence 
Studies in the US and Europe have reported a PD incidence between 12-19 cases/100.000 inhibitants per year 
(Twelves et al., 2003; Hirtz et al., 2007). Pringsheim and colleagues showed that the prevalence of PD in 
patients between 70 and 79 years old differed strongly depending on the geographical region: in North-
America, Europe and Australia a prevalence of 1601 cases/100000 inhabitants has been reported, whereas a 
prevalence of 646 cases/100000 inhabitants has been reported in Asia. Furthermore, the same study observed 
that the prevalence of PD increased with age (Pringsheim et al., 2014). Another study reported that PD affects 
up to 1% of the population at 65-70 years of age, increasing to 4-5% of the population at the age of 85 (Fahn, 
2003). Since age is considered the single greatest risk factor for the development of PD and the life expectancy 
of Western population is generally increasing, the number of PD cases is expected to increase (Dorsey et al., 
2007). Compared to women, the prevalence of PD is 1.4 times higher in men (Twelves et al., 2003; Hirtz et al., 
2007; Wirdefelt et al., 2011).  
 
4.1.4 Etiology 
Up to date the exact etiology of PD remains undetermined, however it is considered a multifactorial disease in 
which both genetic and environmental factors can play a role (Wirdefelt et al., 2011; Mhyre et al., 2012; 
Kannarkat et al., 2013). In 5-10% of the PD patients, the disease is the result of specific gene mutations, such as 
mutations in the α-synuclein-encoding gene (PAK1/4, SNCA), in the Leucin-Rich Repeat Kinase 2 (LRRK2-) 
encoding gene (PARK8, LRRK2), in the parkin (PARK2) locus and the Phosphatase and Tensin Homolog (PTEN)-
induced Putative Kinase 1 (PINK1) encoding gene (Wirdefelt et al., 2011; Mhyre et al., 2012; Kannarkat et al., 
2013). Mutations in the α-synuclein encoding gene and the LRRK2 gene have been associated with dominantly 
inheritable parkinsonism, whereas mutations in PINK and parkin encoding genes have been associated with 
recessively inheritable parkinsonism (Tansey et al., 2007).  
The majority of the PD cases are classified as sporadic/idiopathic Parkinsonism (IP), since the etiology remains 
unknown. However, different studies have identified several lifestyle and environmental risk factors for the 
development of IP. Generally, a negative association between smoking and coffee drinking on the one hand 
and the development of PD on the other hand has been reported (Wirdefelt et al., 2011; Mhyre et al., 2012). 
Additionally, a negative correlation between the occurrence of PD and physical activity, alcohol consumption 
and dietary intake of antioxidants has also been suggested. However, further research is recommended to 
confirm these associations. Besides, protracted pesticide exposure and the consumption of dairy products are 
considered as risk factors for the development of PD (Wirdefelt et al., 2011). Interestingly, some studies have 
mentioned the positive association between PD and rural living, well water consumption and farming. 
However, these findings were not confirmed by other researchers (Wirdefelt et al., 2011). This association was 
initially declared by the repeated protracted exposure to agrochemicals (Wirdefeldt et al., 2011). However, a 
study in 2002 showed that the mortality from PD among farmers from 26 US states was clearly elevated among 
live-stock farmers, but was lower than in non-farmers and arable farmers (Lee et al., 2002). 
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4.2 Pathogenesis of PD: dysfunction of neural barriers 
In PD, neuro-inflammation is believed to contribute to neurodegeneration with activation of microglia, the 
residential macrophages of the central nervous system (Mhyre et al., 2012). Peripheral inflammation can 
activate microglia, in particular when the brain barriers are disturbed (Alvarez-Arellano et al., 2014). The brain 
is protected by four specialized brain barriers: the blood-brain barrier (BBB), the blood-cerebrospinal fluid 
barrier (blood-CSF barrier), the blood-retina barrier and the arachnoid barrier. These barriers determine what 
will (and what will not) enter the brain, and account for many physiological properties of their specific neural 
environments (De Bock et al., 2014). The focus in this PhD thesis lays on the BBB and the blood-CSF barrier. In 
the next section, information will be provided on these two neural barriers (BBB and the blood-CSF barrier) and 
their role in PD.  
 
4.2.1 Blood-brain barrier  
The BBB is located at the level of the capillaries of the CNS and is responsible for the regulation of the fluid 
exchange between the systemic blood circulation and the CNS. This neural barrier is formed by capillary 
endothelial cells and supported by surrounding astrocytes and pericytes (Figure 8), also referred to as the 
neurogliovascular unit (Ramsauer et al., 2002). Beside their supporting function of the endothelial cells, 
astrocytes play a role in the regulation of the expression of several tight junctions (Wolburg et al., 1994). 
 
Figure 8 : Illustration of the BBB, consisting of capillary endothelial cells, astrocytes and pericytes (adapted from De Bock et 
al., 2014). 
 
In order to prevent paracellular diffusion of different molecules, including toxic agents and cytokines from the 
systemic circulation to the brain, capillary endothelial cells are connected by tight junctions and adherens 
junctions (Figure 9) (Ek et al., 2006). Tight junctions, also referred to as zonulae occludentes (ZO), are formed 
by multiple transmembrane claudins in which occludin is incorporated (Furuse et al., 1998a, Furuse et al. , 
1998b). Claudin-3, -5 and -12 play an important role in the connection between the capillary endothelial cells at 
the BBB (Nitta et al., 2003; Wolburg et al., 1994; Coisne et al., 2011). In contrast, occludin, which mainly has a 
supportive function, is not strictly necessary for the formation of the tight junctions (Furuse et al., 1998b; De 
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Bock et al., 2014). The tight junctions are mainly anchored to the actin (Figure 9) of the cytoskeleton of the 
endothelial cells by ZO proteins, ZO-1 and ZO-2 (De Bock et al., 2014). The adherence junctions are mainly 
formed by transmembrane cadherin proteins. This calcium-dependent adhesion molecule is responsible for 
cell-cell contact and it can be associated with other γ-catenines, such as β-catenine. In turn these molecules are 
connected with the cytoplasm of the cell by α-catenin (Vleminckx et al., 1999; Corada et al., 1999; Ek et al., 
2006).  
 
Figure 9 : Illustration of the tight junctions and adherens junctions of the blood-brain barrier. The tight junctions are formed 
by multiple claudins in which occludin is incorporated. In turn, occludin and claudin interact with the actin cytoskeleton via 
adaptor proteins, including the zonulae occludens proteins. The adherence junctions are formed by transmembrane 
proteins belonging to the cadherin family and are linked to actin via the catenins. ZO: zonulae occludens; TJ: tight junction; 
AJ: adherence junction (adapted from De Bock et al., 2014). 
 
Disturbance of the BBB has been reported in patients suffering from PD (Stolp et al., 2009; Nielsen et al., 2012; 
Lee et al., 2014). Both local and systemic inflammation have been suggested to play a role in the increased 
permeability of the BBB. As a result of signaling through the endothelial cells, several locally or systemically 
produced cytokines, such as Il1-β, Il-6 and TNF-α, may cause alterations in the tight junction structure, thereby 
inducing an increased BBB permeability. The increased BBB permeability along with elevated levels of cytokines 
and inflammatory mediators, such as ROS, may cause neuro-inflammation and oxidative stress, leading to 
further BBB disruption and brain damage (Stolp et al., 2009; Lee et al., 2014). Furthermore, migration of white 
blood cells through the BBB as a result of the central inflammatory response has been suggested as well (Stolp 
et al., 2009).  
 
4.2.2 Blood-cerebrospinal fluid barrier  
The blood-CSF barrier is established by the single epithelial cell layer in the choroid plexus and is present in all 
four brain ventricles (Chodobski et al., 2001). The blood-CSF barrier is located between the CSF and the 
fenestrated capillaries of the choroid plexus (De Bock et al., 2014; Mortazovi et al., 2014). The cubical choroid 
plexus epithelial cells (CPEs) possess multiple microvilli and cilia at their apical side and a well perfused 
extracellular matrix, consisting of connective tissue in combination with collagen, fibroblasts, macrophages and 
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dendritic cells, at their basal side (Figure 10) (Dohrmann et al., 1970; Mortazavi et al., 2014). They are the main 
producers of CSF (Cushing, 1914) and the remaining 10-30% of the CSF volume originates from the interstitial 
fluid in the brain (Cserr et al., 1986). The CSF is responsible for the transportation of necessary nutrients and 




ventricle to the 
subarachnoid space of the brain (Chodobski et al., 2001). Additionally, the choroid plexus participates in the 
elimination of harmful substances and degradation products in the CSF (Coisne et al., 2011) and plays an 
important role in the communication between the peripheral immune system and the CNS. Indeed, after 
leakage from the fenestrated capillaries, B cells, T cells and monocytes are able to migrate from the choroid 
plexus into the brain via specific transport mechanisms (Provencio et al., 2005; Meeker et al., 2012; 
Demeestere et al., 2015). Inflammation has already been linked with increases in the transport of these 
immune cells, resulting in a higher number of immune cells in the CSF (Vercellino et al., 2008). Furthermore, an 
upregulation of the expression of cytokines and inflammatory mediators has been reported in case of systemic 
inflammation (Kim et al., 2012; Vandenbroucke et al., 2012). Indeed, there is evidence that peripheral/systemic 
inflammation influences the pathophysiology of PD. In PD patients, there are gradients of objective measures 
of PD facets on serum cortisol and TNF-α, and of clinical motor scores on peripheral blood mononuclear cell 
production of cytokines and NF-κB expression (Charlett et al. 1998; Dobbs et al. 1999; Reale et al, 2009). Serum 
cortisol is elevated (17%) in PD, as is IL-6. Moreover, in a prospective study, a higher concentration of IL-6, in 
blood collected 4 years previously, predicted incident PD (Chen et al. 2008). There are also gradients of 
objective measures of facets of PD on blood leucocyte subtypes counts (Dobbs et al, 2012). Both 
brady/hypokinesia and flexor rigidity are worse the higher the NK count. 
 
Figure 10 : Illustration of the blood-cerebrospinal fluid barrier formed by the choroid plexus epithelial cells. These cells form 
a barrier between the CSF and the fenestrated capillaries of the stroma of the choroid plexus and they are localized in all 
four brain ventricles. CP: choroid plexus; ISF: interstitial fluid; CSF: cerebrospinal fluid; BBB: blood-brain barrier (adapted 
from De Bock et al., 2014). 
ependymal cells 
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Like the endothelial cells in the BBB, the CPEs are inter connected by a network of tight junctions. Together 
they allow the strict regulation of transport through the blood-CSF barrier (De Bock et al., 2014). Whereas 
claudin-3, -5 and -12 are important in the BBB, the main tight junction proteins expressed in the blood-CSF 
barrier are claudin-1, -2, -3 and -11. Claudin-2 in necessary for the formation of paracellular water channels 
(Rosenthal et al., 2010; Kratzer et al., 2012). As for the BBB, the transmembrane claudins are connected to the 
cytoskelet of the cells via the ZO-1 and ZO-2 proteins (De Bock et al., 2014). Since the barrier formed by the 
choroid plexus cells is less tight compared to the BBB, the blood-CSF barrier is more susceptible to systemic 
alterations and inflammation and thereby this neural barrier is strongly subjected to immunologic influences 
(De Bock et al., 2014). 
PD has also been associated with an increased permeability of the blood-CSF barrier (Vawter et al., 1996; Pisani 
et al., 2012). Significantly elevated levels of transforming growth factor beta (TGF-β) were demonstrated in the 
CSF of PD patients compared to controls. The same study suggested that some of the TGF-β in the CSF 
emanated from the plasma as a result of leakage (Vawter et al., 1996). Another study reported a significant 
increase in the albumin ratio (CSF albumin/serum albumin) in advanced-stage PD patients, compared to early-
stage PD patients and healthy controls (Pisani et al., 2012).  
 
4.3 Involvement of a H. pylori infection in PD: what is known so far? 
As already mentioned above, the association between PD and gastrointestinal complaints has been suggested. 
Constipation, resulting from infrequent bowel movements and slow gut-transit (Abbott et al., 2001; Dobbs et 
al., 2016), has been described as one of the most common co-morbidities in PD patients (Parkinson, 1817; 
Dobbs et al., 2016). Schwab and colleagues were the first to propose the association between PD and the 
presence of gastric and duodenal ulcers (Schwab et al., 1961). In 1965, this was confirmed by Strang who 
reported an excess of previously diagnosed peptic ulcers in PD (Strang, 1965). Subsequently, the speculation 
that an infectious agent might be involved in both PD and peptic ulcers was suggested (Szabo, 1979). After the 
discovery of H. pylori in the stomach of human patients suffering from gastritis and peptic ulcers in 1984 
(Warren and Marshall, 1984), Altschuler and collegues were the first to explicitly suggest the causal link 
between PD and H. pylori (Altschuler et al., 1996). Ever since, the association between IP and an infection with 
H. pylori has been described by multiple other authors (Dukowicz et al., 2007; Nielsen et al., 2012; Dobbs et al., 
2008; Dobbs et al., 2012; Tan et al., 2015; Csoti et al., 2016; Dobbs et al., 2016; Tan et al., 2015).  
Up to date, a high prevalence of H. pylori infections has been reported in PD patients (Rees et al., 2011; Nielsen 
et al., 2012). Additionally, H. pylori seropositivity was 3 times more likely to occur among PD patients compared 
to control patients (Brady et al., 1998; Charlett et al., 1999). The same study showed that, compared to a 
control group, siblings of PD patients were more likely to be H. pylori seropositive and present Parkinson-like 
symptoms, such as brady/hypokinesia of gait, bradykinesia of hands, abnormal posture and rigidity (Brady et 
al., 1998; Charlett et al., 1999). Furthermore, compared to age-matched control patients, an increase of the 
level of H. pylori antibodies was reported in a group of patients (younger than 80 years) displaying Parkinson-
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like symptoms (Dobbs et al., 2000). Another study described that the odds of parkinsonism increased fivefold 
(up to the age of 80) in case of CagA-positivity in combination with VacA negativity and urease B negativity 
(Weller et al., 2005). Moreover, increased numbers of natural killer cells have recently been associated with 
shorter stride, slower gait and elevated flexor rigidity in patients suffering from PD (Dobbs et al., 2012). 
Interestingly, the same study described higher numbers of natural killer cells in case of urea-breath test 
positivity as well as additional reduction in stride and speed in H. pylori-positive PD patients (Dobbs et al., 
2012).  
H. pylori eradication therapy, consisting of 20 mg omeprazole, 500 mg clarithromycin and 1 g amoxicillin, 
resulted in the improvement of the stride length in PD patients (Bjarnason et al., 2005; Dobbs et al., 2010). 
Despite a worsening of the upper limb flexor rigidity, an overall improvement of PD-related symptoms, 
irrespective of anti-parkinsonian medication, could be observed after biopsy-proven successful eradication of 
H. pylori in PD patients (Dobbs et al., 2010). Clarithromycin and/or amoxicillin were replaced by administration 
of 500 mg tetracycline and/or 400 mg metronidazole in case of in vitro resistance of H. pylori isolates (Dobbs et 
al., 2010; Dobbs et al., 2013).  
Furthermore, H. pylori eradication therapy in patients suffering from PD resulted in an improved response to 
the administration of L-3,4-dihydroxyphenylalanine (levadopa) in combination with an amelioration of motor 
symptoms and life quality. Levadopa, which is mainly absorbed in the duodenum, is used as treatment of PD, as 
it is a precursor of dopamine. Since H. pylori infections may induce a disruption of the gastrointestinal mucosa 
(Hashim et al., 2014; Caron et al., 2015), an infection with this bacterium may thus interfere with the 
absorption of levadopa, resulting in decreased plasma levels of levodopa and thereby in a faster progression of 
PD-related symptoms (Pierantozzi et al., 2001; Fasano et al., 2013; Hashim et al., 2014). However, Dobbs et al. 
(2005) did not find any major differences in hypokinesia improvement following biopsy-proven H. pylori 
eradication between PD patients receiving levadopa and PD patients who were never treated with levodopa, 
suggesting that the effect on hypokinesia was not due to improved absorption of levodopa as a result of H. 
pylori eradication. 
Several hypotheses have been proposed to declare the association between PD and H. pylori: it has been 
suggested that a chronic infection with H. pylori results in acquired immune suppression by the continuous 
antigenic stimulation from H. pylori infection in combination with increased circulating IL-6, thereby leading to 
autoimmunity (Dobbs et al., 2000). Another hypothesis is that there might be molecular mimicry between 
antigens from humans and H. pylori. Possible candidates are the heat shock proteins (hsp), which appear to be 
highly conserved from bacteria to mammals. Indeed, hsp60 antibodies have been detected in both H. pylori-
positive patients and PD patients (Dobbs et al., 2000).  
In conclusion, these data suggest that gastric infections with H. pylori might be associated with PD. In contrast, 
no information is currently available on whether there might be a possible link between PD and H. suis 
infections in human patients. Further research is required to obtain more information on the role of gastric 
Helicobacter infections in PD.  
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Helicobacter pylori (H. pylori) is considered to be the most important pathogen involved in gastric disease in 
humans. Besides causing inflammation and lesions in the stomach, infection with this agent has also been 
linked to extragastric manifestations, including brain disorders (Holtmann and Talley, 2014). Gastric pathologies 
in humans have, however, also been associated with spiral-shaped, gastric Helicobacter species different from 
H. pylori (non-H. pylori helicobacters (NHPH)). H. suis, an organism with a corkscrew-like morphology that 
naturally colonizes the stomach of pigs and non-human primates, is considered to be the most prevalent NHPH 
in humans. The role of gastric bacteria, other than H. pylori, in brain functionality is largely unknown. There is, 
however, a case report suggesting that infections with H. suis might also be associated with Parkinson’s disease 
(PD) (Dobbs et al., 2005).  
 
Therefore, the general aim of this thesis was to evaluate if and how a gastric infection with H. suis might be 
linked to PD in human patients.  
Since it became clear during these studies that the current diagnostic tests used for detection of H. suis 
infections suffered from severe shortcomings, an additional aim of the thesis was to improve diagnostic assays.  
 
It has been reported that an H. pylori infection might be associated with PD. Overall in idiopathic parkinsonism 
(IP), successful H. pylori eradication was shown to improve brady/hypokinesia. A poorer response was seen in 
the anti-nuclear antibody seropositive, who may have had residual Helicobacter, undetected by culture and 
PCR. Overt failure was accompanied by marked deterioration. Apart from H. pylori infections, IP has also been 
associated with rural-living and farm-experience, especially live-stock farm-experience. To determine whether 
there might be an association between PD and H. suis infections in humans, the first specific aim of this thesis 
was to compare the prevalence of H. suis in gastric biopsies between patients suffering from IP and controls.  
 
In our first study we showed that the frequency of H. suis was significantly higher in IP patients compared to 
control patients. However, it remained unclear if an infection with this gastric microorganism might play a role 
in aethiopathogenesis. The brain is protected from alterations in the systemic circulation by several specialized 
neuro-epithelial barriers, such as the blood-brain barrier and the blood-cerebrospinal fluid (CSF) barrier, that 
determine what will (and what will not) enter the brain. Dysfunction of these brain barriers has been 
implicated in the pathogenesis of PD. It has been suggested that systemic inflammation could play an 
important role in the onset of neurodegenerative disorders: it might be accompanied by barrier disruption 
associated with immune/inflammatory mediators. Since gastric Helicobacter infections have been proposed to 
be associated with systemic inflammation, the second specific aim of this thesis was to evaluate whether and 
how a H. suis infection could have an impact on the brain homeostasis. 
 
In order to determine the importance of an H. suis infection in gastric and extragastric disorders in human 
patients, accurate diagnostic methods for the specific detection of H. suis in gastric biopsies are required. 
Currently, the diagnosis of infections with this spiral-shaped bacterium is hampered by its fastidious nature, the 
low colonization density and the patchy distribution of H. suis in the human stomach. Additionally, when using 
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the conventional ureA-based SYBR green RT-PCR for the detection of H. suis infections, non-specific 
interactions with host DNA and DNA from other Helicobacter spp. may occur, as was noticed during our first 
study. Thus, the third specific aim of this thesis was to optimize the currently used methods for demonstration 
of H. suis in the stomach. We first developed and validated a new, probe-based RT-PCR that allowed detection 
and quantification of H. suis in gastric tissue samples. Secondly, a mouse-passage-based protocol was 
optimized for the isolation of low numbers of H. suis bacteria.  
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Abstract 
Background: There is increased proportional mortality from Parkinson’s disease (PD) amongst livestock 
farmers. The hypokinesia of Parkinson’s disease has been linked to Helicobacter pylori (H. pylori). Helicobacter 
suis (H. suis) is the most common zoonotic Helicobacter in man. 
Aims: To compare the frequency of H. suis, relative to H. pylori, in gastric biopsies of patients with idiopathic 
parkinsonism (IP) and controls from gastroenterology services. 
Methods: Coded DNA extracts, archived at a Helicobacter Reference Laboratory, from IP patient and 
gastroenterology service biopsies were examined for H. suis, using species-specific RT-PCR. 
Results: Relative risk of having H. suis in 60 IP patients compared with 256 controls was 10 times greater than 
that of having H. pylori. In patients with IP and controls, respectively, frequencies of H. suis were 27 (exact 
binomial 95% C.I. 15, 38) and 2 (0, 3)%, and of H. pylori, 28 (17, 40) and 16 (12, 21)%. Excess of H. suis in IP held 
when only the antral or corporal biopsy was considered. Of 16 IP patients with H. suis, 11 were from 19 with 
proven H. pylori eradication, 3 from 17 pre-H. pylori eradication, 2 from 24 H. pylori culture/PCR negative. 
Frequency was different between groups (P = 0.001), greatest where H. pylori had been eradicated. Even 
without known exposure to anti-H. pylori therapy, H. suis was more frequent in IP patients (5/41) than in 
controls (1/ 155) (P = 0.002). Partial multilocus sequence typing confirmed that strains from IP patients (6) and 
control (1) differed from RT-PCR standard strain. 
Conclusions: Greater frequency of H. suis in idiopathic parkinsonism appears exaggerated following H. pylori 
eradication. Multilocus sequence testing comparison with porcine strains may clarify whether transmission is 
from pigs/ porcine products or of human-adapted, H. suis-like, bacteria. 
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INTRODUCTION  
The broad brush of epidemiology has provided enigmatic aetiopathogenic clues in Parkinson’s disease (PD). It 
has been linked, albeit inconsistently, with rural living and farm experience (Wirdefeldt et al., 2011). Such 
associations have long been explained away by putative exposure to agrochemicals. However, a mortality study 
in 26 US states found increased proportional mortality from PD among livestock, but not arable, farmers (Lee et 
al., 2002). From a total of 6 million death certificates, 267479 decedents were classified as either crop or 
livestock farmers. Amongst white males, the proportional mortality from PD was significantly higher in livestock 
farmers than in non-farmers, but lower in crop farmers. Zoonotic infections were considered as an explanation, 
but it was noted that the pesticides used in animal infestations are different from those used on crops. These 
effects were not replicated in the much smaller numbers of White female or of African American decedents. 
The 1965 finding of prodromal peptic ulcers in PD (Strang, 1965) paved the way to exploring any link between 
(the then undiscovered) Helicobacter pylori (H. pylori) and PD (Dobbs et al., 2008; 2012; 2010; 2013). The 2012 
Maastricht IV Consensus Report (Malfertheiner et al., 2012) acknowledges interesting associations. In a 
randomised placebo-controlled trial, we found that biopsy-proven H. pylori eradication had differential effects 
on objective measures of PD facets: improvement in hypokinesia and worsening rigidity over the year post-
eradication, both plateauing over the next year (Dobbs et al., 2010). Overall, there was clinically relevant 
improvement. This was independent of any (stable, long t½) anti-parkinsonian medication. Receipt of levodopa 
was an exclusion. Moreover, the effect on hypokinesia was indication-specific (Dobbs et al., 2013). A 
longitudinal observational study confirmed improvement in hypokinesia following H. pylori eradication. Anti-
microbials for other indications had no such effect, but successive courses were associated with cumulative 
increase in rigidity. 
Could, then, zoonotic-transmission of gastric non-H. pylori Helicobacter species (NHPH) contribute to PD? The 
term NHPH represents a group of closely related, but distinct, bacterial species found in different animal 
species, such as H. suis in pigs, and H. felis, H. salomonis, H. bizzozeronii, H. heilmannii sensu stricto, H. 
cynogastricus and H. baculiformis in cats and dogs (Haesebrouck et al., 2009). Although infection with these 
bacteria has been associated with human gastric disease in a substantial number of patients (Debongnie et al., 
1995; Morgner et al., 1995; Stolte et al., 1997; Trebesius et al., 2001; O’Rourke et al., 2004; Van den Bulck et 
al., 2005; Joosten et al., 2013), human NHPH strains have been isolated on only three occasions (Andersen et 
al., 1996; Kivisto et al., 2010; Wüppenhorst et al., 2013). Subsequent identification to species level has revealed 
these to be H. bizzozeronii in two cases (Kivisto et al., 2010; Javala et al., 2001) and H. felis in the other 
(Wüppenhorst et al., 2013). Based on histopathology of gastric biopsy, the prevalence of NHPH in patients with 
gastric disease has been estimated at between 0.2% and 6%, depending on geographical distribution (Stolte et 
al., 1997). Several studies have demonstrated that H. suis is the most frequent NHPH species in humans 
(Haesebrouck et al., 2009; Trebesius et al., 2001; Van den Bulck et al., 2005). However, its in vitro culture, 
starting from human gastric mucosa, has been unsuccessful so far, underlining the extreme fastidiousness of 
gastric NHPH in general and H. suis in particular.  
We report the frequency of H. suis DNA in archived DNA extracts from gastric biopsies in a group of PD patients 
and a group of gastroenterology patients, as part of a service evaluation. The relative prevalence of H. pylori 
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immunoblot seropositivity in people with and without PD (37% and 31% respectively) has been reported 
(Charlett et al., 2009). Here, we standardise the frequency of H. suis positivity against that recorded for H. 
pylori (culture, or if negative, PCR), in order to compare the two sets of archived DNA extracts. 
 
METHODS 
Service evaluation  
The term ‘H. heilmannii’ was commonly used to describe spiral gastric helicobacters seen on histopathology. 
The diagnostic service of the Gastrointestinal Reference Unit, Public Health England, for PCR detection of ‘H. 
heilmannii-like organisms’ in gastric biopsy material (Chisholm et al., 2003) was re-evaluated, using coded 
archived DNA extracts. As H. suis is the commonest reported NHPH in humans and a species-specific assay is 
now available (O’Rourke et al., 2004), it is a good starting point for evaluating whether NHPH cases are being 
missed. Interestingly, the original ‘H. heilmannii’ assay was set up in response to a case of a spiral Helicobacter 
in PD (Dobbs et al., 2005). 
Sourcing coded DNA extracts  
The Helicobacter Reference Laboratory in the Gastrointestinal Bacteriology Reference Unit, Public Health 
England, held DNA from gastric biopsies, extracted (at time of receipt) over the last decade, stored at -80 °C. 
Biopsies had been received with request for Helicobacter culture (isolation/identification/anti-microbial 
susceptibility) and, if biopsy culture-negative, detection of H. pylori-specific DNA. Culture-negative biopsies had 
been tested using a PCR targeting 16S rRNA (primer pair HP1⁄HP2) (Ho et al., 1991) and vacA 
(Vac3624F⁄Vac3853R) (Chisholm et al., 2001) genes. To detect ‘Helicobacter heilmannii-like organisms’ a 16S 
rRNA assay had been used (Chisholm et al., 2003). For the service evaluation, archived DNA extracts, identified 
only by their accession number, were couriered to the Laboratory of Veterinary Bacteriology and Mycology, 
Ghent University. All extracts archived over this decade (paired antral and corporal biopsies) from 60 patients 
with ‘clinically definite’ idiopathic parkinsonism (IP) (Calne et al., 1992), diagnosed at a National clinic, were 
retrieved. Clinically definite IP refers to any combination of three of the four cardinal features: resting tremor, 
rigidity, brady/hypokinesia, impaired postural reflexes. Alternatively sufficient is having two of the features, 
with one of first three asymmetrical (Responsiveness to a dopaminergic drug challenge was not a requirement). 
Details of anti-microbials used in any previous anti-H. pylori treatment (19/60) had been recorded on the 
request form. 
DNA extracts from biopsies originating from English gastroenterological services, selected for attention to 
documenting any exposure to anti-Helicobacter therapy on the request form, were used as ‘controls’. This 
criterion yielded extracts from 256 patients, archived over a similar period (single biopsy on given occasion 
except in four, where two sites sampled). There had been previous exposure to anti-Helicobacter therapy in 
101, no recorded exposure in the rest. No request form mentioned Parkinson’s disease, or any other issues 
outside the context of diagnostic endoscopy. Crude prevalence rate estimates for PD in 34 European studies 
range widely, from 65.6 to 12500 per 100000 (von Campenhausen et al., 2005): that is, 0–32 diagnosed cases 
would be expected in the gastroenterological services’ patient group, even if they had no particular 
predisposition. 
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Frequencies of Helicobacter species reported here are not construed as prevalence: there is selection in the 
controls (for adequate documentation by above criterion) and of IP patients (for a clinic with particular interest 
in the gastroenterological aspects of PD). Any direct estimate of association between presence of H. suis and 
PD could be biased by cohort selection. We therefore obtain an estimate of the risk of H. suis in patients with IP 
compared with those from gastroenterological services by standardizing for the relative risk of having H. pylori, 
and by setting H. suis frequency in context of exposure to anti-Helicobacter therapy. No analysis of the 
relationship of H. suis status to gastric symptoms was planned: the request form did not contain a checklist. 
H. suis detection  
The presence of H. suis DNA in the extracts was determined using a H. suis-specific quantitative real time (RT)-
PCR, based on the ureA gene. For generating the standard, part of the ureAB gene cluster (1236 bp) from H. 
suis strain HS5 was amplified using primers U430F and U1735R, as described previously (O’Rourke et al., 2004). 
The standard consisted of 10-fold dilutions, starting at 10
8
 PCR amplicons, for each 9 µL of reaction mixture. 
One microliter of extracted DNA template was added to 9 µL reaction mixture, consisting of 0.25 µL of both 
primers located within the 1236 bp fragment (to yield a 150 bp PCR product), 3.5 µL HPLC water and 5 µL 
SensiMixTM SYBR No-ROX (Bioline Reagents Ltd, London, UK). Sense primer was BF_HsuisF1: 5′-AAA ACA MAG 
GCG ATC GCC CTG TA-3′. Anti-sense primer was BF_HsuisR1: 5′-TTT CTT CGC CAG GTT CAA AGC G-3′. Annealing 
temperature was 62 °C. Both standards and samples were run in duplicate on a CFX96TM RT-PCR System with a 
C1000 Thermal Cycler (Bio-Rad, Hercules, CA, USA). To confirm the presence of H. suis DNA, all positive samples 
were sequenced (Joosten et al., 2013). All 413 available extracts (including replicate biopsies at a given time 
and any follow-up biopsies) were assayed on two separate occasions to estimate between-assay agreement. To 
demonstrate that the H. suis DNA in the biopsy extracts was different from the H. suis strain HS5 DNA used as 
standard in the RT-PCR, multilocus sequence typing (MLST) was performed with seven housekeeping genes, as 
previously described (Liang et al., 2013). 
Statistical analysis  
Use of exact binomial confidence intervals provided an estimate of the uncertainty in estimates of proportions. 
The risk ratio, risk of having H. suis in IP patients to that in controls compared with relative risk of having H. 
pylori, was estimated from the paired data on the two species, using a conditional Poisson regression with 
robust standard errors (Cummings, 2011). 
 
RESULTS 
The distribution of age at time of first biopsy in controls [mean 52 (data interval 24, 81) years] encapsulated 
that in the IP patients [62 (45, 79) years]. There was no significant difference in the proportion of male patients: 
57% of the IP patients were male (34/60), 47% (120/256) of the controls. Overall agreement (99.3%) between 
the two H. suis RT-PCR assay runs on separate occasions was strong (n = 413, Kappa = 0.95, P < 0.001: null 
hypothesis of no agreement rejected) and there was no significant difference between the first and second run 
{exact McNemar’s test, ratio of paired proportions 1.11 [95% confidence interval (CI) 0.99, 1.24], P = 0.25}. 
Thirty-one of the 413 extracts were positive in either run, 28 in both. Nucleotide sequencing of positive 
samples, and subsequent Basic Local Alignment Search Tool (BLAST) analysis, revealed 95–100% homology with 
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known H. suis strains. The frequency of detection of H. suis and H. pylori in the extract(s), held in the archive 
from the 60 IP patients and 256 controls, is shown in Table 1. In patients biopsied on more than one occasion, 
only the first occasion is considered. Overall, H. suis DNA was present in 27 (binomial exact 95% CI 15, 38)% of 
the IP patients and in 2 (0, 3)% of controls. It was present in 18 (10, 30)% of antral biopsies and 13 (6, 25)% of 
corporal biopsies from IP patients. Thus, the excess H. suis frequency was not an artefact due to sampling both 
regions in IP, but only one region (46% antral, 1% corporal, 2% duodenal, rest ‘gastric’) in all but four controls 
(2 had antral and corporal biopsies, 1 antral and duodenal, in 1 both were labelled ‘gastric’). 
Table 1: Frequency of H. suis contrasted with H. pylori in gastric biopsy DNA extracts from IP patients and 
controls with and without known exposure to anti-H. pylori therapy. 
 
Frequency 
IP patients % (no. with 
species/total) 
Controls % (no. with 
species/total) 
H. suis  
  Previous exposure to anti-H. pylori 
therapy 
58 (11/19)* 3 (3/101) 
No known exposure  12 (5/41)# 1 (1/155) 
Total 27 (16/60)** 2 (4/256)** 
H. pylori 
  
Previous exposure to anti-H. pylori 
therapy 
0 (0/19) 22 (22/101) 
No known exposure  41 (17/41) 13 (20/155) 
Total 28 (17/60) 16 (42/256) 
*: Anti-microbial prescription was guided by in vitro sensitivities:- Of the 11 with H. suis, 10 had received 1 week of 
amoxicillin, clarithromycin and proton pump inhibitor (PPI) (1 a further course of metronidazole, tetracycline, PPI and 
tripotassium dicitratobismuthate when he remained urea breath test-positive) and 1 had received 1 week of clarithromycin, 
tetracycline and PPI. Of 8 without H. suis, 7 had received 1 week of amoxicillin, clarithromycin and PPI and 1 had received 1 
week of clarithromycin, tetracycline and PPI.  
#: Three extracts also positive for H. pylori. 
**: Mean age (gender) of the 16 IP patients with H. suis was 58 (range 47–68) years (10 male, 6 female), of the 4 controls, 
54 (43–64) years (1 male, 3 female). 
 
The relative risk of having H. suis in IP patients compared with controls was 9.9 times greater than that of 
having H. pylori {i.e. [(16/60)/(4/256)]/[(17/60)/(42/256)] = 17.07/1.73}. The 95% confidence interval (3.0, 32.7) 
did not include 1, indicating that the two relative risks are significantly different. This was despite a higher 
frequency of H. pylori in IP patients [28 (binomial exact 95% C.I. 17, 40)%] than in controls [16 (12, 21)%]. Of the 
16 IP patients with H. suis, 11 were from the 19 with proven H. pylori eradication, 3 from the 17 pre-H. pylori 
eradication and 2 from the 24 who were H. pylori-negative. Frequency of H. suis detection differed significantly 
among these three groups (Fisher’s exact test, P = 0.001), being greatest in those who had undergone anti-H. 
pylori therapy than in the remainder. There was no significant difference in the anti-H. pylori regimen 
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(clarithromycin/amoxicillin/proton pump inhibitor or other: footnote Table 1) between those with and without 
H. suis in its aftermath. Even in those without known previous exposure to anti-H. pylori therapy, H. suis was 
more frequent in IP patients (5/41) than in controls (1/155) (P = 0.002). The low frequency of H. suis in the 256 
controls precluded estimation of any increased risk with exposure to anti-H. pylori therapy. Partial MLST results 
for the H. suis DNA found in extracts from 6 IP patients and 1 control are shown in Table 2. The allele pattern in 
these samples differed from that in the HS5 DNA standard: that is, the sample results were not due to 
contamination. It was not possible to obtain complete MLST sequence types, due to interference from human 
DNA and the low amount of H. suis DNA found in some extracts. None of the samples had been reported as 
positive for ‘Helicobacter heilmannii-like organisms’ on the original assay 16S rDNA assay. 
 
Table 2: Partial H. suis MLST results on DNA extracts from gastric biopsies of IP patients and a control 
  Allele no. 
DNA extract atpA efp mutY ppa trpC ureAB yphC 
IP patient 1 4   11         
IP patient 2   1           
IP patient 3           1   
IP patient 4   1 11         
IP patient 5     5     1 1 
IP patient 6   1 5         
Control patient   1 1     1   
HS5* 4 2 4 1 1 1 1 
*: positive control in the quantitative RT-PCR assays. 
 
DISCUSSION 
Relative frequency of H. suis in IP  
The frequency of finding H. suis DNA in extracts from gastric biopsies in a well-defined disease state, clinically 
definite IP, contrasts sharply with the apparently ‘sporadic’ nature in patients from gastroenterological services 
undergoing diagnostic endoscopy. The statistical significance of the finding withstood standardization for the 
relative frequency of H. pylori in the two patient groups. However, defining the strength of association 
between presence of H. suis DNA in gastric biopsies and PD will clearly require representative cohorts of IP 
probands and controls. As human infection with NHPH is characteristically sparse and patchy (Stolte et al., 
1997), we may be underestimating the true frequency of H. suis in both patient groups. There are no previous 
studies of the frequency of NHPH in PD for comparison. 
Proposed pathophysiological role of Helicobacter species in IP  
The concept of ‘brain-altering’ remote infections is receiving increasing attention. Neuro-inflammation in IP 
may not merely be the adverse effect of microglial scavenging of degenerating neurons and reaction to 
aberrant protein (Tansey et al., 2007; Zipp et al., 2006). If PD is driven by systemic immuno-inflammatory 
processes (Dobbs et al., 2008; 2012), intervention against them, or their driving forces, could modify its course 
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(Dobbs et al., 2013; Malfertheiner et al., 2012). A U-turn in brady/hypokinesia and weight gain was described 
after eradicating a spiral Helicobacter, associated with antral gastritis, in a cachectic IP patient, who had been 
wheelchair-bound without assistance for over a year (Dobbs et al., 2005). The aetiopathogenic significance of 
zoonotic helicobacters in IP remains to be explored. Finding clinical correlates (e.g. epidemiological, such as 
mortality, and pathophysiological, such as circulating inflammatory markers) would suggest that H. suis DNA in 
gastric mucosa is of significance in IP. Autoimmunity is suggested as the mechanism of the effect of H. pylori 
eradication on hypokinesia (Dobbs et al., 2008; 2010; 2012). Response appears unrelated to infection load. 
Poor response is associated with anti-nuclear antibody seropositivity. There are HLA-DR risk loci for PD. If NHPH 
eradication has a similar effect, then the immune hypothesis could move to a pattern recognition response 
rather than classical HLA-restricted autoimmunity. 
Optimizing diagnosis of human H. suis infection  
Diagnosing NHPH in IP is problematic. Our experience is that the urea breath test is usually negative, except 
where H. pylori co-exists. A serological test for H. suis would provide a useful screen for infection, or any 
memory of it, in potentially high-risk patient or occupational groups, but none is currently available. The 16S 
rDNA assay for ‘Helicobacter heilmannii-like organisms’ (Chisholm et al., 2003) did not detect the H. suis found 
on RT-PCR. It may, in part, be a question of sensitivity. Helicobacter heilmannii-like DNA (Chisholm et al., 2003) 
had been detected in a urea breath test-positive case (Dobbs et al., 2005): re-evaluation by the methodology 
used here showed this to be H. suis. There appears to be advantage in taking more than one biopsy to 
determine NHPH status by molecular microbiology. Low infection load (Stolte et al., 1997) will hamper 
histological confirmation. Sensitivity and specificity of the RT-PCR will need to be determined for introduction 
into routine clinical use. This is not as problematic for H. suis as for other NHPH, since it is the only gastric 
Helicobacter isolated from pigs in Europe, where infection is very common and load high. The gold standard of 
seeing spiral gastric helicobacters, in a histological section adjacent to the biopsy for DNA extraction, can be 
applied. Greater frequency of H. suis in IP where H. pylori has been eradicated points to need for post-
treatment endoscopic biopsy. New infection in a particularly susceptible host cannot be excluded, although 
adult transmission of another gastric Helicobacter, H. pylori, is unusual. It is likely that the IP patients were co-
infected with H. pylori and H. suis prior to eradicating H. pylori, and H. suis filled the niche afterwards. Indeed, 
susceptibility testing of isolates from sows suggests relative intrinsic insensitivity to amoxicillin and 
metronidazole, greater intrinsic susceptibility to tetracycline (Vermoote et al., 2011). Current use of 
tetracycline in first-line treatment strategies is limited (Malfertheiner et al., 2012). Information on in vitro anti-
microbial susceptibility of H. suis in man is needed. 
Transmission of H. suis  
Contact with pigs is a risk factor for human gastric H. suis infection (Meining et al.,1998). It was demonstrated, 
using MLST, that a H. suis strain from the stomach of a pig veterinarian with gastric complaints was closely 
related to porcine strains (Joosten et al., 2013). This illustrates the zoonotic potential of this species: direct 
contact with pigs can be a source for human H. suis infection. Moreover, H. suis can be present, and survive, in 
minced pork (De Cooman et al., 2013): raw or undercooked porcine products might be another source of 
infection. Complete MLST sequence types were not obtained for any of the H. suis strains from patients, 
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precluding comparison with sequence types present in pigs. Although all alleles of the housekeeping genes 
detected in patients have been found in pig H. suis strains (Liang et al., 2013), the patients’ strains could be H. 
suis-like, human-adapted bacteria. Isolation of strains from patients’ stomachs could throw light on their origin. 
Challenges are the fastidious nature of H. suis, and obtaining fresh human biopsies from infected mucosa, 
where infection is not confluent and biopsies are small, non-targeted and limited in number (Haesebrouck et 
al., 2009). Horizontal and/or vertical transmission of NHPH might contribute to explaining the epidemiology of 
IP. Whilst we do not know if NHPH can be passed between humans, most H. pylori infections are transmitted 
where there is close contact, as between parent or sibling and infant. This fits with the siblings of IP patients 
sharing facets of the syndrome and increased frequency of H. pylori seropositivity (Dobbs et al., 2008). Adult 
transmission of a causative factor is suggested by spouses of IP patients being a short, but highly significant, 
‘distance-down-the-pathway’ (Dobbs et al., 2008), with marked, multifarious, relevant differences between 
spouses and control couples. These are difficult to explain by selective mating or learnt/reactive behavior. 
Future directions  
Irrespective of association of H. suis with PD, its known association with gastric pathology requires its detection 
to be added to diagnostic microbiology on gastric biopsies from patients in high-risk groups. Feedback of 
results of the service evaluation to individual IP patients, who were traceable by the single clinic, has been 
made, with the option of re-biopsy in those with historical H. suis infection. A natural progression of the work is 
to examine the archived samples for zoonotic helicobacters commonly associated with cats and dogs. 
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Abstract  
Several studies suggest a link between shifts in gut microbiota and neurological disorders. Recently, we 
reported a high prevalence of Helicobacter suis in patients with Parkinson’s disease. Here, we evaluated the 
effect of acute gastric H. suis infection on the brain in mice. One month of infection with H. suis resulted in 
increased brain inflammation, reflected in activated microglia. Two communication pathways between the 
gastrointestinal tract and the brain were shown to be involved. We detected choroid plexus inflammation and 
disruption of the epithelial blood-cerebrospinal fluid (CSF) barrier upon H. suis infection, while the endothelial 
blood-brain barrier (BBB) remained functional. These changes were accompanied by leakage of the 
gastrointestinal barrier and low-grade systemic inflammation, suggesting that H. suis-evoked gastrointestinal 
permeability and subsequent peripheral inflammation induces changes in brain homeostasis. Additionally, H. 
suis infection caused changes in the signaling of vasoactive intestinal peptide (VIP). Interestingly, systemic 
administration of VIP reversed the inflammation-induced disruption of the blood-CSF barrier integrity. In 
conclusion, this study shows for the first time that H. suis infection induces inflammation in the brain and that 
the choroid plexus is a novel player in the stomach-brain axis.  
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Introduction  
The healthy human gastrointestinal tract harbors approximately 100 trillion commensal bacteria (Clemente et 
al., 2012; Foster and McVey Neufeld, 2013). An increasing number of recent studies indicate that the shifts in 
the gastrointestinal microbiome caused by a broad variety of triggers, including gastrointestinal infections, 
might have a significant effect on our health (Ochoa-Reparaz and Kasper, 2014; Walters et al., 2014; Zhang et 
al., 2015). Indeed, dysbiosis has been associated with a wide range of human health problems (Clemente et al., 
2012; Zhang et al., 2015; Boulange et al., 2016), including neurological disorders such as depression, anxiety-
like behavior, autism, Alzheimer's disease and Parkinson’s disease (Parracho et al., 2005; Bercik et al., 2011; 
Bravo et al., 2011; Zhang et al., 2015; Hu et al., 2016; Mulak and Bonaz, 2015). 
The genus Helicobacter is a group of gram-negative, spiral-shaped bacteria colonizing the gastrointestinal tract 
of humans and animals. Helicobacter pylori (H. pylori) is the best-known gastric human pathogen and is one of 
the major causes of gastric cancer (Kusters et al., 2006). Besides H. pylori, other Helicobacter species, referred 
to as gastric non-Helicobacter pylori Helicobacter (NHPH) species, have also been associated with severe 
human gastric malignancies (Haesebrouck et al., 2009). The most common NHPH species in humans is H. suis 
(Haesebrouck et al., 2009), which naturally colonizes the stomach of pigs (Liang et al., 2013) and non-human 
primates (Bosschem et al., 2016). Most likely, transmission of H. suis occurs through direct or indirect contact 
between animals and humans. Additionally, H. suis can be present and survive in minced pork, suggesting that 
raw or undercooked pork may be a source of H. suis infection of humans (De Cooman et al., 2013).  
Recently, an exceptionally high frequency (27%) of H. suis DNA was found in gastric biopsies from human 
patients with Parkinson’s disease compared to a control group with no clinical parkinsonism (2%) (Blaecher et 
al., 2013). Besides, H. suis DNA was also detected in a blood sample from a patient with both parkinsonism and 
Alzheimer’s disease (unpublished results). The patient was a middle-aged male, who was treated with 
tetracycline, clarithromycin, bismuth and a proton pump inhibitor to eradicate H. suis. This therapy resulted in 
a temporary improvement of the well-being as well as the gastric and neurological symptoms of the patient 
(Dobbs et al., 2013). This finding suggests that the inflammatory effects caused by Helicobacter are not 
restricted to the stomach.  
To prevent disturbance of brain homeostasis due to alterations in the systemic blood composition, the brain is 
protected by a series of barriers, including the blood‒brain barrier (BBB) and the blood‒cerebrospinal fluid 
(CSF) barrier (De Bock et al., 2014). It has been suggested that systemic inflammation may contribute to the 
impairment of the BBB (Kortekaas et al., 2005; Stolp and Dziegielewska, 2009) and the blood‒CSF barrier 
(Vandenbroucke et al., 2012; Demeestere et al., 2015). Furthermore, several neurodegenerative disorders, 
including Parkinson’s disease and Alzheimer’s disease, have been associated with disruption of the BBB (Stolp 
and Dziegielewska, 2009; Lee and Pienaar, 2014; Li et al., 2015) and the blood‒CSF barrier (Vawter et al., 1996; 
Pisani et al., 2012; Bergen et al., 2015; Balusu et al., 2016a; Gorle et al., 2016). Because it has been proposed 
that Helicobacter infections cause systemic inflammation (Blaecher et al., 2013; Alvarez-Arellano and 
Maldonado-Bernal, 2014), gastric infection with H. suis could influence the integrity of the brain barriers and 
thereby contribute to the pathophysiology of neurodegenerative disorders.  
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In this study, we investigated the effect of gastric H. suis infection on brain homeostasis. Our results show that 
H. suis induces inflammation not only in the stomach, but also in the brain. Moreover, we identified two 
possible pathways of communication between the gastrointestinal tract and the brain. On the one hand, 
leakage of the gastrointestinal barrier induced systemic inflammation and caused loss of the blood-CSF barrier 
integrity. On the other hand, H. suis-induced alterations in VIP signaling might affect brain homeostasis 
because we found that administration of VIP can reverse systemic inflammation-induced blood-CSF barrier 
leakage and brain inflammation. 
 
Materials and methods 
Mice. For the Helicobacter infection experiments, female C57BL/6 mice (5 weeks old) were purchased from 
Harlan (Harlan Laboratories, Horst, The Netherlands). The animals were housed in filtertop cages in groups of 
5-10 mice/cage with free access to food and water and with a 12-hour light/12-hour dark cycle in a 
conventional animal house. All experiments were approved by the ethical committee of the Faculty of 
Veterinary Medicine of Ghent University. For the VIP experiment, female C57BL/6 mice (7 weeks old) were 
purchased from Janvier (Janvier Labs, Le Genest-Saint-Isle, France). Mice were housed with 4-6 mice/cage in a 
specific pathogen-free animal facility with free access to food and water and with a 14-hour light/10-hour dark 
cycle. This experiment was approved by the ethics committee of the Faculty of Sciences of Ghent University.  
Cultivation of H. suis bacteria. H. suis bacteria (strain HS1) were grown biphasically on 1.5% Brucella agar 
(Immunosource, Halle-Zoersel, Belgium), supplemented with 1 ml skirrow (Oxoid, Hampshire, United Kingdom), 
3 ml vitox (Oxoid, United Kingdom), 5 µg/ml amphotericin B (Sigma-Aldrich, Germany), 0.05% HCL (Sigma-
Aldrich, Taufkirchen, Germany) and 20% inactivated fetal bovine serum (Perbio, Thermo Scientific Hyclone, 
Cramlington, United Kingdom) with on top Brucella broth (Immunosource, Belgium), supplemented with 0.05% 
HCL (Sigma-Aldrich, Germany)(Baele et al., 2008). The plates were incubated at 37°C under micro-aerobic 
conditions (10% CO2, 5% O2 and 85% N2). Using a counting chamber (Neubauwer Improved Assistant) the 
bacteria were counted and diluted to 10
8
 viable H. suis bacteria/ml. 
In vivo infection procedure. At the age of 6 weeks, animals were anaesthetized with 2.5% isoflurane and 
intragastrically inoculated with either 300 µl of a stock solution containing 10
8
 viable H. suis bacteria/ml or with 
300 µl of the growth medium of the bacteria (control group). One month after infection, mice were euthanized 
for further analysis by the administration of an overdose of ketamine/xylazine followed by decapitation. In 
order to perform the different analyses, mice were divided into 4 different groups: the first group of mice (10 
controls and 10 H. suis infected mice) was used to determine blood-CSF barrier and BBB permeability, the 
second group (5 controls and 5 H. suis infected mice) was used for quantification of gastrointestinal 
permeability, the third (5 controls and 5H. suis infected mice)  and fourth group (10 controls and 10 H. suis 
infected mice) were used for immunohistochemical stainings and DNA, RNA and protein analyses of stomach 
and brain samples, respectively. 
VIP experiment. Mice were intraperitoneally (ip) injected with lipopolysaccharide (LPS) from Salmonella 
enterica ser. Abortus equi (Sigma) dissolved in D-PBS. The dose was 120 μg/20 g body weight. Control animals 
received ip injections of D-PBS. Additionally, mice were injected twice with 5 nmol VIP (05-23-2101-1MG, 
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Millipore, Merck, Overijse, Belgium) intravenously (iv): together with and 2h after LPS injection. Six hours after 
LPS injection, CSF was isolated and used to determine blood-CSF permeability as described below and choroid 
plexus and hippocampus were isolated for gene expression analysis.  
Tissue collection. For RNA and protein analysis, mice were transcardially perfused with D-PBS/heparin (0.2% 
heparin) supplemented with 0.5% bromophenol blue. The stomach (including a small part of the duodenum) 
was collected and cut open via the curvatura major. After rinsing with sterile Hank’s Buffered Salt Solution 
(Gibco by Thermo Fisher Scientific, Gaithersburg, USA), samples from the antrum and the corpus of the 
stomach and duodenum were collected and stored in RNAlater (Qiagen, Antwerpen, Belgium) at -70°C or snap 
frozen in liquid nitrogen for RNA and protein extraction, respectively. Brain tissue was dissected out. The 
choroid plexus from all four ventricles was collected and snap frozen in liquid nitrogen, while hippocampus 
samples were stored in RNAlater (Qiagen). 
For immunohistochemical analyses, mice were transcardially perfused with 4% paraformaldehyde (PFA). Brain 
tissue and samples from the antrum and corpus of the stomach and duodenum were collected. The brain was 
divided into the left and right hemisphere. The right hemisphere was successively fixated in 4% PFA and 
embedded in paraffin for paraffin sections. The stomach and duodenum samples were either embedded in 
cryoprotectant (Thermo Scientific™, Waltham, USA), underwent rapid freezing on dry ice and were stored at -
70°C or were fixated overnight in a solution of 3.7% formaldehyde (Chem-lab, Zedelgem, Belgium) and 
subsequently embedded in paraffin (Labo-nord, VWR, Leuven, Belgium). 
DNA extraction and quantification of colonizing H. suis bacteria in the stomach and duodenum. Stomach and 
duodenum samples stored in RNAlater were homogenized using the MagNAlyser (Roche diagnostics, Vilvoorde, 
Belgium) and RNA and DNA were separated as described before (Joosten et al., 2013). The number of 
colonizing H. suis bacteria per mg tissue was determined in the DNA samples using Real-Time (RT)-quantitative 
(q) Polymerase Chain Reaction (PCR). RT-qPCR detection of H. suis DNA was performed using the ureA-based 
primers (Table 1) (Blaecher et al., 2013) and the standard was generated as described before (O'Rourke et al., 
2004). Standard and samples were run in duplicate on a CFX384™ RT-qPCR System with a C1000 Thermal Cycler 
(Bio-Rad, Temse, Belgium) according to the manufacturer’s instructions. 
RNA extraction and RT-qPCR for gene expression. Using the RNeasy mini kit (Qiagen), total RNA was extracted 
from the antrum and the corpus of the stomach, the duodenum, hippocampus and choroid plexus according to 
the manufacturer's instructions and measured using Nanodrop equipment (Nanodrop ND-1000, Fisher 
Scientifics). cDNA was synthesized using a cDNA Synthesis Kit (Bio-Rad). RT-qPCR analysis of the stomach and 
duodenum samples was performed on a CFX384
TM
 RT-qPCR System with a C1000 Thermal Cycler (Bio-Rad), 
using the 2xSensimix (Sybr No-Rox kit; Bioline, London, UK), while for brain samples the RT-qPCR was 
performed on the Light Cycler 480 system (Roche) using the 2xSensimix (Sybr No-Rox kit; Bioline). Expression 
levels were normalized to the expression of 3 reference genes: Hprt, H2afz and Ppia for stomach and 
duodenum samples, Hprt¸ Rpl and Ubc for choroid plexus samples and Gapdh, Rpl and Ubc for hippocampus 
samples. The primer sequences are shown in Table 1. 
Cytokine/chemokine measurements. The snap frozen gastrointestinal samples were lysed using lysis buffer 
containing 0.5% CHAPS (Sigma-Aldrich) and a protease inhibitor complete tablet (Roche Applied Science; 11 
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873 580 001). Protein concentration of the samples was measured using the Pierce BCA protein assay kit 
(Thermofisher Scientific). Cytokines and chemokines in serum, CSF and protein lysates were measured using 
the Bio-Plex cytokine assays (Bio-Rad) according to the manufacturer’s instructions. 
Quantification of the gastrointestinal permeability. Gastrointestinal permeability was determined as 
previously described (Vandenbroucke et al., 2014; Van Hauwermeiren et al., 2015). Briefly, 4 kDa FITC-dextran 
(Sigma) was intragastrically administered five hours before collection of blood. Blood was collected in EDTA 
tubes (Sarstedt, Wexford, Ireland) by means of heart punction followed by centrifugation. Subsequently, 
plasma was isolated and diluted twice in sterile D-PBS. Gastrointestinal leakage was determined by 
measurement of fluorescence at λex/λem = 488/520 nm. 
Quantification of blood-CSF barrier and BBB permeability. Blood-CSF barrier and BBB permeability were 
determined as previously described (Vandenbroucke et al., 2012; Brkic et al., 2015). Briefly, 4 kDa FITC-dextran 
(Sigma) was injected iv 1 h before CSF collection. CSF was obtained from the fourth ventricle using the cisterna 
magna puncture method (Vandenbroucke et al., 2012; Brkic et al., 2015). Subsequently, mice were perfused 
with D-PBS/heparin (0.2% heparin) and brain tissue was isolated. CSF samples were diluted 100-fold in sterile 
D-PBS, and blood-CSF barrier leakage was determined by measurement of fluorescence at λex/λem = 488/520 
nm. Brain samples were cut into small pieces, incubated overnight at 37°C in formamide while shaking and 
supernatant was collected after centrifugation for 15 min at maximum speed. Brain fluid was diluted 2-fold in 
sterile D-PBS, and BBB leakage was determined by measurement of fluorescence at λex/λem = 488/520 nm. 
Histopathology and immunohistochemistry. In order to evaluate inflammation in the stomach and duodenum, 
paraffin sections of 5 µm were cut using a microtome (Microm, Prosan, Thermo-Fisher). Sections were stained 
with Hematoxylin Gill III Prosan (Merck) and Eosine Yellow (VWR) according to standardized protocols. Gastric 
tissue was examined using a light microscope (Leica DM2000). The H&E stainings of the stomach were used to 
determine the grade of overall gastritis, using the modified visual analog scale similar to the adapted Updated 
Sydney System as previously described (Flahou et al., 2010). 
For zonula occludens 1 (ZO1) immunostaining of the stomach, 30 µm cryosections were cut using a cryostat 
(Micron HM500) and mounted on slides. After air drying for 1 h, sections were fixated with 1% PFA for 10 min, 
washed for 5 min in PBS, and permeabilized for 10 min with 0.1% NP-40. After two rinses with PBS, samples 
were blocked for 1 h at room temperature with 5% goat serum and then incubated with primary antibody 
(Invitrogen, ZO1, 1:100, Merelbeke, Belgium). After incubation overnight at 4°C, they were washed with PBS-T 
and incubated with secondary antibody (Thermo Scientific; goat anti-rabbit-DyLight633, 1:300) diluted in 5% 
serum for 90 min at room temperature. Finally, a Hoechst staining was performed to counterstain the nuclei, 
the slides were dehydrated and xylene-based mounting medium was applied. Cells were visualized using a 
confocal microscope (Zeiss LSM780). 
For the MUC13 staining of the stomach sections of 5 µm were cut from paraffin embedded tissue, using a 
microtome (Microm, Prosan, Thermo-Fisher), and placed on a microscope slide. Deparaffinization was 
performed by the addition of successively, xylene for 10 min, isopropyl alcohol for 5 min, 95% ethanol for 5 
min, 50% ethanol for 5 min and aqua destillata for 5 min. Antigen retrieval was performed in citrate buffer (10 
mM, pH6) using a pressure cooker, where after samples were rinsed with washing buffer (Dako, Santa-Clara, 
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USA). Endogenous peroxidase was blocked for 5 min with peroxidase blocking reagent (Dako) and rinsed with 
aqua destillata and washing buffer (Dako). Successively slides were incubated for 30 min with the primary in-
house polyclonal mouse MUC13 antibody, diluted in antibody diluent (1/1000, Dako, S3022). After a rinse step 
with washing buffer (Dako), samples were incubated with labeled polymer-HRP anti-mouse for 30 min at room 
temperature (Evision+ system-HRP (DAB) (K4007)). Samples were rinsed 2 times with washing buffer (Dako), 
where after DAB + substrate (Dako) and DAB + chromogen (Dako) were added during 5 min. Finally, a 
counterstaining with hematoxyllin was performed during 10 min, followed by a rinse step of 1 min in running 
tap water and a dehydration step. Gastric tissue was visualized using a light microscope (Leica DM2000).  
For IBA1 immunostaining, paraffin sections of the brains were processed as described before using the anti-
IBA1 antibody (Wako, 019-19741, Neuss, Germany) (Brkic et al., 2015). Imaging of whole brain sections was 
done using Zeiss Axio Scan.Z1 followed by quantification using Fiji (http://fiji.sc/Fiji). Quantification of the 
percentage of brown color was done via color thresholding, with correction for the total amount of tissue, 
while microglia were classified into resting and activated in the subventricular zone according to adopted 
criteria (Hains and Waxman, 2006). Representative images were taken using an Olympus BX51 microscope. 
For Claudin 1 (CLDN1) (Invitrogen, 51-9000) and VIP (Immunostar, 20077, Hudson, USA) immunostaining, 
paraffin-embedded brain and stomach tissues were sectioned at 5 µm, dewaxed, and rinsed in water and PBS. 
Antigen retrieval was done using citrate buffer (Dako; S2031), followed by washing in PBS. For CLDN1 staining, 
endogenous peroxidase was blocked by incubating the slides in 3% H2O2 in methanol for 10 min, followed by 
washing in PBS. All samples were blocked with 5% goat serum in antibody diluent (Dako; S2022) for 30 min at 
RT, followed by incubation overnight at 4°C with primary antibody (CLDN1, Invitrogen, 51-9000, 1:100; VIP, 
Immunostar, 1/50). The next day, slides were washed with PBS. For CLDN1 immunostaining, slides were 
incubated with secondary antibody coupled to HRP (Dako; E-K4003), and washed with PBS. An amplification 
step was performed using tyramide (TSA kit, Perkin Elmer, Zaventem, Belgium) and visualization was done 
using ABC (Vector, Brussel, Belgium) and DAB. Slides were counterstained with haematoxylin, dehydrated and 
xylene-based mounting media was applied. Cells were visualized using an Olympus BX51 microscope. For VIP 
immunostaining, slides were incubated with secondary antibody (Thermo Scientific; goat anti-rabbit-
DyLight633, 1:1000) diluted in 5% serum for 1 h at room temperature. Finally, a Hoechst staining was 
performed to counterstain the nuclei, the slides were dehydrated and xylene based mounting medium was 
applied. Cells were visualized using a confocal microscope (Leica TCS SP5). 
Statistics. Data were analyzed by Mann-Whitney test using GraphPad Prism or SPSS and are presented as 
means  standard error of mean (SEM), unless stated otherwise. Significance levels are indicated on the graphs 
*, 0.01 ≤ P < 0.05; **, 0.001 ≤ P < 0.01; ***, 0.0001 ≤ P < 0.001; ****, P < 0.0001.  
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Results 
Colonization by H. suis induces gastric inflammation 
One month after infection, colonization by H. suis was confirmed by analyzing the stomach and small intestine. 
The mouse stomach consists of a non-glandular part and a glandular part. In this study, we analyzed only the 
glandular part, consisting mainly of the corpus and the antrum of the stomach. As shown in Figure 1a, the 
corpus and antrum of the stomach of H. suis-infected animals were colonized by an average of 4.51E+05 and 
7.30E+05 bacteria per mg tissue, respectively. No H. suis DNA was detected in the stomach of control mice 
(Figure 1a). Additionally, H. suis DNA was also detected in the duodenum of infected mice but at a lower level 
than in the stomach (Figure 1a).  
Analysis of H&E-stained stomach of control animals showed no or negligible infiltration of mononuclear and 
polymorphonuclear cells in the mucosa and the submucosa, which agrees with the normal histological image of 
the stomach (Figure 1b). In contrast, pronounced infiltration of mononuclear and polymorphonuclear cells was 
detected in the stomach of H. suis-infected animals (Figure 1c), indicating gastric inflammation as scored by the 
Updated Sydney System (Figure 1d). Furthermore, inflammation was also associated with changes in the 
expression levels of pro-inflammatory cytokines. Gene expression analyses revealed that the mRNA levels of 
the murine interleukin 8 (IL8) homologue keratinocyte chemoattractant (Kc) and lipopolysaccharide-induced 
CXC chemokine (Lix) were significantly up-regulated in corpus (Figure 1e) and in antrum (Figure 1f) of H. suis-
infected mice. A significant increase in gene expression of Il1β was observed only in the corpus of those 
animals (Figure 1e) and a significant decrease of Il10 only in the antrum (Figure 1f). Additionally, a significant 
increase in protein levels of IL1β and IL17 was observed in the corpus of the stomach of H. suis-infected mice 
(Figure 1h-i). In contrast, no significant changes in the expression of cytokines and chemokines were found in 
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Figure 1. Analysis of colonization and inflammation in the stomach and duodenum after one month of Helicobacter suis 
(H. suis) infection. (a) H. suis colonization in stomach (corpus and antrum) and duodenum of C57BL/6 mice one month after 
H. suis infection compared to control mice (n = 7-10). (b-c) Representative H&E images of stomach sections of control (b) 
and H. suis-infected (c) C57BL/6 mice one month after infection. (d) Inflammation score based on H&E staining of stomach 
of H. suis-infected and control mice (n = 5). (e) Inflammatory gene expression analysis (represented as fold change) of 
interleukin 1β (Il1β), lipopolysaccharide-induced CXC chemokine (Lix), keratinocyte chemoattractant (Kc), Il10 and Il17 in 
corpus of stomach in C57BL/6 mice after one month of infection with H. suis compared to control mice (n = 7-10). (f-g) 
Expression of the inflammatory genes interleukin 1β (Il1β), lipopolysaccharide-induced CXC chemokine (Lix), keratinocyte 
chemoattractant (Kc), Il10 and Il17 in the antrum of the stomach (f) and in the duodenum (g) in C57BL/6 mice after one 
month of infection with Helicobacter suis (H. suis) compared to control mice, represented as fold change (n = 3-9). (h-i) 
Levels of IL1β (h) and IL17A (i) in protein lysates determined using Bioplex of stomach (corpus and antrum) and duodenum 
after inoculation with H. suis or growth medium. Data were analyzed by Student’s t-test (n = 5). 
 
 
Gastric H. suis infection induces inflammation and activation of microglia in the brain 
To determine whether H. suis affects the brain, cerebrospinal fluid (CSF) and brain tissue were analyzed for 
inflammation. Bioplex analysis of CSF revealed no significant changes in cytokines and chemokines (Figure 2a). 
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However, a significantly higher concentration of soluble tumor necrosis factor receptor 1 (sTNFR1) was found in 
the CSF of H. suis-infected mice (Figure 2b). Despite the limited changes in the CSF, a significantly stronger 
expression of Il6 was detected in the brain hippocampus, while Tnf, Il1β, Kc and inducible nitric oxide synthase 
(iNos) expression was unaffected (Figure 2c). Since microglia are important mediators of brain inflammation, 
we stained brain sections for ionized calcium binding adaptor molecule 1 (IBA1), a marker for microglia (Figure 
2d-e). Automatic analysis showed a significant increase in the total IBA1-positive signal in the brain (Figure 2f). 
Additionally, manual quantification of the percentage of activated microglia in the subventricular zone, based 
on the morphology of IBA1-positive cells, revealed increased numbers of ramified microglia in H. suis-infected 
animals compared to control mice (Figure 2g). These data indicate that H. suis activates a pro-inflammatory 
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Figure 2. Analysis of brain inflammation in response to one month Helicobacter suis (H. suis) infection. (a) Levels of 
interleukin 1β (IL1β), IL6, tumor necrosis factor (TNF) and keratinocyte chemoattractant (KC) in cerebrospinal fluid (CSF) 
determined using Bioplex. Data were analyzed by Student’s T-test (n = 4-5). (b) Concentration of TNFR1 in the cerebrospinal 
fluid (CSF) of control mice and mice infected with H. suis (n = 10). (c) Expression of inflammatory genes Il1β, Il6, Tnf, Kc and 
inducible nitric oxide synthase (iNos) in the hippocampus of C57BL/6 mice infected with H. suis compared to control mice, 
represented as fold change. Data were analyzed by Student's T-test (n = 3-5). (d-e) Representative images of ionized 
calcium-binding adapter molecule 1 (IBA1) staining of brain sections at the subventricular zone from C57BL/6 of control 
mice (d) and of mice after one month infection with H. suis (e). (f) Quantification of the percentage brown staining (IBA1) in 
the whole brain of H. suis-infected and negative control mice (n = 5). (g) Quantification of the percentage activated 
microglia in H. suis-infected and negative control mice (n = 5). 
 
H. suis infection induces loss of the blood-CSF barrier but does not affect BBB integrity. 
The presence of tight brain barriers, including the BBB and the blood-CSF barrier, ensure brain homeostasis (De 
Bock et al., 2014), but several inflammatory triggers are known to disrupt barrier integrity (Nielsen et al., 2012; 
Vandenbroucke et al., 2012; Alvarez-Arellano and Maldonado-Bernal, 2014; Brkic et al., 2015; Gorle et al., 
2016). Here, we studied whether the effect of H. suis on the brain is associated with loss of barrier integrity. No 
change in BBB permeability was observed (Figure 3a). In contrast to the BBB, a significant increase in blood‒CSF 
barrier permeability was seen after one month of infection (Figure 3b). Gene expression analysis of the blood‒
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infection. As shown in Figure 3c, gene expression of claudin 1 (Cldn1) and occludin (Ocln) was significantly 
down-regulated in the presence of H. suis infection. Other tight-junction genes, such as Cldn5, zona occludens 1 
(Zo1) and Zo3 decreased, but not significantly so. Finally, immunostaining was performed to determine the 
subcellular localization of CLDN1. The arrowheads in Figure 3d-e point to loss of apical localization of CLDN1 in 
the choroid plexus epithelial cells of H. suis-infected mice. These data indicate that H. suis infection 






Figure 3. Brain barrier analysis in response to one month of Helicobacter suis (H. suis) infection. (a) Relative blood-brain 
barrier (BBB) permeability one month after inoculation with growth medium or H. suis (n = 5). (b) Relative blood-
cerebrospinal fluid (CSF) barrier permeability one month after inoculation with growth medium or H. suis (n = 8‒10). (c) 
Expression of the tight junction genes claudin 1 (Cldn1), Cldn5, occludin (Ocln), zonula occludens (Zo1) and Zo3 in choroid 
plexus tissue from C57BL/6 mice infected with H. suis compared to control mice (n = 5). (d-e) Representative images of 
choroid plexus tissue stained for CLDN1 of control mice (d) and H. suis-infected mice (e). CP: choroid plexus. 
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H. suis infection induces loss of gastric mucosal barrier integrity and subsequent systemic 
inflammation 
Increased gastrointestinal permeability, which could lead to leakage of pro-inflammatory mediators and 
bacterial metabolites from the gut into the systemic circulation, is considered one of the gut‒brain axis 
pathways (Cryan and Dinan, 2012; Mayer et al., 2014). In our study, we used oral gavage of FITC-dextran to 
investigate the influence of gastric H. suis infection on the gastrointestinal barrier. Plasma fluorescence analysis 
revealed a significant increase in gastrointestinal permeability after one month of H. suis infection (Figure 4a). 
The gastric mucosal barrier is composed of the gastric mucosa (epithelium, lamina propria and muscularis 
mucosa), with a mucus layer on top (Linden et al., 2002; Kawakubo et al., 2004; Yamashiro, 2006, McGuckin, 
2011 #321). This gastric mucus layer, consisting mainly of secreted mucins, is the first barrier pathogens 
encounter. The membrane-associated mucins, located underneath this mucus layer, also provide a barrier, 
thereby limiting access to the epithelial cell surface (McGuckin, 2011). Changes in mucin distribution and 
expression might affect the integrity of the gastric mucosal barrier (Kufe, 2009). Therefore, we analyzed gastric 
mucin expression. RT-qPCR analysis revealed a significantly increased gene expression of the transmembrane 
mucin 13 (Muc13) in the corpus of H. suis-infected mice, while the expression of Muc5ac, Muc5b and Muc6 
were unaffected (Figure 4b). This finding was confirmed histologically (Figure 4e-f): compared to control mice 
(Figure 4e), apical membrane and cytoplasmatic MUC13 staining (brown) was much more pronounced in the 
mucus-secreting epithelial cells of the stomach of H. suis-infected mice (Figure 4f). In contrast, Muc13 gene 
expression did not change in antrum and was significantly down-regulated in duodenum of H. suis-infected 
animals (Figure 4c-d).  
The gastric epithelium located underneath the mucus layer is formed by epithelial cells connected by tight 
junction proteins (Caron et al., 2015). We performed immunostaining to determine whether the H. suis-
induced alterations in gastrointestinal barrier integrity were correlated with changes in junctional proteins in 
the stomach. Confocal imaging revealed that expression of ZO1 was disturbed. Compared to control mice, in 
which ZO1 was enriched mainly at the apical side of the stomach epithelial cells (Figure 4g), the ZO1 signal was 
much more diffuse in stomach samples from H. suis-infected animals (Figure 4h). The changes in the expression 
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Figure 4. Analysis of the gastrointestinal barrier after one month of Helicobacter suis (H. suis) infection. (a) Relative 
gastrointestinal permeability of control mice compared to mice infected with H. suis (n = 5). (b) Expression of mucins 
Muc5ac, Muc5b, Muc13 and Muc6 in the corpus of the stomach of C57BL/6 mice inoculated with H. suis and of control 
mice, represented as fold change (n = 7-10). (c-d) Expression of the mucin Muc13 in antrum of the stomach (c) and in 
duodenum (d) in C57BL/6 mice one month after infection with Helicobacter suis (H. suis) compared to control mice, 
represented as fold change (n = 5-9). (e-f) Representative images of immunostaining of MUC13 in the stomach of control 
mice (e) and H. suis infected mice (f). (g-h) Representative confocal images of zonula occludens 1 (ZO1) staining in the 
stomach of control mice (g) and H. suis-infected C57BL/6 mice (h).  
 
Disruption of the gastric mucosal barrier might result in leakage of pro-inflammatory cytokines, chemokines 
and bacterial metabolites from the stomach into the blood, leading to systemic inflammation (Cryan and Dinan, 
2012). Additionally, recent studies indicated that alterations in circulating cytokine levels may directly influence 
the functionality of the brain barriers and the brain (Cryan and Dinan, 2012; Vandenbroucke et al., 2012; Balusu 
et al., 2016b). Therefore, the presence of systemic inflammation was evaluated by analyzing the serum of 
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control and H. suis-infected mice. As shown in Figure 5a, the levels of the pro-inflammatory cytokine IL1β and 
chemokine MIP1α increased significantly in the serum of H. suis-infected mice. These findings indicate that the 
loss of blood-CSF barrier integrity observed in our study might have been caused by a low grade, systemic 
inflammation induced by H. suis. In agreement with this finding, gene expression analysis of choroid plexus 
tissue revealed a significantly increased expression of pro-inflammatory cytokines Il1β and iNos (Figure 5b).  
Figure 5 
 
Figure 5. Analysis of systemic inflammation after one month of Helicobacter suis (H. suis) infection. (a) Levels of serum 
interleukin (IL) 1β, IL6, macrophage inflammatory protein (MIP1α), tumor necrosis factor (TNF) and keratinocyte 
chemoattractant (KC) determined using Bioplex after inoculation of mice with H. suis or growth medium,. Data were 
analyzed by Student's t-test (n = 3-4). (b) Expression of the inflammatory genes Il1β, Il6, Tnf, Kc and Inos in choroid plexus 
tissue of C57BL/6 mice inoculated with H. suis or growth medium, represented as fold change (n = 3-5). 
 
H. suis infection disturbs VIP signaling 
Another important link between the gastrointestinal system and the brain are neuropeptides, such as the 
vasoactive intestinal peptide (VIP) (De Vadder et al., 2015). Indeed, VIP seems not only to be involved in the 
maintenance of the gastrointestinal epithelial barrier integrity (Conlin et al., 2009) but might also play a role in 
brain homeostasis (Delgado et al., 2004). Additionally, VIP reactive neurons have been found in the enteric 
nervous system and in the choroid plexus (Lindvall et al., 1978; Delgado et al., 2004). One month after infection 
with H. suis, the expression of Vip in the corpus of the stomach was significantly decreased (Figure 6a), whereas 
expression of the receptor, Vipr1, was significantly up-regulated and Vipr2 remained stable (Figure 6a). 
Additionally, immunofluorescent stainings revealed that VIP was retained in the lumen of the gastric glands of 
H. suis-infected animals (Figure 6b-c). To evaluate whether alterations in VIP levels could affect the blood-CSF 
barrier integrity and thereby brain homeostasis in a LPS-induced systemic inflammation model, mice were 
treated with VIP. As in the infection with H. suis, injection of LPS in mice resulted in increased leakage of the 
blood‒CSF barrier as described before (Vandenbroucke et al., 2012) (Figure 6d); this was reversed by VIP 
treatment (Figure 6d). LPS-induced increased leakage of the blood‒CSF barrier was associated with significant 
down-regulation of the tight junction proteins Cldn5, Ocln and Zo3 in the choroid plexus (Figure 6e). 
Downregulation of Ocln was significantly less in LPS-injected mice treated with VIP (Figure 6e). Expression of 
Cldn1 was increased significantly by LPS injection, whereas expression of Zo1 decreased when LPS and VIP were 
combined (Figure 6e). LPS injection also increased inflammatory gene expression in the choroid plexus, 
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reflected by an increase of Il1β, Il6, Tnf, Kc and iNos; the increases in Il6, Tnf, Kc and iNos were significantly 
reduced by VIP treatment (Figure 6f). Together, these data indicate that VIP might play a protective role in the 
preservation of brain homeostasis in the presence of systemic inflammation, and it might be important in the 
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Figure 6. Analysis of vasoactive intestinal peptide (VIP) signaling after one month of Helicobacter suis (H. suis) infection. 
(a) Expression of vasoactive intestinal peptide (Vip), VIP receptor (VipR1) and VipR2 in the corpus of the stomach of 
C57BL/6 mice inoculated with H. suis or growth medium, represented as fold change (n = 6-10). (b-c) Representative 
confocal images of VIP staining in the stomach of control (d) and H. suis infected (e) C57BL/6 mice. (d) Relative blood‒
cerebrospinal fluid (CSF) barrier permeability as a result of systemic inflammation induced by intraperitoneal (ip) injection 
of 120 µg/ 20 g body weight lipopolysaccharide (LPS), followed by intravenous (iv) injection of PBS or VIP, compared to 
controls (n = 5-8). (e) Relative expression of the tight junction proteins Claudin 1 (Cldn1), Cldn5, Occludin (Ocln)¸ Zonula 
occludens 1 (Zo1) and Zo3 in the choroid plexus as a result of systemic inflammation, followed by iv injection of PBS or VIP, 
compared to controls (n = 8-10). (f) Relative expression of the inflammatory cytokines interleukin 1β (Il1β), Il6, tumor 
necrosis factor (Tnf), keratinocyte chemoattractant (Kc) and inducible nitric oxide synthase (iNos) in the choroid plexus as a 
result of systemic inflammation, followed by iv injection of PBS or VIP, compared to controls (n = 8-10)
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Discussion  
Alterations in the gut microbiome are believed to contribute to many different human health problems 
(Parracho et al., 2005; Bercik et al., 2011; Bravo et al., 2011; Clemente et al., 2012; Zhang et al., 2015). Next to 
the direct effects H. pylori infection on the gastrointestinal system (Kusters et al., 2006; Mayer et al., 2014; Li et 
al., 2016), it has been associated with the occurrence of different neurodegenerative disorders, including 
Alzheimer’s disease (Wirdefeldt et al., 2011; Alvarez-Arellano and Maldonado-Bernal, 2014; Wong et al., 2014) 
and Parkinson’s disease (Wirdefeldt et al., 2011; Blaecher et al., 2013; Alvarez-Arellano and Maldonado-Bernal, 
2014; Wong et al., 2014). We recently highlighted in a similar way the importance of gastric H. suis infections in 
Parkinson’s disease (Blaecher et al., 2013). However, it remains unknown how gastric Helicobacter infection in 
general influences the brain.  
The gastrointestinal system and the brain are connected through neural, endocrine and immune pathways. 
Here, we demonstrated that one month of infection with H. suis resulted in increased brain inflammation. In 
particular, we observed a moderate but significant up-regulation of Il6 gene expression in the hippocampus, 
elevated levels of sTNFR1 in CSF (a biomarker for Alzheimer’s disease) (Jiang et al., 2011), and an increased 
amount of activated microglia in the brain. Interestingly, elevated brain levels of IL6 have also been reported in 
traumatic brain injury (Goodman et al., 1990; Kossmann et al., 1995), depression (Brietzke et al., 2009), 
Parkinson’s disease (Boka et al., 1994) and Alzheimer’s disease (Angelopoulos et al., 2008), suggesting a role for 
IL6 in the above-mentioned neuropathologies. Furthermore, microglia activation has been observed in H. pylori 
infection (Lo et al., 2009), and priming of the microglia by prior pathology accelerates the pathology in the 
brain (Cunningham, 2013). To ensure homeostasis in the CNS, the brain is protected from fluctuations in the 
systemic blood composition by a series of brain barriers, including the BBB and the blood-CSF barrier (De Bock 
et al., 2014). Our results indicate that gastric H. suis infection can induce leakage of the blood‒CSF barrier but 
not of the BBB. This disturbance was accompanied by loss of tight junctions, and specifically by a significant 
decrease in the expression of Cldn1 and Ocln and disturbed localization of CLDN1 protein in the choroid plexus 
epithelium. 
Although the observed H. suis-induced blood-CSF barrier leakage was rather limited, dysfunction of the choroid 
plexus epithelium is known to be destructive to the brain (Redzic et al., 2005; Marques et al., 2007; Johanson et 
al., 2011; Balusu et al., 2016a). Moreover, increased blood-CSF barrier permeability has been observed in 
several neuroinflammatory disorders, including Alzheimer’s disease, aging and Parkinson’s disease (Pisani et al., 
2012; Marques et al., 2013; Brkic et al., 2015; Balusu et al., 2016a; Gorle et al., 2016). The choroid plexus 
epithelium is uniquely positioned between blood and brain, and we and others believe that this blood‒CSF 
interface is an essential player in the communication between the periphery and the brain. Indeed, several 
studies reported that choroid plexus epithelial cells sense inflammatory changes in the periphery, which in turn 
induces changes in functionality of the choroid plexus epithelial cells (Thouvenot et al., 2006; Marques et al., 
2007; Marques et al., 2009; Vandenbroucke et al., 2012; Balusu et al., 2016b). Also in our study, we observed 
H. suis-induced systemic inflammation characterized by increased levels of IL1β and MIP1α in the serum, which 
could have contributed to disruption of the blood-CSF barrier and subsequently to brain inflammation. 
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Disruption of the gastric mucosal barrier might lead to leakage of inflammatory cytokines, chemokines and 
bacterial components from the stomach into the systemic circulation (Cryan and Dinan, 2012; Mayer et al., 
2014), thereby inducing systemic inflammation. In our study, the extent of colonization of the stomach by H. 
suis was similar to what has been reported (Flahou et al., 2010). DNA from H. suis was also found in the 
duodenum, but it is not clear whether this pathogen colonized the duodenum or, otherwise, the qRT-PCR 
picked up DNA from bacteria colonizing the stomach. Furthermore, H. suis infection evoked a pro-inflammatory 
immune response in the stomach characterized by infiltration of innate immune cells and up-regulation of IL1β 
and murine IL8 homologue genes Lix and Kc; these observations are in line with previous studies (Flahou et al., 
2010; Flahou et al., 2012; Bosschem et al., 2016; Bosschem et al., In submission). Inflammation in the stomach 
was also accompanied by increased gastrointestinal barrier permeability and changes in the localization of the 
tight junction protein zonula occludens 1 (ZO1). Concordant with our study, co-culture of primary human 
gastric epithelial cells with H. pylori resulted in disruption of membrane ZO1 (Wrobleski, 2011).  
Aberrant expression of transmembrane mucins has also been shown to play a role in disturbance of mucosal 
barrier integrity (Kufe, 2009). In our study, an inappropriate overexpression of the membrane-associated mucin 
MUC13 was seen. This mucin, which is predominantly expressed in the intestine and only at very low level in 
the stomach, seems to be induced by IL1β in the inflamed stomach during Helicobacter infection (Cheng et al., 
2016). Inappropriate overexpression of transmembrane mucins can affect gastric mucosal barrier integrity by 
disrupting cell polarity and cell-cell interactions (Kufe, 2009), but further investigations are necessary to 
confirm the role of MUC13 in gastric mucosal barrier dysfunction. Taken together, gastric H. suis infection 
induced inflammation in the stomach, which was associated with gastric mucosal damage resulting in leakage 
of inflammatory mediators into the blood and leading to systemic inflammation.  
The gastrointestinal tract and the brain communicate through the systemic pathway, but they might also 
interact via neural communication (Mayer et al., 2014). Vasoactive intestinal peptide (VIP) is a neuropeptide 
with diverse functions and was recently identified as a component of the gut-brain axis (De Vadder et al., 
2015). VIP has been shown to promote homeostasis of the mucosal barrier of the gastrointestinal tract and has 
been implicated in tight junction regulation (Conlin et al., 2009; Chen et al., 2015). In our study, VIP expression 
was changed in the stomach of H. suis infected animals, which agrees with the previously described altered 
density of VIP immunoreactive nerves in mice in response to H. pylori infection (Bercik et al., 2002). Alterations 
in VIP expression might thus also contribute to dysfunction of the gastric mucosal barrier seen in our study.  
In the brain, VIP can prevent overactivation of microglia in LPS-induced inflammation (Kim et al., 2000; Delgado 
and Ganea, 2003). VIP has been described as protective in Parkinson’s disease (Delgado and Ganea, 2003) and 
Alzheimer’s disease (Song et al., 2012). To determine whether alterations in the peripheral VIP levels affect the 
blood-CSF barrier during peripheral inflammation, mice were injected in the peritoneum with LPS and then 
treated with VIP. Our results indicate that administration of VIP in LPS-induced disruption of brain homeostasis 
could reverse inflammation in the choroid plexus. VIP reactive nerves had been demonstrated in the choroid 
plexus (Lindvall et al., 1978) and their contribution to the regulation of choroid plexus activity had been 
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described (Nilsson et al., 1991). These reports are in line with our finding that administration of VIP reduces 
LPS-induced leakage of the blood‒CSF barrier. 
In conclusion, we have identified the pivotal role of the choroid plexus in the communication between the 
gastrointestinal tract and the brain. Our results indicate that disruption of the blood-CSF barrier is induced by 
H. suis-associated systemic inflammation and/or dysregulated VIP signaling. Although further research is 
required to unravel the specific mechanisms of gastrointestinal‒brain communication, VIP is a potential 
candidate for treatment of neurodegenerative diseases because it can restore the blood-CSF barrier and 
thereby reduce the neuroinflammation associated with gastrointestinal infections. 
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Tables 
Table 1. Overview of used qRT-PCR primer sequences. 
 Forward primer sequence Reverse primer sequence 
H2afz GGTATCACCCCTCGTCACTT TCAGCGATTTGTGGATGTGT 
Hprt (stomach) CAGGCCAGACTTTGTTGGAT TTGCGCTCATCTTAGGCTTT 
Ppi AGCATACAGGTCCTGGCATC TTCACCTTCCCAAAGACCAC 
Il1β CACCTCACAAGCAGAGCACAAG GCATTAGAAACAGTCCAGCCCATAC 
Kc GCTGGGATTCACCTCAAGAA TCTCCGTTACTTGGGGACAC 
Mip2 TGCCTGAAGACCCTGCCAAGG GTTAGCCTTGCCTTTGTTCAG 
Lix CTCAGTCATAGCCGCAACCGAGC CCGTTCTTTCCACTGCGAGTGC 
Ocln CCAGGCAGCGTGTTCCT TTCTAAATAACAGTCACCTGAGGGC 
Cldn1 TCTACGAGGGACTGTGGATG TCAGATTCAGCAAGGAGTCG 
Cldn5 GCAAGGTGTATGAATCTGTGCT GTCAAGGTAACAAAGAGTGCCA 
Muc5ac Purchased from Qiagen (Qt01196006) 
Muc5b CAGATCCATCCATCCCATTTCT TATCTGACTACCACTTGTTGATGTGACT 
Muc6 TGCTCCCAGAATGAGTACTTCGA CAGAGGTGGAACTGTGAAACTCAGT 
Muc13 GCCAGTCCTCCCACCACGGTA CTGGGACCTGTGCTTCCACCG 
Vip AGTGTGCTGTTCTCTCAGTCG GCCATTTTCTGCTAAGGGATTCT 
VipR1 GATGTGGGACAACCTCACCTG TAGCCGTGAATGGGGGAAAAC 
VipR2 GACCTGCTACTGCTGGTTG CAGCTCTGCACATTTTGTCTCT 
Tnf ACCCTGGTATGAGCCCATATAC ACACCCATTCCCTTCACAGAG 
iNos CAGCTGGGCTGTACAAACCTT CATTGGAAGTGAAGCGTTTCG 
Zo1 AGGACACCAAAGCATGTGAG GGCATTCCTGCTGGTTACA 
Zo3 ACCCTATGGCCTGGGCTTC CCCGGGTACAACGTGTCC 
Hprt choroid plexus AGTGTTGGATACAGGCCAGAC CGTGATTCAAATCCCTGAAGT 
Rpl CCTGCTGCTCTCAAGGTT TGGTTGTCACTGCCTGGTACTT 
Ubc  AGGTCAAACAGGAAGACAGACGTA TCACACCCAAGAACAAGCACA 
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Gapdh TGAAGCAGGCATCTGAGGG CGAAGGTGGAAGAGTGGGAG 
H. suis  AAAACAMAGGCGATCGCCCTGTA TTTCTTCGCCAGGTTCAAAGCG 
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Abstract 
Background: Helicobacter suis is a very fastidious micro-organism associated with gastritis, gastric ulcers and 
mucosa-associated lymphoid tissue (MALT) lymphoma in humans. In vitro isolation of this agent from human 
patients has so far been unsuccessful.  
Materials and methods: A probe-based real-time (RT-) PCR for the rapid detection of H. suis in gastric biopsies 
was developed. Secondly, a mouse-passage-based protocol was optimized for isolation of low numbers of 




) and kept for 4 
weeks to allow multiplication of this pathogen. 
Results: The probe-based real-time (RT)-PCR exhibited a high degree of diagnostic specificity and analytical 
sensitivity, high linear correlations (r2 between 0.995 and 0.999) and high amplification efficiencies (> 90%) for 
H. suis. No cross-reactivity was detected with human, porcine, non-human primate and murine DNA nor with 
DNA from other bacteria including Helicobacter spp. and Campylobacter spp.  
H. suis was successfully re-isolated from the stomach of mice inoculated with at least 10
4
 viable H. suis, using a 
biphasic medium (pH 5), consisting of Brucella agar with Brucella broth on top, both supplemented with vitox 
supplement, Campylobacter-selective supplement, amphotericin (5 µg/ml), HCl (0.05 %), fetal bovine serum 
(20 %) and linezolid (5 µg/ml). Linezolid was necessary to inhibit proliferation of contaminants, including 
lactobacilli. 
Conclusion: The methods described in this paper can be implemented for detection or isolation of H. suis from 
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Introduction 
Helicobacter pylori (H. pylori) is associated with a wide range of gastric disorders, including gastritis, ulcers and 
cancer (Montecucco and Rappuoli, 2001). However, gastric disease in humans has also been associated with 
other Helicobacter species. These are collectively called non-H. pylori Helicobacter spp (NHPH). They are long, 
spiral-shaped organisms most commonly colonizing the stomachs of domestic animals (Haesebrouck et al., 
2009). Reported estimates of prevalence of NHPH in human populations range from 0.2 to 6 % (Haesebrouck et 
al., 2009). However, due to difficulties in the diagnosis of NHPH infections these estimates are certainly biased 
and most probably underestimate the true prevalence. Moreover, it cannot be excluded that infections with 
these agents sometimes remain asymptomatic or cause only mild symptoms which are not rigorously 
examined. The prevalence of H. pylori in the Western world is decreasing, leaving a niche for infection with 
NHPH (Haesebrouck et al., 2009; Overby et al., 2016). 
H. suis appears to be the most important amongst the NHPH. Not only does it represent the most common of 
the NHPH detected in the stomach of people suffering from gastric disorders, but it has also been detected in 
27 % of Parkinson’s disease (PD) patients and only in 2 % of controls from gastroenterology-services using an 
ureA-based SYBR green RT-PCR assay on gastric biopsies with positivity on amplicon sequencing (Blaecher et 
al., 2013).  
Pigs are the main reservoir of H. suis (Haesebrouck et al., 2009; De Bruyne et al., 2012), but H. suis has also 
been found in the stomach of rhesus and crab-eating macaques (O’Rourke et al., 2004; Martin et al., 2013; 
Bosschem et al., 2016). H. suis is transmitted to humans most likely through direct or indirect contact with pigs 
(Joosten et al., 2013). Additionally, this bacterium can be present and persist in minced pork, suggesting that 
raw or undercooked pork may also constitute a source of H. suis infections in humans (De Cooman et al., 2013). 
H. suis has been associated with gastritis, peptic and duodenal ulcers, and low-grade mucosa-associated 
lymphoid tissue (MALT) lymphoma in humans. Compared to H. pylori, gastritis caused by H. suis appears less 
active and less severe, but the risk of developing MALT lymphoma is higher (Nakamura et al., 2007; Nakamura 
et al., 2008; Matsui et al., 2014). 
The diagnosis of gastric Helicobacter infections is extremely difficult and usually involves endoscopic sampling 
of gastric biopsies. Commercial non-invasive tests to specifically diagnose infections with H. suis are currently 
unavailable. Attempts to isolate H. suis from human gastric biopsies, either directly, or after mouse-passage 
(Matsui et al., 2014) have been unsuccessful so far. Direct isolation from biopsies may be hampered by the low 
colonization density of this agent (Blaecher et al., 2013), whilst isolation after mouse-passage has been 
hampered by overgrowth of Lactobacillus spp. (Matsui et al., 2014; Aiba et al., 2015). Analysis of the gastric 
biopsies by molecular methods currently appears to be the only feasible way to identify infections with H. suis. 
One available molecular method makes use of RT-PCR based on the ureA gene for identification and 
quantification of H. suis bacteria (Blaecher et al., 2013; Flahou et al., 2010). In this assay, additional sequencing 
of the positive PCR amplicons is necessary, since cross-reactivity with host DNA and DNA from other gastric 
NHPH may occur (unpublished results). Recently, a new H. suis–specific PCR has been developed, using primer 
pairs targeting the carR gene. Compared to ureA, this carR gene is a good candidate for the identification of H. 
suis, since it is not present in other gastric Helicobacter genomes (Matsui et al., 2013). However, this novel 
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assay required further investigation, as it is not known whether the carR-specific primers react with other 
bacterial or host DNA. 
The purpose of the present study is to further improve diagnostic tests for the detection of H. suis. We first 
developed and validated a carR probe-based RT-PCR that allows detection and quantification of H. suis in 
gastric tissue samples. Secondly, a mouse-passage-based protocol was further optimized for the isolation of 
low numbers of H. suis bacteria. Since mouse-passage of H. suis might influence strain characteristics, we also 
sequenced the genome of a porcine H. suis strain before and after passage in mice.  
 
Materials and methods 
1) CarR probe-based RT-PCR 
Bacterial strains and in vitro culture conditions 
H. suis , H. heilmannii, H. ailurogastricus and Lactobacillus spp. (L. reuteri and L. gasseri) (Table 1) were 
cultivated biphasically on Brucella agar (Immunosource, Halle-Zoersel, Belgium) plates, supplemented with 1 ml 
Skirrow (Oxoid, Hampshire, United Kingdom), 3 ml Vitox (Oxoid), 5 µg/ml amphotericin B (Sigma-Aldrich, 
Steinheim, Germany), 0.05 % HCL (Sigma-Aldrich) and 20 % inactivated fetal bovine serum (Perbio, Thermo 
Scientific Hyclone, Erembodegem; Belgium) (H. suis growth medium) (Baele et al., 2008) H. bizzozeronii, H. felis, 
H. salomonis, H. pylori, H. cynogastricus, H. baculiformis, H. cetorum, H. cholecystus, H. trogontum, H. 
acinonychis, H. mustellae, H. pullorum, H. marmotae, H. mesocricetorum, H. bilis, H. equorum, H. canadensis 
and Campylobacter spp. (C. jejuni, C. coli, C. fetus and C. upsaliensis) (Table 1) were grown on brain heart 
infusion (BHI) agar (Bio-rad, Nazareth, Belgium) plates supplemented with 10 % horse blood (E&O Laboratories, 
Bonnybridge, UK), Skirrow, Vitox, and 5 µg/ml amphotericin B. All Helicobacter spp. and Campylobacter spp. 
were cultivated under micro-aerobic conditions (10 % CO2, 5 % O2 and 85 % N2; 37°C). Staphylococcus aureus, 
Staphylococcus pseudintermedius, Streptococcus suis, Streptococcus equi subsp. equi, Streptococcus equi subsp. 
zooepidemicus, Pasteurella multocida, Mannheimia haemolytica, Pseudomonas aeruginosa, Klebsiella 
pneumoniae, Proteus vulgaris, Bacillus licheniformis, Salmonella Typhimurium, Trueperella pyogenes, 
Escherichia coli, Aeromonas hydrophila, Enterococcus faecalis and Actinobacillus equuli were grown aerobically 
on commercially available Columbia agar plates supplemented with 5 % sheep blood (Oxoid) at 37°C. 
Clostridium perfringens and Fusobacterium gastrosuis (Table 1), grown on Columbia agar plates (with 5% sheep 
blood), were incubated anaerobically at 37°C, whereas Yersinia pseudotuberculosis was grown on Columbia 
agar plates (with 5 % sheep blood) and incubated aerobically at 30°C (Table 1). 
 
Primer and probe design 
Analysis and comparison of the carR-gene sequence from H. suis strains HS1 (Genbank accession no. 
ADGY00000000), HS5 (Genbank accession no. HDAO00000000), TKY (EMBL/Genbank/DDBJ database accession 
no. AB849014), SNTW101 (EMBL/Genbank/DDBJ database accession no. AB849015), HS8 
(EMBL/Genbank/DDBJ database accession no. AB849016) and HS10 (EMBL/Genbank/DDBJ database accession 
no. AB849017) resulted in the selection of a specific 149 bp region. Based on this region (149 bp), primers and a 
probe (20 bp) were developed: sense primer carR-FQ1 (5'-TGT GGC TAG RTG TTT GCC -3'), antisense primer 
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carR-RQ1 (5'-CT GCA GGC AAY GCT GTT GTT -3') and carR probe (5'- ACC ACG CCT GCA GGC AAC AA-3'). The 
melting temperature and GC% of the primers and probe were calculated and optimized using the 
OligoAnalyser3.1 (Integrated DNA technologies, Leuven, Belgium). Subsequently, the primers and probe were 
verified using BLASTN to ensure that amplification of genes from other organisms or species was unlikely. 
Finally, the probe was combined with the dye 6-carboxyfluorescein (FAM) and the quencher ZEN/3IABkFQ.  
 
Bacterial DNA extraction and quantitation of standards  
DNA was extracted from the different bacterial species using the Prepman
TM
 reagent (Life Technologies, 
Ledeberg, Belgium) according to the manufacturer’s instructions. For generation of the standard for the RT- 
PCR assay, part of the carR gene (423bp) from H. suis HS5 was amplified using primers cbcarR-fq (5'- ATG TAC 
AAG SGC TCT TGA GGG -3') and cbcarR-rq (5'- GAT GGC TGC TTG GAA ACT AGC -3') with an annealing 
temperature of 57°C. Subsequently, the DNA concentration of the PCR products was measured and diluted to a 
concentration of 10
10
 Genomic equivalents (GE). The standard consisted of 10-fold-dilution series starting at 
10
9
 GE for each 10 μl of reaction mixture. 
 
H. suis ureA-based SYBR green RT-PCR 
The H. suis SYBR green assay based on the amplification of part of the gene encoding the urease A subunit was 
carried out as described before (Blaecher et al., 2013). 
 
H. suis carR SYBR green RT-PCR 
The H. suis carR RT-PCR was first evaluated using SYBR green. Two μl of DNA template (samples and standard) 
was suspended in a 10 μl reaction mixture consisting of 3.5 μl HPLC water, 6 μl SensiMix™ SYBR No-ROX 
(Bioline Reagents Ltd, London, UK) and 0.25 μl of primers carR-FQ1 and carR-RQ1 located within the 423 bp 
fragment to yield a 149 bp PCR product. The amplification conditions consisted of 95°C for 15 min followed by 
47 cycles of denaturation (30 seconds at 95°C), annealing (30 sec at 56°C) and elongation (30 sec at 72°C). The 
final elongation step took place at a temperature of 95°C for 15 min. Melting curve data were obtained starting 
at 65°C to 95°C with a velocity of 0.5°C per 5 sec. The standard and bacterial DNA samples were run in 
duplicate on a CFX384
TM
 RT-PCR System or a CFX96
TM
 RT-PCR System with a C1000 Thermal Cycler (Bio-Rad).  
 
H. suis carR probe-based RT-PCR and optimization 
Assays were performed on a CFX96 real-time system (Bio-rad). Primer concentrations were determined in a 
checkerboard system with a standard probe concentration of 250 nM. Subsequently, the probe concentration 
was optimized with the previously determined optimal primer concentrations (Blooi et al., 2013). The reaction 
mixture of 12 µl consisted of 6 µl of IQ
TM
 Supermix (Bio-rad), 3.25 µl of HPLC water (Merck Millipore, Overijse, 
Belgium), 0.3 µl of both primers (carR-FQ and carR-RQ), 0.15 µl of the probe and 2 µl DNA template (standards 
and samples). The amplification conditions consisted of 95°C for 10 min followed by 47 cycles of denaturation 
(20 sec at 95°C), annealing (30 sec at 62.5°C) and elongation (30 sec at 73°C). The final elongation step took 
place at a temperature of 95°C for 15 min. Both standards and samples were run in duplicate. The precision, i.e. 
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the reproducibility and repeatability of the developed H. suis carR probe-based RT-PCR was evaluated by 
determining inter- and intra-assay variability, both expressed by the standard deviation (SD) (Bustin et al., 
2009). Intrarun variability was ascertained by comparing the obtained cq-values for the standard ten-fold 
dilution series (starting from 10
9
GE) within one RT-PCR run, whereas interrun variability was evaluated by 
comparing those values between 3 RT-PCR runs. The diagnostic specificity of the carR-based SYBR green RT-
PCR, the carR probe-based RT-PCR and the ureA-based SYBR green RT-PCR was evaluated by assaying DNA 
extracts of different Helicobacter spp., Campylobacter spp. and other bacteria (Table 1). The amplification 
efficiency, slope and r
2
 were calculated by linear regression analysis using the Bio-Rad CFX Manager v1.6 
software (Bio-Rad, Hercules, CA,USA). 
 
Gastric tissue samples for validation of the carR probe-based RT-PCR 
To validate the use of the carR probe-based RT-PCR to detect H. suis in gastric tissue samples and exclude 
reactivity with host DNA, we applied the optimized protocol to analyze 80 human biopsies in which H. suis 
infection was or was not detected by ureA-based SYBR green RT-PCR with positivity on amplicon sequencing 
(Blaecher et al., 2013; Table 2), 9 gastric samples from pigs with or without known natural H. suis infection 
(Table 2), 9 gastric samples from non-human primates with or without known natural H. suis infection 
(Bosschem et al., 2016; Table 2) and 8 gastric samples from mice experimentally inoculated with H. suis or with 
the growth medium of the bacterium (Table 2). The human gastric biopsies originated from a previous 
experiment with approval from the ethics committee of Ghent University (EC UZG 2011/393) and from the 
diagnostic service of the Gastrointestinal Reference Unit, Public Health England. The non-human primate 
gastric samples originated from rhesus macaques and crab-eating macaques, residing at the Biomedical 
Primate Research Centre (Rijswijk, The Netherlands), accredited by the association for Assessment and 
Accreditation of Laboratory Animal Care (EU Directive 63/2010), and which were euthanized for reasons 
unrelated to the study. The stomach samples from control mice and mice experimentally infected with H. suis 
originated from an experiment with approval from the ethics committee of the faculty of Veterinary Medicine, 
Ghent University (approval no. EC 2014/73). The gastric tissue samples from pigs, used in the study by De Witte 
and colleagues (De Witte et al., 2016), were included in the analyses as well.  
DNA from all gastric tissue samples was extracted using the Qiagen Blood and Tissue kit (Qiagen, Venlo, The 
Netherlands), according to the manufacturer’s instructions.  
 
2) Optimization of a mouse-passage-based isolation protocol for Helicobacter suis 
Mice and experimental procedure 
Six-week-old, female specific pathogen free (SPF) C57BL/6JolaHsd mice were purchased from Harlan NL (Horst, 
The Netherlands). The animals were housed in individual filter top cages, had free access to water and food (an 
autoclaved commercial diet: TEKLAD 2018S, containing 18 % protein; Harlan) throughout the experiment and 
were monitored daily. The experimental protocol was approved by the ethics committee of the faculty of 
Veterinary Medicine, Ghent university, Belgium (approval no. EC 2012/58).  
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H. suis HS1, grown biphasically as described above, was used as inoculum. After incubation under micro-
aerobic conditions, the bacteria were harvested. Ten-fold dilution series were prepared in Brucella broth. The 




viable H. suis bacteria/ml. For each bacterial concentration, 2 mice 
were anaesthetized on two successive days with 2.5% isoflurane and then intragastrically inoculated with 
300 µl using a feeding canula. At 4 weeks post-inoculation, animals were euthanized by cervical dislocation 
under deep isoflurane anaesthesia (5%). The stomach of each mouse was resected for isolation purposes. 
 
Isolation of porcine H. suis strain from the murine stomach after mouse-passage 
The H. suis isolation protocol, which has successfully been applied on porcine and non-human primate 
stomachs highly colonized with H. suis (Baele et al., 2008; Bosschem et al., 2016), was further optimized for use 
on murine gastric tissue with low numbers of H. suis bacteria. We found that supplementation with linezolid at 
5 µg/ml to both phases of the H. suis growth medium did not inhibit H. suis cultivation, whereas the growth of 
contaminants present in the murine stomach was prevented (unpublished results).  
This 5 µg/ml linezolid containing selective medium was evaluated in the experimentally infected mice. The 
murine stomachs were opened via the greater curvature. The gastric content was removed and the stomachs 
were washed and submerged in a 1 % HCl solution for 45 min. Each stomach was homogenized and half of it 
was inoculated onto the linezolid-supplemented H. suis growth medium, whereas the other half was inoculated 
onto the H. suis growth medium without linezolid supplementation (control sample). Subsequently, 
approximately 150 µl Brucella broth with or without (control sample) supplementation of 5µg/ml linezolid was 
added on top of the inoculum. The plates were incubated at 37°C under micro-aerobic conditions, daily 
checked for growth and humidified with the linezolid-supplemented Brucella broth or the Brucella broth 
without linezolid (control samples). Finally, pure isolates were transferred to H. suis growth medium without 
linezolid and stored at -70°C until further use. 
 
Whole genome sequencing of H. suis isolates obtained after mouse-passage 
The genomic DNA of 4 isolates obtained after mouse-passage of the porcine H. suis HS1 strain (isolate 
HS1_output (O)1, isolate HS1_O2, isolate HS1_O3 and isolate HS1_O4, originating from 4 different mice) and 
the original porcine HS1_input (I)1 isolate, retrieved from the pig’s stomach and used for mouse-passage, was 
extracted using the Qiagen Blood and Tissue kit (Qiagen) according to the manufacturer’s guidelines. Whole 
genome sequencing was performed as described before (Joosten et al., 2015). Briefly, 1 ng genomic DNA was 
used for library generation. Sequencing libraries were then prepared using Nextera XT chemistry (Illumina Inc., 
San Diego, CA, USA) in accordance with the manufacturer’s recommendations. Subsequently, libraries were 
sequenced for a 250-300 bp paired-end sequencing run using the Miseq personal sequencer (Illumina). All 
genomes were assembled with the CLC Genomics Workbench, version 7 and annotated using the RAST server 
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Identification of recombination events in the genomes of H. suis isolates obtained after mouse-passage 
Homologous recombination in 4 H. suis isolates obtained after mouse-passage of the porcine H. suis strain HS1 
was assessed using an iterative application of ClonalFrameML as follows (Didelot & Wilson, 2015). From the 
obtained genome assemblies, a core genome alignment was first created using the genome profiler (GeP) 
software tool (Zhang et al., 2015). Subsequently, a maximum-likelihood input phylogeny was inferred using 
RaxML v7.0.43 (Stamakis, 2006) under the General Time-Reversible model. Both the RaxML tree and the core 
genome alignment were then analyzed by ClonalFrameML. This assay was rerun several times until the number 
of recombination events and phylogeny remained stable. Estimates of recombination parameters and the set 
of recombination events were recorded from the final run.  
 
Nucleotide sequence accession numbers 
The genome sequences determined in this study have been deposited in the EMBL database under  
BioProject record numbers: PRJEB15615, PRJEB15616, PRJEB15617, PRJEB15618, PRJEB15619 and received the 
following accession numbers: FMSU01000000, FMSQ01000000, FMSS01000000, FMST01000000 and 
FMSR01000000. 
 
RESULTS AND DISCUSSION 
1) CarR probe-based RT-PCR 
CarR probe-based RT-PCR assay optimization 
The primer and probe concentrations used for this assay were the lowest concentrations that yielded the 
lowest quantitation cycle (cq) value and the highest ΔRn. This latter is the Rn value (the fluorescent emission of 
the reporter dye, normalized to the background fluorescence) of the complete reaction mixture (including 
template) minus the Rn value of a negative control (Blooi et al., 2013). This resulted in a final reaction mixture 
of 12µl composed of 6µl of IQ
TM
 Supermix (Bio-rad, Belgium), 3.25 µl of HPLC water (Merck Millipore, Belgium), 
H. suis-specific carR forward primer carR-FQ1 at a concentration of 0.5 µM, H. suis-specific carR reverse primer 
carR-RQ1 at a concentration of 0.5 µM, H. suis-specific carR FAM-labeled probe at a concentration of 0.25 µM 
and 2 µl template. By application of a temperature gradient for analysis of the standard curve, the optimal 
annealing temperature for the combination of carR-FQ1, carR-RQ1 and the carR probe was set at 62.5°C, 
leading to a run amplification efficiency between 90-100%, the square of the linear correlation (r²) between 
0.995 and 0.999 and a slope of -3.53 (Figure 1). With the exception of a change in the annealing temperature, 
the amplification conditions of the carR probe-based RT-PCR were identical to the conditions used in the H. suis 
ureA-based SYBR green RT-PCR.  
In 2004, Schabereiter-Gurtner and co-workers (Schabereiter-Gurtner et al., 2004) developed an ureA probe-
based RT-PCR and a 23S rRNA probe-based RT-PCR for the detection of H. pylori in stool samples. In contrast to 
our developed carR probe-based RT-PCR assay, no information on the linear correlation of the ureA/23S rRNA 
probe-based RT-PCR assays for the detection of H. pylori was provided in this study. However for these latter 
assays, a slope of -3.7 was reported for both standard curves, consisting of tenfold dilution series. Using the 
formula, E=10^-(1/slope)-1, an efficiency of 86 % could be calculated for both the ureA and 23S rRNA probe-
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based RT-PCR assays. Since the carR probe-based RT-PCR in our study resulted in a slope of -3.53 and the 
optimal slope for a tenfold dilution series is considered -3.32 (Real-time PCR application guide, Bio-Rad 
Laboratories, 2006), the carR probe-based RT-PCR is characterized by a higher amplification efficiency 
compared to the ureA/23S rRNA probe-based RT-PCRs. As amplification efficiency is a measure for the 
percentage of DNA template amplified in each cycle and a slope of -3.32 for a tenfold dilution series equals an 
amplification efficiency of 100% (Real-time PCR application guide, Bio-Rad Laboratories, 2006), the 
amplification of DNA template is more efficient in the carR probe-based RT-PCR assay for the detection of H. 
suis compared to the H. pylori-specific ureA/23S rRNA probe-based RT-PCR assays. 
Figure 1 
 
Figure 1: Standard curve along with efficiency and linear correlation of carR probe-based RT-PCR. Standards were run in 
duplicate. The carR probe-based RT-PCR is characterized by a high efficiency (>90 %) and a linear correlation (r
2
) between 
0.995 and 0.999. 
 
Analytical sensitivity and diagnostic specificity 
The analytical sensitivity of the carR probe-based RT-PCR was tested with the described quantitation standard 




GE were assayed. In all replicates, cq-values were 
generated, suggesting that the limit of detection (LOD) of H. suis DNA using the carR probe-based RT-PCR assay 
is 1 GE per PCR. In theory, a DNA dilution of 10
0 
will contain 1 GE per PCR. However, Bustin (Bustin et al., 2009) 
highlighted that the most sensitive LOD is 3 GE per PCR assuming a Poisson distribution, a 95% chance of 
including at least 1 GE per PCR and 1GE detection (Bustin et al., 2009). This means that in case of a dilution of 
10
0
 GE, 37 % of the aliquots will contain no GE, another 37% will contain 1 GE and the final 26 % will contain 2 
or more GE (Bustin et al., 2009).
 
A similar detection limit has been reported for the H. suis-specific ureA-based 
SYBR green RT-PCR (Blaecher et al., 2013; Bosschem et al., 2015).  
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To verify the diagnostic specificity of the carR probe-based RT-PCR, DNA samples from several bacteria (Table 
1), including different Helicobacter spp., Campylobacter spp. and members of the Enterobacteriaceae family 
(Schabereiter-Gurtner et al., 2004; Moyaert et al., 2008; Matsui et al., 2014), were analyzed. Of all 77 different 
bacterial non-H. suis samples and in contrast to the ureA-based SYBR green RT-PCR (Table 1), the carR probe-
based RT-PCR amplified only H. suis DNA and not the DNA from the other 77 bacterial non-H. suis samples 
(95 % confidence interval: 95%-100%), indicating a high degree of diagnostic specificity. No aspecific reactions 
with DNA from gastric and enterohepatic Helicobacter spp., Campylobacter spp. and other bacteria were 
observed (Table 1). Identical results were obtained using the carR-based SYBR green RT-PCR, highlighting the 
diagnostic specificity of the carR primers for H. suis. 
 
Assay performance and precision 
To determine the assay performance and precision of the carR probe-based RT-PCR with the described 
quantitation standards of H. suis, intrarun and interrun variability was defined as described before (Blooi et al., 
2017). Both inter- and intrarun assays of the carR probe-based RT-PCR were characterized by high squared 
linear correlation (r
2
> 0.995) and amplification efficiency (≥90 %) values, together with low intra- and inter-
assay variabilities (SD < 1; Figures 2 and 3). The cq-values for the dilution series of H. suis bacteria in a run and 
between 3 different runs were similar (Figure 2 and 3). Within a run the highest variation was observed at 10
9 
GE, resulting in a standard deviation of 0.97 (Supplementary Table 1), whereas between different runs the 




GE, resulting in a standard deviation of 0.76 and 0.62, 
respectively (Supplementary Table 2). The separate cq-values of each inter- and intrarun assay are presented in 
Supplementary Table 1 and 2. The above results demonstrate that the probe-based RT-PCR has a high 
reproducibility as well as a good performance over the tested quantitation range.  
Figure 2 
 
Figure 2: Overview of the cq-values of the standard dilution series in 1 run. The cq-values for the dilution series of H. suis 
bacteria within 1 run were similar. Inside 1 run the highest variation was observed at 10
9 
GE, resulting in a standard 
deviation of 0.97. The separate cq-values of one run are demonstrated in Supplementary Table 2. 
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Figure 3: Overview of the mean cq-values of the standard dilution series between 3 different runs. Between 3 different 




 GE, the highest standard deviation of 
the cq-values between the 3 runs amounted 0.76 and 0.62, respectively. The separate cq-values of the 3 different runs are 
demonstrated in Supplementary Table 3. 
 
Validation on gastric tissue samples 
To validate the developed H. suis-specific carR probe-based RT-PCR, DNA from human, non-human primate, 
murine and porcine gastric tissue samples was assayed (Table 2 and Supplementary Table 3). All tested samples 
were run in the H. suis-specific ureA-based SYBR green, the carR-based SYBR green and the carR probe-based 
RT-PCR assay to compare variability in cq-values between the assays. Out of the 80 human gastric biopsy 
samples, the ureA-based SYBR green RT-PCR identified 7 positive human gastric samples. Six of these also 
reacted positive using the carR probe-based RT-PCR. None of the human gastric samples tested positive for H. 
suis DNA using the carR-based SYBR green RT-PCR (Table 2 and Supplementary Table 3). The number of H. suis 
positive non-human primate samples identified by the ureA-based SYBR green RT-PCR and the carR probe-
based RT-PCR were 9 and 8, respectively, whereas only 6 of the 9 samples tested positive for H. suis DNA using 
the carR-based SYBR green RT-PCR (Table 2 and Supplementary Table 3). Finally, for both murine and porcine 
gastric tissue samples, all known negative and positive H. suis samples were properly identified using both carR 
probe-based RT-PCR and ureA-based SYBR green RT-PCR. However, none of the known positive murine and 
porcine gastric samples were identified using the carR-based SYBR green RT-PCR (Table 2 and Supplementary 
Table 3). 
Additional sequencing was performed for the samples reacting positive in ureA-based SYBR green RT-PCR. One 
human and one non-human primate sample, which tested negative for H. suis using the carR probe-based RT-
PCR, were false positive in the ureA-based SYBR green RT-PCR (Table 2 and Supplementary Table 3). The 
sequence of the amplicon obtained within the human gastric sample corresponded to that of human DNA. That 
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of the non-human primate gastric sample corresponded to the ureA/B gene sequence of an unknown 
Helicobacter sp.  
In contrast, none of the human, porcine and murine samples tested positive for the presence of H. suis DNA 
using the carR-based SYBR green RT-PCR. Although the melting curve obtained for these human, porcine and 
murine samples did not correspond with that of H. suis, high cq-values were detected for these samples using 
the carR-based SYBR green RT-PCR. Sequencing of the amplicons obtained in the SYBR green RT-PCR with carR-
based primers revealed that human, porcine, murine and primate DNA was amplified, indicating that these 
primers do not only bind to the H. suis carR gene, but also to host DNA which is present in large quantities in 
gastric samples. This renders the carR-based SYBR green RT-PCR detection of amplicons inefficient and a 
method that specifically detects DNA sequences amplified from the H. suis carR gene is required. In the present 
study, this was realized using a probe that detects a specific part of the carR gene. Indeed, the SYBR green RT-
PCR assay emits a fluorescent signal when the fluorophore binds to any amplified double stranded DNA. In 
contrast, the probe binds on a specific region within the amplicon of single stranded DNA. The emission of 
fluorescence only takes place when the reporter dye is separated from the quencher by the DNA polymerase.  
Since the true positive samples, derived from the human, non-human primate, murine and porcine stomachs, 
tested false negative using the carR-based SYBR green RT-PCR assay, they are not reliable and therefore not 
included in the evaluation of the variability between the different assays. Compared to the results from the 
ureA-based SYBR green RT-PCR, the cq-values from the H. suis positive samples obtained by the carR probe-
based RT-PCR were less variable resulting in a lower cq-mean and standard deviation (Table 3 and 
Supplementary Table 3). This finding clearly indicates a higher diagnostic specificity and analytical sensitivity for 
the carR probe-based RT-PCR.  
In our study, no aspecific reactions with human, non-human primate, murine and porcine DNA nor with DNA 
from other bacteria could be observed when using the carR probe-based RT-PCR. As only relatively low 
amounts of H. suis DNA have been detected in human gastric biopsies using RT-PCR and large amounts of host 
DNA are present in these samples, the use of the target-specific carR probe may be very useful to detect H. suis 
DNA in human gastric biopsies.  
 
2) Optimization of a mouse-passage-based isolation protocol for Helicobacter suis 
Optimization of a mouse-passage H. suis isolation method 
Overgrowth with Lactobacillus spp. has been reported as one of the main reasons for failure of H. suis isolation 
from the murine and human stomach (Matsui et al., 2014; unpublished data). In order to inhibit the growth of 
contaminants, including Lactobacillus spp., and allow cultivation of H. suis, linezolid was added to the biphasic 
H. suis isolation medium. Linezolid is a synthetic oxazolidone, inhibiting the protein synthesis by binding to the 
50S ribosomal subunit of the peptidyltransferase center of the bacterial ribosomes. It is active against a broad 
spectrum of Gram-positive bacteria, including many Lactobacillus species (Agar and Gould, 2012), and has a 
relatively low activity (MIC90 8 µg/ml) against H. pylori (Sanchez et al., 2000). 
The linezolid-supplemented biphasic growth medium and the H. suis growth medium without linezolid (control 
sample) were inoculated with homogenized gastric tissue samples from mice, infected for 4 weeks with a 
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dilution series of viable H. suis. All plates with growth medium that did not contain linezolid, were overgrown 
by contaminants, making isolation of H. suis impossible. On linezolid-supplemented biphasic growth medium 










bacteria, pure H. suis 
isolates were obtained. H. suis bacteria could be observed after 2-3 days of in vitro cultivation. On the contrary, 
after two weeks of incubation, attempts to isolate H. suis from the stomach of mice infected with fewer than 
10
4
 viable bacteria remained unsuccessful, indicating that the minimal infection dose of H. suis in mice is at 
least 10
4
 viable H. suis bacteria/ml. This finding has also been confirmed in other reports (Matsumoto et al., 
2009; Matsui et al., 2014).  
 
Low recombination events and maintenance of integrity in the H. suis genome 
Whole genome analysis of the 4 isolates obtained after mouse-passage of porcine H. suis HS1 strain (HS1_O1, 
HS1_O2, HS1_O3 and HS1_O4) and the original porcine HS1_I1 isolate, showed that mouse-passage of H. suis 
did not result in major recombination events within the H. suis genome (Figure 4). Similar findings were 
reported for H. pylori after mouse-passage (Lundin et al., 2005). This may indicate that H. suis strains obtained 
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Figure 4 
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Figure 4: Phylogenetic tree in combination with an overview of the recombination events. Shown are the different 
recombination events in combination with their position detected after whole genome comparison of the different H. suis 
strains, successively HS2, HS1_I1, HS1_o4, HS1_O3, HS1_O1, HS1_O2, HS7, HS3, HS5, HS10, HS6, HS4, HS8, HS9. 
 
Conclusions 
The developed carR probe-based RT-PCR appears to be a reliable and accurate diagnostic method that can be 
applied for the detection and quantitation of H. suis in gastric samples. Since no interactions with other NHPH, 
nor with host DNA could be observed, the use of this technique is recommended for the screening of gastric 
biopsies, derived from human patients and animals. Using the optimized isolation protocol, we succeeded in 
isolating relatively low numbers of H. suis bacteria from the mouse stomach. Application of this technique may 
help to obtain and characterize pure human-derived H. suis isolates after mouse-passage of H. suis-infected 
human gastric biopsies.  
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LEGENDS OF SUPPLEMENTARY TABLES 
Supplementary Table 1 Overview of the separate cq-values, means and standard deviations for the standard 
dilution series within one run using the carR probe-based RT-PCR 
Supplementary Table 2 Overview of the separate cq-values, means and standard deviations for the standard 
dilution series between 3 different runs using the carR probe-based RT-PCR 
Supplementary Table 3 Detailed overview on the H. suis status and the obtained cq mean values after analysis 
of the gastric samples from different hosts with the ureA-based SYBR green RT-PCR, the carR probe-based RT-
PCR and the carR-based SYBR green RT-PCR
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TABLES 
Table 1 Overview of the bacteria used to verify the diagnostic specificity of the probe-based RT-PCR for H. suis . 

















Epsilonproteobacteria Campylobacterales  No No No 



















Epsilonproteobacteria Campylobacterales  No No No 
H. cynogastricus JKM4 Epsilonproteobacteria Campylobacterales  Yes No No 
H. baculiformis m50 Epsilonproteobacteria Campylobacterales  Yes No No 
H. cetorum 015903/016202 Epsilonproteobacteria Campylobacterales  No No No 
H. cholecystus r3555 Epsilonproteobacteria Campylobacterales  No No No 
H. trogontum r3554 Epsilonproteobacteria Campylobacterales  No No No 
H. acinonychis Hacino1-3 Epsilonproteobacteria Campylobacterales  No No No 
H. mustellae img8776 Epsilonproteobacteria Campylobacterales  No No No 
H. pullorum cb103 Epsilonproteobacteria Campylobacterales  No No No 
H. marmotae cb55 Epsilonproteobacteria Campylobacterales  No No No 
H. 
mesocricetorum 
ccug45420 Epsilonproteobacteria Campylobacterales  No No No 
H. bilis atcc49320 Epsilonproteobacteria Campylobacterales  No No No 
H. equorum EqF1 Epsilonproteobacteria Campylobacterales  No No No 
H. canadensis H7163 Epsilonproteobacteria Campylobacterales  No No No 
Campylobacter 
spp. 
C. jejuni KC40/TB4 Epsilonproteobacteria Campylobacterales  No No No 
C. coli Grp028 Epsilonproteobacteria Campylobacterales  No No No 
C. upsaliensis img19529 Epsilonproteobacteria Campylobacterales  No No No 
C. fetus V24-6 Epsilonproteobacteria Campylobacterales  No No No 
Other bacteria 
Lactobacillus 
reuteri/ L. gasseri 
Cb110/Cb108 Bacilli Lactobacillales No No No 
Clostridium LR3869 Clostridia Clostridiales No No No 
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LR3843/LR3821 Bacilli Bacillales No No No 
Streptococcus 
suis/ S. equi 





Bacilli Lactobacillales No No No 
Pasteurella 
multocida 
LR3892 Gammaproteobacteria  Pasteurellales No No No 
Mannheimia 
haemolytica 




LR3798 Gammaproteobacteria Enterobacteriales No No No 
Pseudomonas 
aeruginosa 
LR3861 Gammaproteobacteria Pseudomonadales No No No 
Klebsiella 
pneumoniae 
LR3806 Gammaproteobacteria Enterobacteriales No No No 
Proteus vulgaris LR1537 Gammaproteobacteria Enterobacteriales No No No 
Bacillus 
licheniformis 
DMS347 Bacilli Bacillales No No No 
Salmonella 
Typhimurium 
LR3862 Gammaproteobacteria Enterobacteriales No No No 
Trueperella 
pyogenes 
LR3863 Actinobacteria Actinomycetales No No No 
Escherichia coli LR3889 Gammaproteobacteria Enterobacteriales No No No 
Aeromonas 
hydrophila 
LR3758 Gammaproteobacteria Aeromonadales No No No 
Fusobacterium 
gastrosuis 
CDW01 Fusobacteria Fusobacteriales No No No 
Enterococcus 
faecalis 
LR3751 Bacilli Lactobacillales No No No 
Actinobacillus 
equuli 
ccug 19799T Gammaproteobacteria Pasteurellales No No No 
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Table 2 Overview of the number of positive gastric samples, using the ureA-based RT-PCR, the carR probe-
based RT-PCR and the carR-based SYBR green RT-PCR. Gastric samples were derived from pigs (natural host), 
humans, non-human primates (natural host) and mice (experimental infections).  
Host gastric samples 
Number of 
samples 
Number of H. 
suis positive 
samples 
Number of positive 
samples using ureA-
based RT-PCR 
Number of positive 
samples using carR 
probe-based RT-PCR 
Number of positive samples 
using carR-based SYBR 
green RT-PCR 
Human (with or 
without natural H. 
suis infection) 
80 6 7 6 0 
Non-human 
primates (with or 
without natural H. 
suis infection) 
9 8 9 8 6 
Mice 
(experimentally 
infected animals and 
control animals) 
8 4 4 4 0 
Pigs (with or without 
natural H. suis 
infection) 
9 5 5 5 0 
 
 
Table 3 Overview of the mean number and standard deviation of H. suis bacteria/µl (cq-mean) in the positive 
gastric samples per host, using ureA-based RT-PCR and carR probe-based RT-PCR respectively. Gastric samples 
were derived from pigs, humans, non-human primates and mice.  
 
Cq-mean ureA-





SYBR green RT-PCR 
Stdev carR probe-
based RT-PCR 
Human positive gastric 
samples 9.68E+02 2.68E+01 2.13E+03 3.49E+01 
Non-human primate positive 
gastric samples 1.38E+06 7.79E+04 3.95E+06 1.55E+05 
Murine positive gastric 
samples 1.14E+04 4.20E+03 3.85E+03 2.41E+03 
Porcine positive gastric 
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SUPPLEMENTARY TABLES 
Supplementary Table 1 
 
1,00E+00 1,00E+01 1,00E+02 1,00E+03 1,00E+04 1,00E+05 1,00E+06 1,00E+07 1,00E+08 1,00E+09 
Standard 1 37.57 33.47 29.07 25.38 21.98 18.49 15.16 11.92 7.53 3.26 
Standard 2 35.03 32.32 29.1 25.92 22.11 18.99 15.21 11.86 7.93 3.59 
Standard 3 36.49 33.11 29.08 26.03 21.93 18.42 15.25 11.98 7.67 3.08 
Standard 4 35.86 32.59 29.28 25.52 22.01 18.98 15.1 11.84 7.52 3.48 
Standard 5 36.99 32.75 28.85 25.5 22.05 18.74 15.04 11.75 7.68 3.57 
Standard 6 35.37 33.03 29.31 25.58 22.09 18.96 15.43 11.85 7.9 3.56 
Mean 36.2183 32.878 29.115 25.655 22.028 18.7633 15.1983 11.8667 7.705 3.42333 
SD 0.97534 0.4094 0.1667 0.25859 0.0682 0.25696 0.13615 0.07789 0.17627 0.20772 
Efficiency 
run (%) 89.9 
         Linear 
correlation 
(r²) 0.998 
          
Supplementary Table 2 
 
1,00E+00 1,00E+01 1,00E+02 1,00E+03 1,00E+04 1,00E+05 1,00E+06 1,00E+07 1,00E+08 1,00E+09 
Run 1 37.07 32.43 28.48 25.09 21.58 18.25 14.92 11.57 6.99 2.47 
 
36.41 31.98 28.42 24.96 21.59 18.28 14.93 11.73 7.11 1.79 
 
36.39 31.66 28.46 25.07 21.56 18.28 14.86 11.46 7.19 2.35 
Run 2 34.66 31.71 28.47 25.15 21.92 18.43 14.8 11.67 6.96 2.97 
 
35.51 32.6 28.54 25.18 21.83 18.45 14.92 11.76 7.76 3.44 
 
36.03 32 28.62 25.17 21.82 18.41 14.93 11.65 7.29 3.07 
Run 3 
no value 
(nv) 32.37 29.18 26.11 22.25 18.6 15.57 12.09 7.83 3.24 
 
36.14 32.62 29.3 25.99 22.37 18.66 15.62 12.13 8.01 3.8 
 
nv 32.78 29.26 25.55 22.24 18.61 15.53 11.97 7.8 3.24 
Mean 36.03 32.239 28.7478 25.3633 21.907 18.4411 15.12 11.7811 7.43778 2.93 
SD 0.7654 0.4125 0.3796 0.42205 0.3131 0.15463 0.34329 0.23267 0.40862 0.62028 
Mean 
efficiency 
run 1,2 and 
3 90.03 
         Mean 
linear 
correlation 
run 1,2 and 
3 0.998 
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Supplementary Table 3 








DNA (n=80)     
human 1 Absent Negative Negative Negative 
human 2 Absent Negative Negative Negative 
human 3 Absent Negative Negative Negative 
human 4 Absent Negative Negative Negative 
human 5 Absent Negative Negative Negative 
human 6 Absent Negative Negative Negative 
human 7 Absent Negative Negative Negative 
human 8 Absent Negative Negative Negative 
human 9 Absent Negative Negative Negative 
human 10 Absent Negative Negative Negative 
human 11 Absent Negative Negative Negative 
human 12 Absent Negative Negative Negative 
human 13 Absent Negative Negative Negative 
human 14 Absent Negative Negative Negative 
human 15 Absent Negative Negative Negative 
human 16 Absent Negative Negative Negative 
human 17 Absent Negative Negative Negative 
human 18 Absent Negative Negative Negative 
human 19 Absent Negative Negative Negative 
human 20 Absent Negative Negative Negative 
human 21 Absent Negative Negative Negative 
human 22 Absent Negative Negative Negative 
human 23 Absent Negative Negative Negative 
human 24 Absent Negative Negative Negative 
human 25 Absent Negative Negative Negative 
human 26 Absent Negative Negative Negative 
human 27 Absent Negative Negative Negative 
human 28 Absent Negative Negative Negative 
human 29 Absent Negative Negative Negative 
human 30 Absent Negative Negative Negative 
human 31 Absent Negative Negative Negative 
human 32 Absent Negative Negative Negative 
human 33 Absent Negative Negative Negative 
human 34 Absent Negative Negative Negative 
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human 35 Absent Negative Negative Negative 
human 36 Absent Negative Negative Negative 
human 37 Absent Negative Negative Negative 
human 38 Absent Negative Negative Negative 
human 39 Absent Negative Negative Negative 
human 40 Absent Negative Negative Negative 
human 41 Absent Negative Negative Negative 
human 42 Absent Negative Negative Negative 
human 43 Absent Negative Negative Negative 
human 44 Absent Negative Negative Negative 
human 45 Absent Negative Negative Negative 
human 46 Absent Negative Negative Negative 
human 47 Absent Negative Negative Negative 
human 48 Absent Negative Negative Negative 
human 49 Absent Negative Negative Negative 
human 50 Absent Negative Negative Negative 
human 51 Absent Negative Negative Negative 
human 52 Absent Negative Negative Negative 
human 53 Absent Negative Negative Negative 
human 54 Absent Negative Negative Negative 
human 55 Absent Negative Negative Negative 
human 56 Absent Negative Negative Negative 
human 57 Absent Negative Negative Negative 
human 58 Absent Negative Negative Negative 
human 59 Absent Negative Negative Negative 
human 60 Absent Negative Negative Negative 
human 61 Absent Negative Negative Negative 
human 62 Absent Negative Negative Negative 
human 63 Absent Negative Negative Negative 
human 64 Absent Negative Negative Negative 
human 65 Absent Negative Negative Negative 
human 66 Absent Negative Negative Negative 
human 67 Absent Negative Negative Negative 
human 68 Absent Negative Negative Negative 
human 69 Absent Negative Negative Negative 
human 70 Absent Negative Negative Negative 
human 71 Absent Negative Negative Negative 
human 72 Absent Negative Negative Negative 
human 73 Absent Negative Negative Negative 
human 74 Present 2.51E+01 2.05E+00 Negative 
human 75 Present 1.07E+02 3.39E+01 Negative 
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human 76 Present 5.78E+03 9.21E+01 Negative 
human 77 Present 4.65E+02 1.74E+00 Negative 
human 78 Absent 2.12E+01 Negative Negative 
human 79 Present 3.32E+02 2.74E+01 Negative 
human 80 Present 4.39E+01 3.69E+00 Negative 
Non-human 
primate DNA (n=9)     
JI 503 biopt a Present 1.49E+02 4.96E+00 Negative 
Ro2019 bio a Present 2.89E+04 2.71E+03 7.14E+02 
r08041 bio a Present 1.74E+04 1.28E+04 Negative 
JI 190 bio a Absent 3.96E+02 Negative Negative 
HSM1Ro40522 dna Present 1.19E+07 4.54E+05 7.60E+05 
baviaan 9 bio a Present 1.03E+05 9.08E+04 2.02E+03 
baviaan 9 bio f Present 2.34E+04 1.34E+04 1.08E+03 
rhesus aap bio a Present 9.36E+04 1.92E+04 2.72E+03 
rhesus aap bio f Present 2.53E+05 3.04E+04 4.79E+03 
Mouse DNA (n=8) 
    
1m2 c1 c Absent Negative Negative Negative 
1m2 c2 c Absent Negative Negative Negative 
1m2 c3 c Absent Negative Negative Negative 
1m2 c4 c Absent Negative Negative Negative 
1m2 s1 c Present 1.22E+04 3.66E+03 Negative 
1m2 s2 c Present 1.60E+04 7.61E+03 Negative 
1m2 s3 c Present 1.08E+04 3.63E+03 Negative 
1m2 s4 c Present 6.68E+03 1.91E+03 Negative 
Pig DNA (n=9) 
    
p17 c Absent Negative Negative Negative 
p18 c Absent Negative Negative Negative 
p20 c Absent Negative Negative Negative 
p11 c Present 1.72E+03 5.14E+02 Negative 
p27 c Present 4.03E+01 8.42E+00 Negative 
p28 c Present 2.22E+01 5.05E+00 Negative 
p33 c Absent Negative Negative Negative 
p49 c Present 7.15E+00 2.25E+00 Negative 
p50 c Present 1.12E+03 7.22E+02 Negative 
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...”all the diseases begin in the gut”... by Hippocrates 
 
Besides the well-known human pathogen Helicobacter pylori (H. pylori), non-Helicobacter pylori Helicobacter 
(NHPH) species from domestic animals have also been associated with gastric disease in humans. Many of 
these very fastidious bacteria have recently been in vitro isolated from their natural hosts, which has led to 
progress in understanding the pathogenesis of NHPH-related pathologies. A distinct feature is their association 
with gastric mucosa-associated lymphoid tissue (MALT) lymphoma in humans, but this is most probably a tip of 
the iceberg… 
 
Increased frequency of gastric H. suis infections in human patients with Parkinson’s disease (PD): coincidence 
or an underlying cause in the pathogenesis of this disease?  
H. pylori may interfere with many biological processes, both inside and outside the stomach, possibly 
influencing or determining the occurrence and/or outcome of many extragastric diseases (Alvarez-Arellano et 
al., 2014; Budzynski et al., 2014; Smyk et al., 2014; Testerman et al., 2014; Wong et al., 2014). While its role in 
idiopathic thrombocytopenic purpura (Radic et al., 2014; Hasni et al., 2011; Yamanishi et al., 2006) and 
sideropenic anemia (Kang et al., 2011; Monzon et al., 2013) has already been acknowledged, emerging 
evidence suggests that H. pylori may be associated with neurodegenerative disorders as well (Csoti et al., 2016; 
Alvarez-Arellano et al., 2014; Budzynski et al., 2014; Dobbs et al., 2008; Dobbs et al., 2010; Dobbs et al., 2016; 
Nielsen et al., 2012; Rees et al., 2011). PD is a degenerative disorder of the central nervous system (CNS) 
characterized by cell death of dopamine-generating neurons in the substantia nigra, a region of the basal 
ganglia of the brain (Wirdefeldt et al., 2011; Mhyre et al., 2012; Kannarkat et al., 2013). The familial form of PD 
is caused by mutations in several different genes (including the α-synuclein gene and the parkin gene), whereas 
the aetiology of non-heritable idiopathic Parkinsonism (IP) remains unknown, although several risk factors, 
such as rural residence, livestock farming, head trauma, well-water drinking, infectious diseases and exposure 
to pesticides, have been associated with the appearance of this disease state (Lee et al., 2002; Schiesling et al, 
2008, Dobbs et al., 2008; Hardy et al., 2006). Besides aberrations in motor functions, increased gastrointestinal 
dysfunction is well-acknowledged in patients with parkinsonism and usually precedes the diagnosis of PD by 
many years (Edwards et al., 1992; Charlett et al., 1997; Abbott et al., 2001; Pfeiffer, 2011; Dobbs et al., 2016). 
The finding of prodromal peptic ulcers in patients with PD in 1965 (Strang, 1965) paved the way to explore any 
link between (the then not yet described (Warren et al, 1983)) H. pylori and PD. Infection with H. pylori has 
been shown to be an arbiter for progression of the poverty of movement (hypokinesia) (Dobbs et al., 2008; 
Dobbs et al., 2010; Dobbs et al., 2012; Dobbs et al., 2013).  
In some cases, decreased absorption of levodopa, which is the main drug used to treat PD, may be involved 
(Pierantozzi et al., 2001; Hashim et al., 2014). Indeed, eradicating H. pylori in PD patients by applying antibiotic 
treatment results in an increased absorption of levodopa and decreased motor fluctuations (Hashim et al., 
2014). Although it remains unknown how H. pylori may interfere with levodopa absorption, several hypotheses 
have been proposed. Since the solubility of levodopa is pH dependent, H. pylori-induced gastric pH alterations 
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might influence absorption (Annibale et al., 2002). Furthermore, levodopa absorption may also be altered by H. 
pylori-associated gastric myoelectric dysfunctioning resulting in delayed gastric emptying (Miyaji et al., 1999). 
Finally, it has been suggested that H. pylori might utilize levodopa for growth (Doherty et al., 2009).  
Whilst influence of H. pylori on levodopa absorption may be relevant to symptomatic treatment of PD, it does 
not provide evidence on aetio-pathogenesis. This was shown in a randomized, double-blind, placebo-controlled 
trial. Objectively-measured gait hypokinesia improved over the year following biopsy-proven (culture and 
polymerase chain reaction (PCR)) H. pylori eradication, and did not deteriorate over the next two years. The 
effect on hypokinesia was seen in patients never given symptomatic treatment for PD, and was no greater in 
those receiving background anti-parkinsonian medication. Thus, it was not due to improved absorption of 
parkinsonian medication (Dobbs et al 2010). This was confirmed in a longitudinal observational study of the 
effects of routine antimicrobial use on PD. Hypokinesia again improved after treating H. pylori infection, but 
antimicrobials given for other indications did not affect it (Dobbs et al 2013).  
Activation of microglia cells, resulting in neuroinflammation and apoptosis of nerve cells as a consequence of 
chronic gastric inflammation may be a possible explanation for the association that was found between 
H. pylori infection and neurodegenerative disorders (Dobbs et al., 2000; Dobbs et al., 2008; Dobbs et al., 2010; 
Dobbs et al., 2012; Kountouras et al., 2012; Dobbs et al., 2016). This is described in more detail in the next 
heading, dealing with the stomach-brain axis.  
Molecular mimicry between H. pylori antigens and human antigens, presented by dopamine producing neurons 
has also been proposed (Dobbs et al., 2000; Schulz et al., 2006; Dobbs et al., 2008; Dobbs et al., 2010; Dobbs et 
al., 2012; Dobbs et al., 2016). There is molecular mimicry between H. pylori and gastric antigens (Appelmelk et 
al., 1997) and other studies reported the presence of auto-antibodies against dopamine-producing neurons in 
blood and the cerebrospinal fluid in patients with PD (Poupard and Emilie, 1984; Fiszer et al., 1996; Schulz et 
al., 2006; Dobbs et al., 2008; Dobbs et al., 2010; Dobbs et al., 2012; Dobbs et al., 2016).  
 
It has been suggested that living or working on livestock farms may increase the risk of PD (Gorell et al., 1998; 
Lee et al., 2002; Wirdefeldt et al., 2011), raising the possibility that zoonotic transmission of animal-associated 
gastric helicobacters might also contribute to the etiology of this disease. There has been much attention to the 
possible dangers of herbicides, but arable farmers have a reduced risk of dying from PD (Lee et al., 2002). H. 
suis is highly prevalent in the stomach of pigs and is the most prevalent NHPH species in humans (Haesebrouck 
et al., 2009). A case report published in 2013 described a H. suis infection in a pig veterinarian suffering from 
reflux esophagitis and general dyspeptic symptoms (Joosten et al., 2013). Using multilocus sequence typing 
(MLST), it was demonstrated that the H. suis strain, detected in the stomach of the pig veterinarian, was closely 
related to porcine strains confirming the zoonotic potential of this Helicobacter species (Liang et al., 2013). It 
has been suggested that direct contact with pigs might be an important source for H. suis infection in humans 
(Haesebrouck et al., 2009; De Groote et al., 2005; Van den Bulck et al., 2005; Baele et al., 2008). Additionally, 
the consumption of raw or undercooked pork might also constitute a source of H. suis infection in humans (De 
Cooman et al., 2013).  
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Only few information about a possible association between gastric H. suis infections and PD was available at 
the onset of this thesis. There was a report of improvement in PD following eradiation of a spiral gastric NHPH, 
reported at that time to be H. heilmannii (Dobbs et al., 2005), but which we showed to be H. suis. Therefore, in 
the first chapter of this thesis, we reinvestigated deoxyribonucleic acid (DNA), extracted from human gastric 
biopsy samples and archived at a Helicobacter reference laboratory, for the presence of H. suis. An exceptional 
high frequency (27%) of H. suis DNA was found in extracts from patients with PD, compared with those from a 
routine gastroenterology service referrals, in whom no PD had been documented (2%). H. suis DNA was more 
often detected in patients with biopsy proven H. pylori eradication. Based on this finding, it can be 
hypothesized that these patients were co-infected with H. pylori and H. suis as described before (Liu et al., 
2015). Triple therapy, usually consisting of amoxicillin, clarithromycin and a proton pump inhibitor, may have 
been ineffective to eradicate H. suis giving this bacterium the opportunity to multiply in the human stomach 
and to cause gastric disease. Results of previous studies gave evidence of intrinsic reduced susceptibility to 
aminopenicillins of porcine H. suis isolates compared to H. pylori (Vermoote et al., 2011). In addition, recent in 
vitro antimicrobial susceptibility testing showed evidence of acquired resistance to clarithromycin among H. 
suis isolates (De Witte Chloë, 2017, personal communication). Both findings strengthen the above mentioned 
assumption. Indeed, in the case referred to above (Dobbs et al 2005), there was short-lived improvement in PD 
following standard triple therapy, which relapsed with recrudescence of H. suis. Successful (biopsy-proven) H. 
suis eradication resulted in long-term improvement. Nevertheless, successful eradication of H. suis has been 
described after treatment with amoxicillin, clarithromycin and a proton pump inhibitor (Joosten et al., 2013; 
Hellemans et al., 2005). These differences in treatment outcome, might support previous suggestions on the 
occurrence of acquired antimicrobial resistance (Vermoote et al., 2011; De Witte et al., 2017, personal 
communications).  
We additionally described the presence of H. suis DNA in a blood sample of a patient with PD and unpublished 
results from recent in vivo experiments in mice showed the presence of Helicobacter antigens in macrophages 
at the level of mesenteric lymph nodes during chronic infection. Together, all these findings suggest that the 
effects caused by H. suis are not restricted to the stomach. Moreover, H. pylori DNA, and even culturable 
organisms have been found in gastric lymph nodes from human surgical specimens (Ito et al., 2008). Clearly, 
the role of Helicobacter in general and H. suis in particular, in PD requires further investigation.  
 
The stomach-brain axis in relation to a H. suis infection: does H. suis affect neuroinflammation?  
Evidence is accumulating that neuroinflammation plays an important role in the pathophysiology of PD. 
Activated microglia can be detected in the brain of PD patients, reflected by a change in morphology from 
ramified to a more round shape (Wang et al., 2015; Tansey et al., 2007; Hirsch and Hunot, 2009). Microglia 
activation results in the release of pro-inflammatory cytokines which can act on neuronal integrity (Wang et al., 
2015; Fonseca et al., 2014). The intermediate stage, “primed microglia”, describes the atypical microglial stage, 
which precedes a further neurotoxic microglial activation as a consequence of a secondary pro-inflammatory 
stimulus which can come from the periphery (Perry et al., 2013). Indeed, peripheral inflammation can activate 
microglia, in particular when the brain barriers are disturbed (Wang et al., 2015). Several specialized CNS 
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barriers, such as the blood-brain barrier (BBB) and the blood-cerebrospinal fluid (CSF) barrier, play a crucial role 
in the maintenance of brain homeostasis, since they determine what will (and what will not) enter the brain 
(De Bock et al., 2014). The BBB, formed by capillary endothelial cells which are connected by tight junctions, 
separates the circulating blood from the extracellular fluid in the CNS. The blood-CSF barrier is established by 
the choroid plexus epithelial cells, which secrete the CSF and have an essential function in the communication 
between the peripheral immune system and the CNS (De Bock et al., 2014). Dysfunction of these brain barriers 
has been implicated in the pathogenesis of PD (Vawter et al., 1996; Pisani et al., 2012; Stolp et al., 2009; Lee et 
al., 2014).  
Interactions between the gastrointestinal tract and the brain are well recognized (Cryan et al., 2012) and in 
particular, a bidirectional communication between the CNS and the gastrointestinal tract via the gut-brain axis 
has been considered. Moreover, it has been suggested that neuroinflammation could emanate from infection 
in the gastrointestinal tract (Dobbs et al., 2000; Dobbs et al., 2008; Dobbs et al., 2010; Ferrari et al., 2011; 
Dobbs et al., 2013; Dobbs et al., 2016). There is evidence that intestinal infection or dysbiosis plays a part in the 
pathogenesis. There are biological gradients between leukocyte subset counts and facets on PD (Dobbs et al 
2012). The same subsets are associated with hydrogen-breath-test positivity for small-intestinal bacterial 
overgrowth. In PD, successive courses of antimicrobials are associated with cumulative increase in flexor 
rigidity (Dobbs et al. 2013), which may suggest progressively increasing colonic dysbiosis (Carethers, 2011). 
There still appears to be a specific effect of Helicobacter: it had an effect on hypokinesia in addition to that on 
natural-killer cell count (Dobbs et al 2012), and routine treatment of Helicobacter produced an indication 
specific improvement in hypokinesia (Dobbs et al 2013). Gastric Helicobacter spp. generally cause a life-long 
gastric infection since the induced host immune response is not able to eradicate the infection, resulting in 
persistent inflammation and gastric epithelial cell damage (Montecucco & Rapuoli, 2001; Flahou et al., 2011; 
Flahou et al., 2012).  
A recently proposed hypothesis is summarized in Figure 1: Helicobacter might influence the brain through the 
blood, since injury of the gastric mucosa might lead to leakage of bacterial components and metabolites, and 
even pro-inflammatory factors into the blood circulation resulting in systemic inflammation (Fukuda et al., 
2001; Sun et al., 2004; Fedwick et al., 2005; Guttman and Finlay, 2009; Wroblewski et al, 2011; Caron et al., 
2015; Cryan et al., 2014; Mayer et al., 2014). These inflammatory mediators may then contribute to 
disturbance of the brain homeostasis leading to neurodegenerative diseases (Dobbs et al., 2000; Dobbs et al., 
2008; Dobbs et al., 2010; Dobbs et al., 2012; Kontouras et al., 2015; Dobbs et al., 2016; Charlett et al. 1998; 
Dobbs et al. 1999; Reale et al, 2009). Furthermore, several reports suggested the involvement of systemic 
inflammation in the impairment of the BBB (Kortekaas et al., 2005; Stolp et al., 2009) and the blood-CSF barrier 
(Vandenbroucke et al., 2012; Demeestere et al., 2015; Villaran et al., 2010; Perry et al., 2013).  
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Figure 1: Stomach-brain axis via systemic circulation. A gastric infection with Helicobacter may evoke inflammation resulting 
in a disruption of the gastric mucosal barrier. In turn this could lead to leakage of bacterial components and pro-
inflammatory factors from the stomach into the systemic circulation, resulting in systemic inflammation. These 
inflammatory mediators may then contribute to disturbance of the brain homeostasis leading to neurodegenerative 
diseases. Figure was adapted from Baele et al., 2008 (H. suis), Cryan et al., 2012 (vessel), Mayer et al., 2014 (brain), Servier 
Medical Art (stomach).  
 
Elaborating on the high frequency of H. suis infections in patients with PD as shown in chapter 1 and keeping in 
mind the above mentioned hypothesis that Helicobacter might influence the brain through the blood, in the 
second chapter of this thesis we examined whether a gastric H. suis infection has an impact on the integrity of 
the gastric mucosal barrier and the brain barriers through the induction of inflammation. For this purpose, mice 
were infected with a virulent H. suis strain as shown before (Flahou et al., 2010). At 4 weeks post-infection, the 
inflammatory response induced by H. suis was characterized by an infiltration of immune cells in the gastric 
mucosa and submucosa as well as by the secretion of interleukin (IL)-1β, IL-17 and the human IL-8-related 
murine cytokines, lipopolysaccharide (LPS)-induced CXC chemokine (LIX) and keratinocyte-derived chemokine 
(KC), at the site of infection. These findings were in line with previous H. suis experimental infection studies as 
well as with in vivo trials with other gastric helicobacters (Flahou et al., 2012; Flahou et al., 2010; Bosschem et 
al., 2016; Peek et al., 2010; Alvarez-Arellano et al., 2014; Hashim et al., 2014). Since the pro-inflammatory 
cytokine IL-1β is a potent inhibitor of gastric acid secretion, it facilitates Helicobacter colonization of the gastric 
mucosa (Joosten et al., 2013; Semper et al., 2014). It also plays a crucial role in the development of gastric 
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pathologies (Joosten et al., 2013). Its secretion depends on the activation of the inflammasome, an intracellular 
multiprotein oligomer implicated in the activation of inflammatory processes (Semper et al., 2014). H. pylori 
induced inflammasome activation in dendritic cells (DCs) requires the nucleotide-binding oligomerization 
domain, leucine rich repeat and pyrin domain containing 3 (NLRP3) (Semper et al., 2014) and depends on the 
presence of the vacuolating cytotoxin (VacA) and cag pathogenicity island (cagPAI) virulence factors (Semper et 
al., 2014; Guo et al., 2015). In contrast to H. pylori, H. suis lacks both VacA and cagPAI (Vermoote et al., 2011). 
It is currently unknown how this bacterium triggers secretion of IL-1β. Screening of a H. suis transposon mutant 
library, as previously developed for H. pylori (Odenbreit et al., 1996), for its ability to activate the 
inflammasome may help to identify the virulence factors involved in this process.  
Besides IL-1β, expression of the IL-8-related murine pro-inflammatory cytokines, LIX and KC were also 
significantly increased in the gastric mucosa exposed to H. suis. IL-8 is an important chemotactic and activating 
factor for neutrophils (Crabtree and Lindley, 1994) and can be upregulated by IL-1β and tumour necrosis factor 
(TNF) through the nuclear factor (NF)-κB signalling pathway (Liu et al., 2016; Crabtree and Lindley, 1994; Kim et 
al., 2001; Torok et al., 2005). Additionally, IL-8 secretion can be stimulated by the presence of IL-17 via the 
extracellular signal-regulated kinase (ERK) 1/2 mitogen-activating protein (MAP) kinase pathway (Kabir, 2011; 
Bagheri et al., 2015). The H. pylori virulence factor cagPAI and several H. pylori outer membrane proteins 
(OMPs) acting as adhesins (e.g. blood group antigen binding adhesion A (BabA), sialic acid binding adhesion A 
(SabA), outer inflammatory protein A (oipA), etc.), have been shown to be involved in the increased IL-8 
production by gastric epithelial cells (White et al., 2015). Both cagPAI and these H. pylori adhesins are absent in 
H. suis (Vermoote et al., 2011). Recently, the Helicobacter outer membrane protein family (Hof)E and HofF 
proteins of H. heilmannii have been shown to be partly involved in the induction of IL-8 expression in the 
gastric epithelium (Liu et al., 2016). These OMPs are also present in H. suis and it remains to be elucidated 
whether they are involved in this process as well.  
The extensive secretion of IL-8 or the related murine cytokines, LIX and KC, by gastric epithelial cells upon 
Helicobacter infection is probably a key factor in host defenses at the mucosal site. Since the immune 
mechanisms usually fail to eradicate H. suis, resulting in chronic infection (Flahou et al., 2010), continued 
upregulation of these pro-inflammatory cytokines could lead to gastric mucosal damage (Crabtree and Lindley, 
1994). Indeed, in our in vivo experiment, the H. suis-evoked gastric immune response was accompanied by a 
disruption of the gastric mucosal barrier. This was characterized by an increased gastrointestinal barrier 
permeability and alterations in gastric tight junction proteins. A disruption of the gastric epithelial barrier, 
characterized by a loss of claudin-4, claudin-5 and occludin (Fedwick et al., 2005; Wroblewski et al., 2011) in 
combination with a reorganization of ZO-1 and claudin-1 (Guttman et al., 2009; Caron et al., 2015) has also 
been described during H. pylori infections.  
Tight junctions regulate cell polarity and their formation is dependent on the pseudo-autosomal region (PAR)3-
PAR6-atypical protein kinase C (aPKC) (PAR) complex (Vermeer et al., 2003). Loss of tight junctions can be 
mediated by receptor tyrosine kinases, which are members of the epidermal growth factor receptor (ErbB) 
family. Activation of ErbB2 has been shown to disrupt polarity by associating with PAR6 and aPKC and blocking 
the interaction with PAR3 (Aranda et al., 2006). Transmembrane mucins, including mucin MUC13, can 
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participate in receptor tyrosine kinase activation and can thereby contribute to the disruption of the PAR 
complex (Ren et al., 2006). Since MUC13 is aberrantly expressed upon H. suis infection and inflammation (Liu et 
al., 2016), it remains to be elucidated whether MUC13 plays a role in gastric mucosal barrier disruption. In 
order to determine whether MUC13 interacts with one of the members of the ErbB family present on the 
gastric epithelial cells, co-immunoprecipitation can be performed. Additionally, the role of the MUC13 signaling 
pathway in the PAR complex and the disruption of tight junctions in the stomach can be investigated using in 
vitro transfection assays. If the transfection experiments indicate that MUC13 plays a role in the tight junction 
regulation, it is recommended to evaluate whether these changes are correlated with a loss of barrier 
functionality using an electrical cell impedance system (ECIS) or transepithelial electrical resistance (TEER) 
measurements in transwells. 
Apart from the γ-glutamyl transpeptidase (GGT) enzyme and urease (Flahou et al., 2011), no other information 
is currently available on H. suis virulence factors involved in gastric mucosal damage. Unpublished results from 
a whole transcriptome analysis of H. heilmannii showed that GGT is significantly upregulated when this 
bacterium is attached to gastric epithelial cells. Other virulence factors which are altered in expression in 
relation to adherence can thus be potential candidates involved in gastric mucosal barrier disruption and 
should be further investigated. This investigation can be facilitated by chromosomal insertional mutagenesis 
approaches and in vitro and in vivo infection assays using the developed mutants.  
Disruption of the gastric mucosal barrier may result in leakage of pro-inflammatory cytokines, chemokines and 
bacterial metabolites and components, such as LPS, into the blood circulation, thereby inducing systemic 
inflammation (Cryan et al., 2012; Mayer et al., 2014). In our study, significantly increased levels of IL-1β and the 
IL-8-related murine cytokine, macrophage inflammatory protein (MIP)1α, were found in the serum of H. suis-
infected mice resulting in systemic inflammation. This might thus lead to brain barrier dysfunction and 
subsequent alterations in brain homeostasis (Alvarez-Arellano et al., 2014; Mulak et al., 2015), as might the 
elevated serum cortisol and IL-6 found in PD (Charlett et al., 1998; Dobbs et al., 1999). Indeed, the integrity of 
the brain barriers in the H. suis-infected mice was compromised. Infection with H. suis resulted in changes in 
tight junction expression of the BBB and the blood-CSF barrier, but increased permeability was only detected at 
the blood-CSF barrier of H. suis-infected animals. Also neuroinflammation, characterized by the activation of 
microglia cells and the upregulation of pro-inflammatory cytokines, in particular IL-1β and inducible nitric oxide 
synthase (iNos) in the choroid plexus and IL-6 in the hippocampus of the brain, was detected. Downregulation 
of tight junction genes in the hippocampus did not result in increased BBB leakage, suggesting that H. suis 
infection has a higher impact on the blood-CSF barrier compared to the BBB. Intraperitoneal injection of mice 
with LPS, a component which is also present in H. suis and other Gram-negative bacteria, also resulted in 
increased leakage of the blood-CSF barrier as shown before (Vandenbroucke et al., 2012).  
Up to date, it remains unknown whether H. suis LPS might be involved in the disruption of the integrity of the 
brain barriers and brain homeostasis. The administration of the antibiotic polymyxin B, which inhibits different 
biological activities induced by LPS, might be useful to answer this question (Cavaillon et al., 1986). Another 
possibility to investigate the role of H. suis LPS is by creating an LPS mutant of H. suis, as already described for 
Escherichia coli (Liu et al., 2015), and repeat the experiment using the LPS-mutant of H. suis.  
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In our studies, fluorescein isothiocyanate (FITC)-dextran was used to determine the BBB and blood-CSF barrier 
permeability. The application of FICT-dextran is considered a valuable method for the characterization of 
alterations in permeability of both the BBB and the blood-CSF barrier (Hoffmann et al., 2011; Vandenbroucke 
et al., 2012). The advantages of the use of FITC dextran as a tool is that FITC dextrans can be obtained in 
different molecular sizes and that they can be used to determine both solute and ion permeability (small 
molecular size) and protein permeability (high molecular size) (Hoffmann et al., 2011). However, it is not 
recommended to use samples from FITC treated animals in combination with paraformaldehyde (PFA) for 
histological examination, because FITC dextran dissolves in PFA, leading to false negative results (Hoffmann et 
al., 2011).  
An important finding throughout our study was the presence of the pro-inflammatory cytokine IL-1β not only in 
the inflamed stomach but also in the serum and choroid plexus of the H. suis-infected animals, highlighting its 
role in the induction of neuroinflammation via systemic communication. The role of IL-1β in the integrity of the 
stomach-brain axis and induction of neuroinflammation requires further investigation. The usage of H. suis-
infected IL-1β
-/-
 mice might shed more light on this.  
Besides systemic communication, neural communication via neuropeptides, such as VIP, Substance P (SP), 
calcitonin-gene related peptide (CGRP), somatostatin and neuropeptide Y, may also play a role (Delgado et al., 
2004; Erin et al., 2012; Mayer et al., 2014; De Vadder et al., 2015). Therefore we have also investigated the 
effect of an H. suis infection on VIP signaling. A remarkable finding in the stomach was the altered expression 
of the vasoactive intestinal peptide (VIP) and its receptor VIPR1 in H. suis-infected animals compared to 
controls. Neuropeptides, such as VIP, have been shown to promote homeostasis of the mucosal barrier of the 
gastrointestinal tract and have thus been implicated in tight junction regulation (Chen et al., 2015; Anlauf et al., 
2003; Mulak et al., 2015). Alterations in mucosal VIP levels have also been reported in biopsies derived from 
human patients with chronic gastritis and ulcers (Erin et al., 2012; Chen et al., 2015; Islek et al., 2016; Li et al., 
2009; Bercik et al., 2002). Changes in VIP expression might thus induce dysfunction of the gastrointestinal 
barrier and in this way contribute to the formation of gastric pathologies.  
Up to date, the mechanisms by which H. suis might induce changes in VIP expression remain to be elucidated. 
However since alterations in VIP and its receptors have been reported in combination with gastric pathology 
(Erin et al., 2012), H. suis-induced gastric inflammation might be a possible explanation for the observed 
alterations in VIP and VIPR1 expression upon H. suis infection.  
VIP does not only contribute to maintenance of the gastrointestinal epithelial barrier integrity (Conlin et al., 
2009), but it might also be involved in brain homeostasis. Indeed, fibers containing VIP have been identified 
close to the choroid plexus and it has been described that VIP regulates CSF secretion of the choroid plexus 
epithelial cells (Delgado et al., 2003; Nilsson et al., 1991; Lindvall et al., 1978). In addition, the protective role of 
VIP in neurodegenerative disorders, such as PD, has been reported (Delgado et al., 2003). Furthermore, it has 
been described that VIP is able to prevent overactivation of microglia in LPS-induced inflammation in the brain 
(Delgado et al., 2003; Kim et al., 2000). In our study, administration of VIP reduced LPS-induced blood-CSF 
barrier leakage and LPS-induced upregulation of IL-6, TNF, KC and iNos in the choroid plexus. Since VIP is 
present and produced in the CNS and the gastrointestinal system, its potential protective role in the 
  General Discussion 
 159  
 
preservation of integrity of the epithelial barriers of gut and brain should not be neglected. The use of a VIP-
knock-out mouse model might provide information on the role of VIP in H. suis-induced disruption of the 
integrity of the gut and brain barriers. 
Taken together, our results suggest that increased gastrointestinal leakage and disturbance of the blood-CSF 
barrier along with neuroinflammation may be induced by H. suis-associated inflammation and dysregulation of 
the VIP signalling. Furthermore, the pivotal role of the choroid plexus in the communication between the 
stomach and the brain via systemic inflammation and dysregulation of VIP signalling has been identified. 
Nevertheless, further research is required to elucidate the underlying mechanisms by which an infection with 
H. suis may influence gastrointestinal‒brain communication.  
 
Optimization of diagnostic tools for the detection of H. suis in human samples 
In general, diagnosing gastric NHPH infections in humans is problematic. Non-invasive commercial tests are 
currently unavailable. The urea breath test, frequently used to diagnose H. pylori infections, is usually negative 
in patients infected with NHPH, except when H. pylori co-exists (Matsui et al., 2014). The patchiness and 
sparseness of the gastric colonization by NHPH is probably the underlying cause for these false-negative results 
(Stolte et al., 1997; Solnick and Schauer, 2001). Serologic tests to screen for NHPH infections are lacking. Up 
until the present day, infection with these fastidious pathogenic agents is diagnosed by the analysis of gastric 
biopsies using histological, molecular and microbiological techniques (Debongnie et al., 1995; De Groote et al., 
2001; Baele et al., 2004; O’Rourke et al., 2004; Matsui et al., 2014).  
PCR has been considered as an analytically sensitive and specific diagnostic method for the identification of 
Helicobacter in human gastric biopsies (Ndip et al., 2003; Ricci et al., 2007). Moreover, real-time (RT)-PCR 
allows quantitation of bacteria in gastric biopsies (He et al., 2002). To identify H. suis in the gastric biopsy 
samples from the study performed in chapter 1, a H. suis-specific ureA-based SYBR green RT-PCR was used. For 
this latter molecular assay, additional sequencing of the positive amplicons was necessary, since cross-
reactivity with host DNA and DNA from other gastric helicobacters occurred, questioning the biological 
specificity of this test. In SYBR green RT-PCR assays, a signal will be emitted when the fluorophore binds to any 
double stranded DNA (Valones et al., 2008). In our assay, aspecific binding of the ureA-based primers with 
other DNA than the H. suis target DNA will thus result in a fluorescent signal and in false-positive results. 
Furthermore, UreA is essential for all gastric helicobacters to resist the acidic environment and to colonize the 
stomach. This virulence factor is, based on its high sequence level identity among the different gastric 
helicobacters, well conserved (Smet et al., unpublished results) explaining the occurrence of cross-reactivity 
with DNA from closely related members in our assay. It can thus be concluded that the ureA gene is actually 
not the optimal candidate target for molecular assays in gastric Helicobacter diagnostics if identification to 
species level is required.  
Recently, a new PCR has been developed, using primer pairs targeting the H. suis carR gene (Matsui et al., 
2014). Based on BLASTN searches in the NCBI database, this gene is absent in other gastric and enterohepatic 
Helicobacter spp., Campylobacter spp. and several other bacteria including members of the Enterobacteriaceae 
family and might thus be, compared to ureA, a better candidate PCR amplicon for the identification of H. suis 
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by reducing the possibility for cross-reactivity with DNA from other bacteria (Matsui et al., 2014). Sensitivity 
and specificity of this carR-based molecular assay was at the onset of this thesis lacking and determination of 
both parameters is essential for its introduction into routine clinical use. Therefore, in the third chapter of this 
thesis, we developed a carR probe-based RT-PCR that allows detection and quantification of H. suis in gastric 
tissue samples. The introduction of a H. suis-specific carR probe increased the specificity by excluding cross-
reactivity with host DNA and DNA from other bacteria. Such probe will bind to a specific region within the 
single-stranded DNA. In contrast to SYBR green assays, in probe-based assays fluorescence will only be emitted 
when the DNA polymerase separates the reported dye from the quencher during amplification, rendering the 
probe-based RT-PCRs more specific (Valones et al., 2008). Our assay validation showed a high degree of 
diagnostic specificity and sensitivity compared to the ureA-based SYBR green RT-PCR. However, further 
application on large numbers of clinical samples is recommended. The optimization of such assay is a major 
progress in H. suis diagnostics in humans and similar assays should be developed for the other zoonotic NHPH 
species as well. Screening and comparison of the recently available NHPH genome sequences (Vermoote et al., 
2011; Schott et al., 2011; Arnold et al., 2011; Smet et al., 2013; Smet et al., unpublished results) might facilitate 
the search for and identification of potential Helicobacter species-specific genes. Subsequently, PCR-based 
molecular diagnostic tools based on the amplification of specific regions within these potential Helicobacter 
species-specific genes may be developed. 
Another method to identify gastric Helicobacter infections in gastric biopsies is isolation and cultivation of 
Helicobacter. For H. pylori, the success rate for cultivation reaches up to 100% (Ndip et al., 2003), but it 
depends on the quality, the quantity and the transportation conditions of the gastric biopsies (Ricci et al., 
2007). Because of the high specificity and sensitivity, cultivation is considered as the gold standard for the 
diagnosis of H. pylori infections (Kusters et al., 2006). For NHPH, however, this method has not yet been 
successful, with H. felis and H. bizzozzeronii being the only 2 species cultivated so far from the human stomach 
(Kivisto et al., 2010; Wüppenhorst et al., 2013). This can mainly be attributed to their very fastidious nature 
(Haesebrouck et al., 2009). For H. suis, it requires a highly enriched biphasic medium at pH 5 and a 
microaerobic atmosphere (Baele et al., 2008). Isolation of this agent from the gastric mucosa of pigs is possible 
but is a long and laborious process due to its slow growth. The risk of overgrowth with other bacteria makes 
frequent subculturing necessary in order to obtain pure cultures and it usually takes several weeks to obtain a 
single H. suis isolate (Baele et al., 2008). Efforts to isolate H. suis from human gastric biopsies, either directly 
(unpublished results) or after mouse-passage (Matsui et al., 2104), remained unsuccessful. The low 
colonization density of this pathogenic agent in the human stomach (Matsui et al., 2014) as well as the relative 
fast overgrowth of the isolation plates with other members of the gastric microbiome, including Lactobacillus 
spp., have no doubt contributed to this failure (Sgouras et al., 2004; Vilaichone et al., 2002; Chenoll et al., 2011; 
Matsui et al., 2014). Furthermore, previous studies have described the inhibitory effects on the growth and 
colonization capacity of H. pylori by lactobacilli and bifidobacteria in the stomach (Vilaichone et al., 2002; 
Sgouras et al., 2004; Francavilla et al., 2008; Medouakh et al., 2010; Aiba et al., 2015; Chenoll et al., 2011). This 
may also be the case for H. suis in vitro. To overcome these obstacles, we improved the mouse-passage-based 
protocol for the isolation of low numbers of H. suis bacteria. Mouse-passage of H. suis-infected gastric biopsies 
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might allow H. suis to multiply and to increase in numbers which might increase the chances for successful 
isolation. In our study, H. suis was successfully re-isolated from the stomach of mice on a biphasic medium, 
specified for this bacterium as described before (Baele et al., 2008), and additionally supplemented with 5 
µg/ml linezolid. This antimicrobial agent is active against a broad spectrum of Gram-positive bacteria, including 
many Lactobacillus species (Yagi and Zurenko, 1997; Agar and Gold, 2012), and has a relatively low activity 
(MIC90 8µg/ml) against Helicobacter (Sanchez et al., 2000). Indeed, in the presence of linezolid, H. suis was able 
to grow whereas lactobacilli proliferation was clearly inhibited. This optimized isolation protocol can now be 
applied to isolate H. suis from human gastric biopsies. A possible drawback is that mice should be inoculated 
with homogenized gastric tissue containing 10
4
 bacteria/ml. Indeed, in our study, the minimal infection dose of 
H. suis in mice was 10
4
 viable H. suis bacteria/ml. The same infection dose has been described before and has 
also been reported for H. pylori infection in rhesus monkeys (Matsui et al., 2014; Solnick et al., 2001). 
Nevertheless, due to the low colonization density and patchy distribution of H. suis in the human stomach, this 
bacterium can still be missed when collecting biopsies. Pooling gastric biopsies obtained from several regions in 
the stomach or taking gastric brushes might counter this problem. 
Isolation of human-derived H. suis would be a major breakthrough in H. suis-related research. First, the 
availability of such isolates would allow in vitro antimicrobial susceptibility testing. Because the increasing 
development of antibiotic resistance in Helicobacter species has been suggested (Van de Bulck et al., 2005; 
Kusters et al., 2001; Megraud et al., 2004; Megraud et al., 2007; Vermoote et al., 2011; Thung et al., 2016; 
Regnath et al., 2016), antimicrobial susceptibility testing of human H. suis isolates would allow to determine an 
appropriate patient-specific eradication therapy, thereby minimizing the occurrence of treatment failures and 
antibiotic resistance (Thung et al., 2016). This has already been applied to eradicate H. pylori infections in 
humans (Draeger et al., 2015). DNA prepared from pure human-derived H. suis isolates could also be used to 
further characterize this agent and to identify the origin and the evolution of these strains by comparing their 
genomes with those from porcine and non-human primate H. suis strains (Vermoote et al., 2011; Liang et al., 
2015; Joosten et al., 2013; Bosschem et al., 2016; Flahou et al., unpublished data). Finally, to study the 
pathogenesis of gastric H. suis infections, experimental infection studies are indispensable. Such in vivo trials 
have already been performed in rodent models using porcine and non-human primate strains (Flahou et al., 
2010; Bosschem et al., 2016). Also infection studies with human-derived H. suis have been carried out in the 
past (O’Rourke et al., 2004; Nakamura et al., 2007; Park et al., 2008; Matsui et al., 2014). However, in those 
mouse experiments, homogenized human gastric tissue was used as inoculum. This implies that other 
microorganisms were inoculated together with H. suis, which might have influenced the results (Flahou et al., 
2010). Infection of laboratory animals with pure human-derived H. suis isolates might therefore provide a more 
accurate image of the pathogenesis of infections with this fastidious bacterium (O’Rourke et al., 2004; 
Nakamura et al., 2007; Flahou et al., 2010; Matsui et al., 2014).  
Taken together, the developed methods may be implemented for diagnosis of H. suis in human-derived gastric 
biopsies. The probe-based RT-PCR can be useful for the detection of H. suis bacteria in the human stomach, 
whereas the application of the optimized mouse-passage-based isolation protocol might enhance the chance 
to obtain and characterize human H. suis isolates and to study their pathogenesis in vivo. 
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Final conclusions and future perspectives 
In conclusion, we observed an increased frequency of gastric H. suis infections in human patients with PD, 
suggesting a possible link between H. suis infection and PD. This was further substantiated by demonstrating 
that an infection with this microorganism may influence the stomach-brain axis via the systemic circulation and 
may affect VIP signaling. Furthermore, the availability of optimized and accurate diagnostic tools to identify H. 
suis infections opens new perspectives for the study of its true prevalence in the human population. 
 
It should be further investigated whether the observed effects of a gastric H. suis infection on the brain barriers 
will sensitize to or enhance the development of PD. This can be determined by the use of different in vivo 
models. PD can be mimicked in mice by intracranial injection of the neurotoxin 6-hydroxydopamine or 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP) or by using A30P α-synuclein transgenic mouse models, 
overexpressing the human A30P α-synuclein gene (Godoy et al., 2008; Plaas et al., 2008; Antony et al., 2011). 
However, both 6-hydroxydopamine and MPTP have been reported to cause impairment of the BBB (Carvey et 
al., 2005; Chen et al., 2008), suggesting that the use of the A30P α-synuclein transgenic mouse models is more 
reliable for the evaluation of the effect of H. suis on the course of PD. On the other hand, Sampson et al. (2016) 
recently described the importance of the gut microbiota for the induction of motor deficits, microglia activation 
and α-synuclein pathology in α-synuclein overexpressing transgenic mouse. Indeed, antibiotic treatment 
improved pathophysiology in adult animals, whereas the pathophysiology was increased by microbial re-
colonization of the animals.  
It might also be interesting to perform similar experimental trials to evaluate the influence of H. suis infections 
on development and/or progression of other neurodegenerative disorders. For example, the influence of H. 
suis on Alzheimer’s disease, the most common neurodegenerative disorder in the current human population 
(Wirdefelt et al., 2011), may be studied by using rodent models. Alzheimer’s disease can be mimicked by 
intrahippocampal injection with the neurotoxin amyloid β, which induces the formation of Aβ-plaques in the 
brain, or by using APP-PS1 transgenic mouse models, overexpressing human amyloid β (Lok et al., 2013; Jean et 
al., 2015). 
Besides studying the integrity of the stomach-brain barriers, loss of dopaminergic neurons in the substantia 
nigra of the brain should be investigated. This can be done by using tyrosine hydroxylase staining with or 
without a silver nucleolar staining technique (Healy-stoffel et al., 2012). Additionally, the presence of lewy 
bodies in the remaining neurons can be determined by immunohistochemical stainings such as the α-synuclein 
immunohistochemical staining (Stefanis, 2012) or the ubiquitin immunohistochemical staining (Chu et al., 
2000). Also, expression of genes associated with PD, such as α-synuclein, parkin (PARK), phosphatase and tensin 
homolog (PTEN)-induced putative kinase 1 (PINK) and mitochondrial ribosomal protein S6 (MRPS6) genes, can 
be measured in the brain (Lewis et al., 2012).  
Apart from impairment of the stomach-brain axis resulting in systemic inflammation and dysregulation of the 
VIP expression, changes in the intestinal microbiome might also play a role in development of PD and/or 
influence its course. Several studies have indeed described a possible link between such changes and brain 
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disorders, including depression, autism, Alzheimer’s disease and PD (Parracho et al., 2005; Bercik et al., 2011; 
Bravo et al., 2011; Zhang et al., 2015; Hu et al., 2016; Mulak et al., 2015). Changes in the gut microbiome may 
be caused by a broad range of triggers, including gastrointestinal infections (Ochoa-Reparaz and Kasper, 2014; 
Walters et al., 2014; Zhang et al., 2015). H. pylori infections have already been shown to affect the 
gastrointestinal microbiota in humans (Engstrand et al., 2013; Budzynski et al., 2014; He et al., 2016). 
Therefore, it might be recommended to evaluate the effect of an H. suis infection on the gut microbiome, for 
instance in experimentally infected mice and in H. suis infected human patients, before and after eradication of 
the infection.  
Additionally, it might be recommended to evaluate wether the induced changes in brain homeostasis are 
directly due to the actual infection with H. suis, or rather to possible H. suis-induced changes in the gut 
microbiome. Intestinal microbiota transplantation from a H. suis infected mice to the intestinal tract of a 
control recipient in order to change the recipient’s gut microbial composition might be useful here (Gupta et 
al., 2016). If it appears that the shift in the composition of the microbiota is associated with changes in brain 
homeostasis, intestinal microbiota transplantation from a healty person to a patient suffering fom a 
neurodegenerative disorder might be a potential therapeutic strategy. Indeed, intestinal microbial 
transplantation has already been suggested as a possible therapy for treatment of IBD, diarrhea, Clostridium 
difficile infections, etc. (Gupta et al., 2016).  
Our results indicate that the administration of VIP might play a protective role in inflammation-induced 
disruption of the blood-CSF barrier integrity and brain homeostasis. The immunomodulatory and 
neuroprotective effect of VIP has already been suggested in the past (Kim et al., 2000; Delgado and Ganea, 
2003; Delgado et al., 2004). Moreover, a protective effect of VIP in PD and Alzheimer’s disease has been 
described (Delgatdo and ganea, 2003; Song et al., 2012). Therefore, the administration of VIP might be another 
possible therapeutic strategy in patients suffering from PD or other neurodegenerative disorders.  
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Helicobacter pylori is the most prevalent Helicobacter species in humans. Infection with this agent has been 
associated with a broad range of gastric disorders, including gastritis, ulcers and cancer. Besides causing 
inflammation in the stomach, H. pylori infection has also been linked to extragastric manifestations, including 
Parkinson’s Disease (PD). Patients with this neurodegenerative disorder frequently display gastrointestinal 
complaints but their symptoms cannot always be assigned to infection with H. pylori. 
Gastric disease in humans has, however, also been associated with spiral-shaped non-Helicobacter pylori 
Helicobacter (NHPH) species, such as H. suis. This zoonotic agent, highly prevalent in pigs and non-human 
primates, is the most prevalent NHPH in humans and has been associated with gastritis, gastric and duodenal 
ulcers and mucosa-associated lymphoid tissue (MALT) lymphoma. The risk for developing MALT lymphoma is 
higher when infected with H. suis than H. pylori. Living in close contact with pigs or the consumption of raw or 
undercooked meat are considered to be risk factors for infection with this agent. 
Compared to H. pylori, diagnosis of H. suis infections is extremely difficult due to the sparse and patchy 
distribution in the human stomach and the fastidious nature of this bacterium.  
At the onset of this thesis, no information was available on the prevalence of H. suis in Parkinson’s disease 
patients, nor was there any information found on how and to what extend an infection with this agent  could 
contribute to the outcome of this neurodegenerative disorder. Additionally, the currently used methods to 
diagnose H. suis infections, lacked optimization in terms of sensitivity and specificity. 
 
In our first study, we investigated the prevalence of H. suis infections in patients suffering from idiopatic 
parkinsonism (IP) and gastric complaints and compared it with the known frequency of H. pylori infection in 
this group. A control group of gastroenterology patients with no clinical parkinsonism was included for the 
purpose of comparison. Archived DNA extracts were examined for the presence of H. suis DNA using an ureA-
based SYBR green RT-PCR assay. Results were confirmed by additional sequencing of the positive PCR 
amplicons. Additionally, multi-locus sequence typing (MLST) was performed to demonstrate that the H. suis 
DNA in the biopsy extracts was different from that of the H. suis lab strain used as positive control in the RT-
PCR assay.  
From the 60 patients with IP, 27% and 28% tested positive for H. suis and H. pylori respectively, whereas only 
2% and 16% from the 256 control patients tested positive for H. suis and H. pylori, respectively. These results 
indicated that the relative risk of having an infection with H. suis was 10 times higher in PD patients compared 
to controls. Interestingly, from the 16 H. suis positive IP patients, 11 were from 19 with proven H. pylori 
eradication, 3 from 17 pre-H. pylori eradication and 2 from 24 H. pylori culture/PCR negative. Remarkably, the 
frequency of H. suis was the highest in the patients where H. pylori has been eradicated. 
Partial MLST results for the H. suis DNA found in extracts from 6 IP patients and 1 control showed that the 
allele pattern in these samples differed from that of the DNA from the in vitro lab strain. This indicated that the 
results were not due to contamination. 
In conclusion, this study highlighted that the prevalence of H. suis was higher in patients with IP compared to 
our control group and that it was even more exaggerated in those following H. pylori eradication therapy.  
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The brain is protected from alterations in systemic circulation by a series of specialized barriers, including the 
blood-brain barrier (BBB) and the blood cerebrospinal fluid barrier (blood-CSF barrier). Dysfunction of these 
barriers has been linked to multiple neurodegenerative disorders, including Parkinson’s disease. Furthermore, 
systemic inflammation might contribute to the impairment of the BBB and the blood-CSF barrier. Since 
infections with Helicobacter have been suggested to induce systemic inflammation, it might be possible that a 
gastric H. suis infection could influence the integrity of the brain barriers and thereby contribute in the 
pathophysiology of neurodegenerative disorders. Therefore, in the second study, we evaluated the influence 
of an experimental infection with H. suis on the integrity of the stomach-brain axis in mice. To investigated this, 
C57BL/6 mice were inoculated intragastrically with viable H. suis and compared to a negative control group. At 
4 weeks post-infection, animals were euthanized and samples from the stomach and brain were analyzed. An 
infection with H. suis induced gastric inflammation, characterized by the infiltration of mononuclear and 
polymorphonuclear cells in the mucosa and submucosa of the stomach. This finding was accompanied by the 
increased expression of interleukin (IL)-1β, murine IL-8 homologs and increased protein levels of IL-1β and IL-
17. A significant increase in the gastric mucosal permeability was associated with abberrant expression of the 
tight junction protein zonula occludens (ZO)-1 and the transmembrane Muc13 mucin. Furthermore, altered 
expression of the vasoactive intestinal peptide (VIP) and its receptor (VIPR1) was detected in the stomach of H. 
suis-infected mice. VIP has been shown to play a regulatory and protective role in barrier integrity, tight 
junction expression and mucin secretion in the gastrointestinal tract. These findings indicated that the loss of 
gastric-mucosal barrier integrity in H. suis infected mice might result in increased gastrointestinal leakage of 
cytokines, chemokines and bacterial compounds which could lead to systemic inflammation. Indeed, increased 
levels of IL-1β and the murine IL-8 homologue, MIP1α were observed in the serum of infected animals. 
Subsequently, the influence of H. suis on the integrity of the brain barriers (BBB and blood-CSF barrier) and 
brain homeostasis was investigated. A significant increase in the blood-cerebrospinal fluid (CSF) barrier 
permeability upon H. suis infection was seen. In contrast, blood-brain barrier permeability was unaffected at 
this acute stage of infection. Disturbance of the blood-CSF barrier was associated with an increased expression 
of the pro-inflammatory cytokine Il-1β and the inducible nitric oxide synthase (iNos) and a decreased 
expression of the tight junction genes of claudin 1 (clnd-1) and Occludin (Ocln) in the choroid plexus epithelium 
that forms the blood-CSF barrier. Additionally, an increase of IL-6 expression in the hippocampus was observed 
upon infection with H. suis. These changes in cytokine expression in the brain were accompanied by the 
activation of microglia cells in H. suis-infected animals. Apart from the involvement of VIP in the maintenance 
of the gastrointestinal epithelial barrier, this neuropeptide also plays a role in brain homeostasis. Systemic 
administration of VIP indeed reversed the inflammation-induced disruption of the blood-CSF barrier integrity. 
In conclusion, we have identified the pivotal role of the choroid plexus in the communication between the 
gastrointestinal tract and the brain. Furthermore, our results indicate that disruption of the blood-CSF barrier is 
induced by H. suis-associated systemic inflammation and/or dysregulated VIP signaling. 
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Diagnosing gastric NHPH infections, in general, in humans is problematic. Non-invasive commercial tests are 
currently unavailable. Nowadays, diagnosis of infection with these fastidious pathogenic agents has been 
performed by the analysis of gastric biopsies using histological, molecular and microbiological techniques. To 
identify H. suis in the gastric biopsy samples, a H. suis-specific ureA-based SYBR green RT-PCR has been 
frequently used. For this molecular assay, additional sequencing of the positive amplicons is necessary, since 
cross-reactivity with host DNA and DNA from other gastric helicobacters occurred, questioning the specificity of 
this test. Attempts to directly and/or indirectly (after mouse-passage) isolate pure H. suis strains from human 
gastric biopsies remained unsuccessful. Direct isolation is hampered by the fastidious nature, the low 
colonization density and the patchy distribution of this pathogen, whereas indirect isolation is hampered by 
overgrowth with gastric contaminants, including Lactobacillus spp. In the third study of this thesis, we first 
developed a probe-based RT-PCR for the detection and quantitation of H. suis DNA in gastric biopsies. This RT-
PCR was based on the amplification of the H. suis-specific carR gene. The probe detects a well-conserved 20bp 
long region within this gene. Validation of the assay revealed a high degree of specificity and sensitivity, high 
linear correlations (r² between 0.995-0.999) and high amplification efficiencies (>90%). In order to exclude 
cross-reaction with host DNA, gastric DNA extracts from human patients, pigs, mice and non-human primates 
were analyzed. In contrast to the ureA-based RT-PCR, no aspecific interactions with human, porcine, murine 
and non-human primate DNA, nor with DNA from other bacteria, including Helicobacter spp. and 
Campylobacter spp., were detected when using the carR-probe based RT-PCR.  
Secondly, a mouse-passage-based protocol was further optimized for the isolation of low numbers of viable H. 




). The animals 
were kept for 4 weeks to allow colonization and multiplication of H. suis. In order to inhibit the proliferation of 
gastric contaminants, including Lactobacillus spp., from the murine stomach, 5µg/ml linezolid was added to a 
biphasic medium consisting of Brucella agar with Brucella broth on top of it, both supplemented with vitox 
supplement, Campylobacter-selective supplement, amphotericin (5µg/ml), HCl (0.05%) and fetal bovine serum 
(20%). Using the optimized isolation protocol, we were able to re-isolate H. suis from the stomach of mice 
infected with at least 10
4
 viable H. suis bacteria. 
Finally, we also sequenced the genome of the porcine H. suis strain before and after mouse-passage in order to 
determine the influence of mouse-passage on the genome of H. suis. Our data shows that mouse-passage of H. 
suis does not result in major recombination events within the genome of this bacterium, suggesting that H. suis 
strains obtained after mouse-passage can be used for further characterization of this pathogen.  
In conclusion, the methods described above can be implemented for detection or isolation of H. suis from 
human gastric biopsies. 
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Helicobacter pylori is de meest voorkomende Helicobacter soort bij de mens. Deze kiem wordt geassocieerd 
met gastritis, peptische ulcera en maagkanker. Daarnaast worden infecties met H. pylori ook gelinkt aan andere 
aandoeningen, zoals de ziekte van Parkinson. Patiënten met de ziekte van Parkinson vertonen vaak 
maagklachten, maar hun symptomen kunnen niet altijd toegeschreven worden aan een infectie met deze 
pathogeen. Maagaandoeningen bij de mens kunnen ook veroorzaakt worden door infecties met niet-H. pylori 
Helicobacter species, zoals H. suis die van nature uit de maag van varkens en primaten koloniseert. Bij de mens 
veroorzaakt dit zoönotisch agens gastritis, peptische ulcera en lymfomen van het lymfoïd weefsel van de 
maagmucosa (MALT-lymfomen). Bovendien is het risico op de ontwikkeling van MALT-lymfomen groter bij een 
H. suis infectie dan bij een infectie met H. pylori. Mensen die in nauw contact leven met varkens of rauw/niet 
doorbakken varkensvlees consumeren, hebben meer kans om besmet te worden met H. suis.  
De diagnose van infecties met H. suis bij de mens is moeilijker in vergelijking met H. pylori omwille van het zeer 
focale kolonisatiepatroon in de maag en de hoge moeilijkheidsgraad om dit agens in vitro te cultiveren. Bij de 
start van dit doctoraatsonderzoek was er nog geen informatie beschikbaar over het voorkomen van H. suis 
infecties bij patiënten met de ziekte van Parkinson. Het was eveneens nog onduidelijk of en in welke mate een 
infectie met deze pathogeen kan bijdragen tot het ziektebeeld van deze neurodegeneratieve aandoening. 
Bovendien bleek dat de aangewende technieken voor de detectie van H. suis infecties bij de mens niet 
optimaal waren.  
 
In een eerste studie werd het voorkomen van H. suis infecties bestudeerd bij patiënten met de ziekte van 
Parkinson die maagklachten hadden en vervolgens vergeleken met de reeds gekende prevalentie van H. pylori 
binnen deze groep. Een controle groep (patiënten met maagklachten, maar zonder de ziekte van Parkinson) 
werd eveneens ingesloten ter vergelijking. Het DNA van de maagstalen werd onderzocht op de aanwezigheid 
van H. suis DNA aan de hand van een op het ureA-gen gebaseerde RT-PCR analyse en sequenering van de 
positieve PCR amplicons. Multi-locus sequence typing (MLST) werd uitgevoerd om na te gaan of het H. suis 
DNA in de maagbiopten verschillend was van dat van de H. suis laboratorium stam die gebruikt werd als 
positieve controle.  
In de groep van patiënten met de ziekte van Parkinson testte 27% positief voor H. suis en 28% voor H. pylori. In 
de controle groep werd H. suis slechts aangetoond in 2% van de patiënten, terwijl 16% van de patiënten 
geïnfecteerd waren met H. pylori. Deze resultaten tonen aan dat een H. suis infectie 10 maal frequenter 
voorkwam bij patiënten met de ziekte van Parkinson in vergelijking met de controle groep. Bovendien bleek dat 
de meeste patiënten met de ziekte van Parkinson die positief testten voor H. suis, een succesvolle H. pylori 
eradicatie therapie achter de rug hadden. Tot slot bleek uit de MLST resultaten dat het H. suis DNA in de 
maagbiopten verschillend was van dat van de laboratorium stam waardoor contaminatie kon uitgesloten 
worden.  
Samengevat beschreven we in deze studie een opmerkelijk hoge prevalentie van H. suis infecties bij patiënten 
met de ziekte van Parkinson en voornamelijk bij de patiënten die voorafgaand een anti-H. pylori therapie 
hadden ondergaan. 
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De hersenen worden beschermd tegen gevaarlijke stoffen in de bloedcirculatie door een aantal 
gespecialiseerde barrières, zoals de bloed-hersen barrière (BBB) en de bloed-cerebrospinaal vocht barrière 
(bloed-CSF barrière). Bij verstoring van deze barrières kunnen cytokines en chemokines vanuit de bloedbaan de 
hersenen binnendringen en inflammatie induceren. Er werd inderdaad reeds aangetoond dat systemische 
inflammatie een belangrijke rol speelt in de ontwikkeling van de ziekte van Parkinson. Bovendien doodt H. suis 
de epitheliale cellen in de maag en wordt de epitheelbarrière ter hoogte van de maag doorbroken, waardoor 
ontstekingsmediatoren ook in de circulatie kunnen terechtkomen. Daarom werd er tijdens de tweede studie 
van deze thesis nagegaan in welke mate en op welke manier een H. suis infectie de BBB en de bloed-CSF 
barrière beïnvloedt. Hiervoor werden C57BL/6 wildtype muizen intragastraal geïnoculeerd met levende H. suis 
bacteriën of met het opgroeimedium van deze kiem (negatieve controle). Vier weken na infectie werden de 
dieren geëuthanaseerd en stalen van de maag en de hersenen werden verzameld en geanalyseerd. Inflammatie 
ter hoogte van de maag werd gekenmerkt door de infiltratie van mononucleaire en polymorfonucleaire cellen 
in de mucosa en de submucosa van de maag en een verhoogde mRNA en/of eiwit expressie van interleukine 
(IL)-1β, IL-17 en de chemokines KC en LIX, die bij muizen tot expressie worden gebracht en homoloog zijn aan 
IL-8 van mensen. Een verhoogde maagpermeabiliteit werd geassocieerd met veranderingen in mRNA en eiwit 
expressie van het transmembranair Muc13 mucine en het tight junction eiwit zonulae occludens (ZO)-1. Bij de 
met H. suis geïnfecteerde dieren werd tevens een onderdrukking van de expressie van het vasoactief 
intestinaal peptide (VIP) vastgesteld. Dit peptide speelt een belangrijke rol in het behoud van de maagmucosa 
integriteit. Een verstoorde mucosale maagbarrière kan leiden tot lekkage van cytokines, chemokines en 
bacteriële componenten vanuit de maag naar de bloedsomloop en kan dus resulteren in systemische 
inflammatie. In deze studie werden in het serum van de met H. suis geïnfecteerde muizen verhoogde titers 
gedetecteerd van IL-1β en MIP1α, een cytokine dat net als KC en LIX door muizen tot expressie wordt gebracht 
en homoloog is aan IL-8 van mensen. Vervolgens werd de impact van een H. suis infectie op de integriteit van 
de hersenbarrières onderzocht. Er werd een significante stijging in de bloed-CSF barrière permeabiliteit 
waargenomen. De permeabiliteit van de BBB, daarentegen, werd niet aangetast in dit acuut stadium van de 
infectie. De verstoring van de bloed-CSF barrière werd geassocieerd met een verhoogde expressie van IL-1β en 
het induceerbare stikstof oxide synthase (iNos), alsook met een gedaalde expressie van de tight junctions 
claudine 1 (clnd-1) en occludine (Ocln) ter hoogte van het choroid plexus epitheel dat de bloed-CFS barrière 
vormt. Tevens werd in de hippocampus van de met H. suis geïnfecteerde dieren een verhoogde expressie 
waargenomen van het gen dat codeert voor IL-6. De veranderingen in de expressie van cytokines in de 
hersenen gingen eveneens gepaard met een activatie van de microgliacellen bij H. suis geïnfecteerde muizen.  
VIP zou niet enkel een rol spelen in het behoud van de integriteit van de maagmucosa, maar eveneens in het 
behoud van de homeostase in de hersenen. Vermits de expressie van VIP verstoord was in de maag van met H. 
suis geïnfecteerde dieren, wilden we in deze studie het effect van VIP op de hersenen nagaan. Hiervoor werden 
muizen intraperitoneaal geïnjecteerd met lipopolysaccharide, wat een ontstekingsreactie en een verstoring van 
bloed-CSF barrière veroorzaakt. Systemische toediening van VIP resulteerde in een herstel van de verstoorde 
bloed-CSF barrière.  
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Samengevat, werd in deze studie aangetoond dat de choroid plexus een centrale rol speelt in de communicatie 
tussen de maag en de hersenen . Bovendien wijzen onze resultaten erop dat een verstoorde bloed-CSF barrière 
het gevolg kan zijn van een door H. suis-geïnduceerde systemische inflammatie en/of een verstoring in de VIP 
huishuiding.  
 
De diagnose van infecties met niet-H. pylori Helicobacter species is problematisch en tot op heden zijn er nog 
geen commerciële testen beschikbaar. Voor het aantonen van H. suis DNA in stalen van de maag wordt er o.a. 
gebruik gemaakt van een SYBR green RT-PCR techniek gebaseerd op het ureA gen van dit agens. Bijkomende 
sequenering van de positieve PCR amplicons is echter noodzakelijk omwille van het voorkomen van 
kruisreactiviteit met humaan DNA en DNA van andere gastrale Helicobacter species. Daarnaast is men er nog 
niet in geslaagd om H. suis te isoleren uit maagbiopten (rechtstreeks of via passage in een muismodel) en te 
cultiveren in vitro. In de derde studie werd dan ook eerst een nieuwe RT-PCR ontwikkeld voor de detectie en 
kwantificatie van H. suis DNA in maagbiopten. De RT-PCR was gebaseerd op de amplificatie van het H. suis-
specifieke carR gen. Om amplicons te detecteren werd er, in plaats van het frequent gebruikte SYBR green, 
geopteerd voor een fluorescent gemerkte probe die een geconserveerde regio van 20 baseparen binnen het 
carR gen detecteert. Validatie van deze techniek toonde een hoge specificiteit en sensitiviteit aan, alsook hoge 
lineaire correlaties (r
2
 tussen 0.995-0.999) en een hoge amplificatie efficiëntie (>90%). Er werd geen 
kruisreactie vastgesteld met DNA van andere bacteriën, humane patiënten, varkens, muizen en niet-humane 
primaten. 
Vervolgens werd een bestaand protocol voor de isolatie van lage aantallen levende H. suis bacteriën uit de 
maag via passage in een muismodel verder geoptimaliseerd. Hiervoor werden muizen intragastraal 




). De dieren werden gedurende 4 
weken aangehouden om kolonisatie en vermeerdering van H. suis mogelijk te maken. Daarna werden ze 
geëuthanaseerd en de maag werd voorbehandeld met een 1% HCl oplossing gedurende 45 minuten. Deze 
voorbehandelde stalen werden dan geïnoculeerd in het bifasische opgroeimedium van H. suis waaraan 5µg/ml 
linezolid was toegevoegd. Dit antibioticum is nodig om te vermijden dat bacteriën die behoren tot de 
microbiota van de muizenmaag, waaronder Lactobacillus spp., het medium overwoekeren en isolatie van H. 
suis onmogelijk maken. Het opgroeimedium bestond uit Brucella agar met daarboven Brucella broth, beiden 
gesupplementeerd met Vitox, Campylobacter-selectief supplement, amphotericine (5µg/ml), HCl (0,05%) en 
geïnactiveerd foetaal kalfserum (20%). Door gebruik te maken van het geoptimaliseerde isolatie protocol 
slaagden we erin om H. suis te isoleren uit de maag van muizen die initieel werden geïnfecteerd met tenminste 
10
4
 levende H. suis kiemen.  
Tot slot werd er ook nagegaan of de passage van H. suis in de muizenmaag een impact heeft op het genoom 
van deze bacterie. Hiervoor werd het genoom van de H. suis stam voor en na isolatie uit de muizenmaag 
gesequeneerd. Uit de genoomanalyses konden geen grote veranderingen in het genoom waargenomen 
worden. Samengevat kunnen we stellen dat de ontwikkelde en geoptimaliseerde diagnostische technieken 
gebruikt kunnen worden voor de detectie en/of isolatie van H. suis in humane maagbiopten. 
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Boyen om mee in te staan voor de organisatie en de financiering van het labo. Prof dr. Pasmans, dank u wel 
voor uw bijdrage als promotor van het FOD project met betrekking tot Helicobacter.  
Sofie DB en Nathalie, heel erg bedankt voor jullie expertise, geduld, ervaring, en al de hulp bij de 
experimenten. Ik was altijd heel erg blij en dankbaar als jullie een handje konden toesteken in mijn onderzoek. 
De momenten die we samen gespendeerd hebben in de flows van het Salmonellalabo en bij de 
muisexperimenten in de stallen zullen me steeds bijblijven. Serge en Arlette, dank jullie wel voor al de hulp 
tijdens de routine en voor de leuke gesprekken die we gevoerd hebben terwijl ik de muizenbakjes aan het 
kuisen was. Serge, nog heel veel succes met de verbouwingen! Arlette, ik hoop dat je revalidatie vlot kan 
verlopen en dat je snel weer de natuur kan gaan verkennen! Koen, jij bent altijd het ‘zonnetje’ op het labo: als 
je vrolijk fluitend in de gang passeerde verscheen er spontaan een glimlach op mijn gezicht. Dank je voor al de 
administratieve zaken die je steeds met een lach voor mij hebt geregeld. Jo, dank je voor al de hulp bij de 
bestellingen en de snelle reactie als ik weer eens snel iets heel dringend moest hebben. Gunther M. , jij was er 
elke dag om me als eerste een ‘goeiemorgen’ toe te wensen. Je stond telkens weer klaar om alles te regelen als 
er weer eens muisjes aangekomen waren. Connie, hoeveel keer hebben we niet samen in de PCR labo’s 
gezeten… dank je voor alle leuke gesprekken die we daar gevoerd hebben. Chana, Julie en Sarah, het was 
steeds een plezier om met jullie samen in het labo te werken, jullie positieve ingesteldheid zal me steeds 
bijblijven. Jackeline, hoewel ik niet echt de tijd heb gehad om je goed te leren kennen, kan ik me jou enkel al 
glimlachend voorstellen en was je altijd te vinden voor een voor een fijne conversatie. Christian, Delphine en 
Joachim: Jullie wisten al hoe laat het was als ik bij jullie binnenkwam hé. “Ze is daar weer met haar muizen-
maagjes” zullen jullie waarschijnlijk vaak gedacht hebben. Erg bedankt om steeds met een brede glimlach mijn 
staaltjes zo snel mogelijk in te bedden, te snijden en te kleuren. Het was een plezier om met jullie samen te 
werken! Sarah L en Marjan, dank jullie voor de snelle uitvoering van de immunohistochemische kleuringen en 
de fijne gesprekken. Marleen, zoals jij lopen er geen twee (ook niet je tweelingzus) op de aarde. Ik ben enorm 
blij dat ik je heb mogen leren kennen. Dank je wel voor de oneindige vriendschap, bezorgdheid, medeleven, 
hulp, advies en steun die je me de afgelopen 4 jaar hebt gegeven. Je ben echt goud waard en ik wens je nog 
veel geluk toe.  
Karen, voor ons begon het allemaal met toertjes lopen rond de faculteit. Tijdens het lopen, hadden we 
natuurlijk veel tijd om te praten en daaruit ontstond een hechte vriendschap. Bedankt voor deze 4 mooie jaren, 
alle leuke momenten en de onvergetelijke herinneringen. Ik ga onze loopsessies heel erg missen. Nog veel 
succes met je doctoraat, ik duim heel erg voor jou. Lieze, de spring-in’t-veld van de vakgroep! Je hebt de gave 
om iedereen van het ene op het andere moment direct gelukkig te maken en te laten lachen. Je gedrevenheid, 
doorzettingsvermogen en enthousiasme zijn een voorbeeld voor iedereen! Bedankt voor alle leuke (soms 
knotsgekke) belevenissen. Nog veel succes verder met je PhD, jullie huisje, de diertjes, en nog zo veel meer . 
Marc, als ik jou tegenkwam, was mijn dag stante pede goed! Je wist me steeds te entertainen, op te beuren, te 
motiveren, aan het lachen te brengen, etc. Elke keer als je langs het raam van onze bureau passeerde werd ik 
begroet met een ‘zwaaitje en een brede glimlach’. Deze kleine, simpele dingen zullen me altijd bij blijven. Heel 
erg bedankt voor alles en ik wens je nog enorm veel geluk en voorspoed toe. Roel, ik denk niet dat er veel 
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mensen zo gedreven, gemotiveerd en gebeten zijn door het onderzoek als jij. Je was een voorbeeld voor ons 
allemaal! Je stond bovendien altijd klaar om mensen te helpen, zelf al moest je daarom je eigen werk uitstellen. 
Heel erg bedankt, nog veel succes in jullie huisje en ik wens je het allerbeste voor de toekomst. Gunther, al wat 
ik hierboven over Roel heb beschreven, is eveneens voor jou van toepassing. Door je brede kennis ben je één 
van de aanspreekpunten in het labo waar iedereen bij terecht kan. Jij gaat het ongetwijfeld nog ver brengen. Ik 
had ook het geluk dat ik je bureaugenoot kon zijn. Dank je wel voor alle leuke momenten! An G, of correcter 
Prof dr. Garmyn, dank je wel voor alle hulp, de steun en vooral de leuke tijd op onze bureau en daarbuiten! 
Justine en Wolf: na de herorganisatie van de plaatsen op de vakgroep zijn jullie onze bureaugenootjes 
geworden. Dank jullie wel voor de vele leuke momenten dat we samen hebben beleefd! Ik wens jullie allebei 
nog enorm veel succes in jullie verdere carrière. Evelien en Jasmien jullie zijn in oktober bij Eva en mij op de 
bureau komen zitten. Dank jullie wel voor de steun bij het schrijven van mijn thesis. Ik wens jullie nog veel 
geluk met jullie onderzoek. Lien, Nele en Maxime, dank jullie voor de vele onvergetelijke momenten dat we 
samen hebben beleefd op het labo maar ook buiten de werkuren! Vanessa, dank je wel voor alle goede raad en 
voor je hulp als ik een probleem had met PCR of RT-qPCR. Met jouw ervaring en kennis ben je quasi onmisbaar 
geworden voor het labo. Evy, we waren ongeveer gelijktijdig aan ons doctoraat aan het schrijven en ik heb 
daardoor veel steun en tips gekregen van jou. Dikke merci hiervoor! Mark, je hebt me enorm geholpen bij het 
ontwikkelen van de probe. Mede dankzij jou heb ik dat tot een goed einde kunnen brengen, waarvoor mijn 
oprechte dank! 
 
Vanaf mijn eerste werkdag voelde ik me onmiddellijk thuis op onze vakgroep. Dit was grotendeels te wijten aan 
de vriendelijke, behulpzame en goedlachse mensen die er rondliepen en nog steeds rondlopen. Hoewel het 
steeds een komen en gaan is van personeel, vormen de collega’s toch een hechte groep waarvan ik deel mocht 
uitmaken. David, Jonas, Ilias, Elin, Alexander, Alex, Annatachja, Anneleen, Astra, Annelies, Ruth, Shaoiji, 
Silvana, Sofie G, Celine, Karolien, Dorien, Evelien, Fien, Filip, Deon, Julie, Keeley, Laura, Leen, Ilse, Tom, 
Lonneke, Melanie, Mojdeh, Pearl, Pudsa, Nathalie, Tijn, Gwij, Jonah en alle professoren: bedankt voor alles!!! 
 
Mijn volgend woord van dank zou ik graag richten naar mijn goede vrienden. Leen, Jeroen en Liesbeth. Jullie 
hebben van in het begin tot op het einde alles in verband mijn doctoraat kunnen meevolgen. Goede of slechte 
momenten, ik kon/kan steeds op jullie rekenen. Dank jullie wel voor jullie oprechte interesse, luisterend oor, 
geduld, raad en steun. Ook de deugddoende afleiding en de onvergetelijke, leuke momenten die we samen 
hebben beleefd zullen me steeds bijblijven. Jullie zijn vrienden voor het leven!!! 
 
Tenslotte zou ik graag mijn familie willen bedanken voor hun eindeloos geluld, hun aanmoedigingen en hun 
onuitputtelijke steun. Mama en Papa, dank jullie wel voor alles wat jullie voor mij hebben gedaan en de kansen 
die jullie me hebben gegeven. De jongens en ik komen voor jullie steeds op de eerste plaats, waarvoor onze 
oprechte dank!!! We kunnen ons geen betere ouders wensen!!! Christophe en Philippe: als jullie ‘grote’ zus wil 
ik enkel het allerbeste voor jullie en dat is duidelijk wederzijds. Jullie staan altijd klaar voor mij en zijn er steeds 
op de momenten dat ik het nodig heb. Dank jullie wel voor alles broertjes! Sanne en Julie, dank jullie om er 
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voor mij te zijn en voor de goede band/vriendschap. Mijn broers hebben fantastische schoonzusjes voor me 
uitgekozen en daar ben ik enorm dankbaar voor!!! Ook aan de rest van mijn familie een welgemeende dank je 
wel!
 
 
 
 
